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ABSTRACT
In the past several decades, advances in our understanding of cells that comprise
our bodies have been remarkable. This is due in large part to the development of
mammalian cell culture practices that allow researchers to mimic conditions in the body.
Cell culture techniques have allowed researchers to study the behavior of cells under
various circumstances that would be impossible to study in humans. While there are some
drawbacks to the reductionism inherent in studying cells in a dish, many medical
treatments have resulted from cell culture experiments. Additionally, many new
therapeutics are only possible due to these improved cell culture techniques.
To that end, this research has encompassed the full spectrum of cell culture
techniques and applications. For example, DNA microarrays can be used to study
glycosylation gene expression in mammalian cells, where glycosylation is an important
quality attribute of recombinant human therapeutic proteins. Specifically, a method is
described to conduct glycosylation experiments. Next, research is described where DNA
microarrays were used to investigate the response to elevated ammonium levels for a
mammalian cell line often used to produce human therapeutics, because it has been show
that elevated ammonium decreases product quality for these recombinant therapeutics.
So, understanding if gene expression controlled the response was important. It was
determined, through DNA microarray and PCR analysis, that glycosylation genes in these
cells are unaffected by the elevated ammonium levels commonly experienced in endstage cultures. Therefore, it was concluded that the effects of ammonium on protein
quality appear to be due to translational or substrate-level effects.
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This research transitioned from analyzing the behavior of NS0 cell cultures to
analyzing the behavior of stem cell cultures. For NS0 cells, the recombinant proteins are
the product of interest. For stem cells, the products are the actual cells, which are
anticipated to serve as starting material for future cell-based regenerative therapies. For
NS0 cells, the goal is to produce high quality protein products. For stem cells, the goal is
to produce robust multipotent stem cells. To that end, we developed a novel method for
buffering the pH of mesenchymal stem cell (MSCs) cultures, such that it might be easier
to culture the MSCs in large volumes without requiring carbon dioxide sparging.
Through the use of PCR and histological staining, it was demonstrated that MSCs were
capable of growth in the absence of an elevated CO2 environment and differentiation into
adipogenic, chondrogenic, and osteogenic lineages. These results provide a route for
simplifying bioreactor control and paving the way for efficient, large-scale generation of
high-quality multipotent stem cells.
Just as elevated ammonium affects the protein quality for NS0 cells and pH
governs the behavior of stem cells, metabolites within tumors affect the behavior of
cancer cells. One such metabolite – lactate – accumulates in tumors and adversely affects
patient outcomes. Interestingly, lactate accumulation is also a major challenge in
therapeutic protein production and cell-based therapy cell production. Thus, gaining a
better understanding of elevated extracellular lactate’s effects on the metabolic behavior
of breast cancer cells was examined. Three breast cancer cell lines were used. A
comprehensive technique called 13C-metabolic flux analysis (MFA) was used to estimate
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intracellular fluxes. All three cell lines has decreased glucose consumption and decreased
lactate production under the elevated lactate compared to the control condition. Under the
elevated lactate conditions, all three cell lines also consumed lactate, an effect seen in
stage late cultures of cells used for recombinant protein production, which might
represent a general cellular mechanism used by a variety of cell lines to deal with
extracellular lactate accumulation. At the same time, all three cell lines increased
reductive carboxylation in the TCA cycle under elevated lactate compared to control, and
this effect has also been observed in cells – both normal and cancerous - under hypoxia.
These results suggest a previously unreported link between hypoxia and lactate, which
demands further investigation.
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CHAPTER 1: INTRODUCTION
1.1 Motivation
Cell culture technology provides an indispensible tool for advancements in the
biomedical and bioengineering fields. Performing studies on cells outside of the complex
environment in the human body allows researchers to derive insights into cell biology
and disease progression that might otherwise be hard to uncover. Additionally, we can
harness the unique attributes of mammalian cells to create complex therapeutics and
hopefully improved cell-based therapies. Ultimately, cell culture experiments allow
researchers to simplify the situation, so that links between environmental factors and cell
behavior can be more clearly discerned. As the scientific and medical communities gather
more knowledge about the causes and effects of phenomena surrounding us, this
knowledge can be used to develop solutions to the problems that we face. Above all, the
motivation for all of my projects – from NS0 cells to stem cells to cancer – stemmed
from the basic desire to contribute to this enterprise: to expand scientific knowledge in
order to improve patients’ lives.
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1.2 Organization
This dissertation contains six chapters. Chapter 1 outlines and explains the motivation
for this research. Chapter 2 is a published methods paper that describes DNA microarray
technology and its application in studying mammalian cell gene expression. My coauthors were Mary Caldwell and Dr. Sarah W. Harcum (Brodsky et al., 2012). Chapter 3
is a published research paper, which follows thematically from the methods paper and
describes the application of this method to NS0 cells and how elevated ammonium levels
affects the expression of key glycosylation genes. My co-authors were Mary Caldwell,
Sooneon Bae, and Dr. Sarah W. Harcum (Brodsky et al., 2014). Chapter 4 is a published
research paper that describes a novel method to expand mesenchymal stem cells (MSCs)
in atmospheric carbon dioxide. My co-authors were Dr. Jing Zhang, Dr. Richard P.
Visconti, and Dr. Sarah W. Harcum (Brodsky et al., 2013). Chapter 5 describes ongoing
research that examines the effects of high extracellular lactate on the metabolism of three
different breast cancer cell lines using

13

C-metabolic flux analysis (MFA). My co-

investigators are Daniel Odenwelder and Dr. Sarah W. Harcum. Chapter 6 describes
future work, mostly related to the 13C-MFA studies.
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CHAPTER TWO: GLYCOSYLATION AND POST-TRANSLATIONAL
MODIFICATION GENE EXPRESSION ANALYSIS BY DNA MICROARRAYS
FOR CULTURED MAMMALIAN CELLS

2.1 Abstract
DNA microarray analysis of gene expression has become a valuable tool for
bioprocessing research aimed at improving therapeutic protein yields. The highly parallel
nature of DNA microarray technology allows researchers to assess hundreds of gene
simultaneously, essentially enabling genome-wide snapshots. The quality and amount of
therapeutic proteins produced by cultured mammalian cells rely heavily on the culture
environment. In order to implement beneficial changes to the culture environment, a
better understanding of the relationship between the product quality and culture
environment must be developed. By analyzing gene expression levels under various
environmental conditions, light can be shed on the underlying mechanisms. This paper
describes a method for evaluating gene expression changes for cultured NS0 cells, a
mouse-derived myeloma cell line, under culture environment conditions, such as
ammonia buildup, known to affect product quality. These procedures can be easily
adapted to other environmental conditions and any mammalian cell lines cultured in
suspension, so long as a sufficient number of gene sequences are publicly available.
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2.2 Introduction
Production of therapeutic proteins in cultured mammalian cells has advanced
significantly over the last few decades. Yields during this time have increased from less
than ten milligrams per liter to over five grams per liter of product mainly due to
improved cell numbers (Hacker et al., 2009). However, there has not been the same level
of improvement in protein quality, specifically with respect to glycosylation and other
post-translational modifications that directly impact a therapeutic protein’s efficacy
(Jenkins et al., 2008; Lim et al., 2010). Much research has examined how culture variants
– including substrate and precursor- feeding, oxygen and carbon dioxide levels, amino
acid additions, and osmolarity – influence protein quality (Ozturk et al., 1990; Patel et al.,
1992; Maiorella et al, 1993; Hayter et al., 1993; Chotigeat et al., 1994; Gawlitzek et al.,
1995; Castro et al., 1995; Gu et al., 1997; Chuppa et al, 1997; Etchevarry et al., 1998;
Kunkel et al., 1998; Hooker et al., 1999; Valley et al., 1999; Kaufmann et al., 1999;
deZengotita et al., 2002; Chung et al., 2001; Baker et al., 2001; Yang and Butler, 2002;
Sung and Lee, 2005), but currently no robust, reliable means to positively influence
protein quality are known (Jenkins et al., 2009).
Many studies have investigated gene expression in mammalian cell culture under
bioreactor conditions designed to improve protein productivity. Earlier work used realtime quantitative reverse transcription polymerase chain reaction (real-time qRT-PCR) to
assess the expression levels of a few particular genes in response to induced culture
variants (Kim et al., 2005; Yoon et al., 2003; Clark et al., 2005; Clark et al., 2004; Chen
and Harcum, 2006; Chen and Harcum, 2007; Wong et al., 2010a; Wong et al., 2010b).
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However, these narrow depictions of gene expression did not provide the global analysis
necessary to formulate comprehensive models of glycosylation and other posttranslational modifications, whereas DNA microarray analysis is beginning to provide
adequate levels of detail (Jaluria et al., 2007).
DNA microarray technology, with its ability to take genome-wide snapshots,
provides a comprehensive tool for gene expression analysis (Jaluria et al., 2007) that
when combined with proteomic and metabolic data will finally provide the inputs needed
to design predictive models for control of post-translational modification, especially
glycosylation (Jenkins et al., 2009; Jaluria et al., 2007; Redestig and Costa, 2011).
However, DNA microarrays are still most effective for genetically sequenced species,
such as mouse cell lines. Thus, the lack of a complete genome prior to July 2011 (Xu et
al., 2011) has limited Chinese hamster ovary (CHO) cell applications, though analysis
using private DNA microarrays has yielded insightful results (Korke et al., 2004;
Wlaschin et al., 2006; Nissom et al., 2006; Gatti et al., 2007; Kumar at al., 2007; Yee et
al., 2009; Kantardjieff et al., 2010; Shen et al., 2010; Qian et al., 2011; Clarke et al.,
2011). Studies have revealed that genes for vesicle trafficking, endocytosis and
cytoskeletal elements critically influenced antibody production (Yee et al., 2009) and that
death receptor- and mitochondria-mediated pathways, not endoplasmic reticulummediated pathways, signaled apoptosis (Nissom et al., 2006). Studies with sodium
butyrate have linked its positive effect on protein productivity and improved
glycosylation to histone modifications, chaperones, lipid metabolism, and protein
processing (Gatti et al., 2007). When sodium butyrate was combined with lower culture
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temperatures, genes associated with the Golgi apparatus, cytoskeleton, and signal
transduction contributed to the improved protein quality, despite diminished growth rates
Kantardjieff et al., 2010). Additionally, hyperosmolarity has been investigated in
hybridoma cells (a mouse-derived cell line) using DNA microarrays and it has been
observed that differential expression of genes associated with catabolism, cell-cycle
regulation, apoptosis, regulation of transcription and translation, and transport and
signaling pathways play a significant part in cell survival. Surprisingly, hyperosmolarity
affected few genes involved in stress response (Shen et al., 2010). The positive affects of
copper sulfate on protein productivity and aggregation have been examined via DNA
microarrays. The down-regulation of the transferrin receptor and lactate dehydrogenase
genes, and the up-regulation of cytochrome P450 family genes were determined to
mediate the positive metabolic responses (Qian et al., 2011). A weighted gene expression
network analysis has been used to identify patterns in gene expression due to relevant
bioprocess conditions from 295 DNA microarrays. As expected, genes associated with
cell cycle, nucleic acid metabolism, and DNA replication were enriched in the clusters
that had positive effects on cell growth and protein production. These clusters may prove
useful in identifying biomarkers indicative of high producing CHO cell lines (Clarke et
al., 2011). As these previous results demonstrate, the parallel, high throughput
capabilities of DNA microarray technology makes it an ideal tool for evaluating a larger
scope of transcriptomic responses to design strategies for improving protein yields and
quality.
This article covers step-by-step protocols for mimicking the elevated ammonium
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stress associated with late-stage bioreactor cultures (Gawlitzek et al., 2000) and using
DNA microarrays to analyze the effect of these culture conditions on glycosylation gene
expression. While the analysis will focus on NS0 cells (a mouse myeloma cell line used
commonly for monoclonal antibody production), these procedures are, in principle, easily
adaptable to CHO cells and other relevant suspension cell lines. Additionally, the
glycosylation and housekeeping gene sequences that are publicly available could be used
with any DNA microarray platform and could be extended to include other posttranslational modification genes.
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2.3 Materials
Cell Lines
1. NS0 cells (ECACC#85110503) from the European Collection of Cell Culture
(a mouse myeloma cell line with lymphoblast morphology, non-secreting clone,
and cholesterol auxotroph).
2. (Alternative) Chinese hamster ovary (CHO) cells from the American Tissue
Culture Collection (ATCC).
Cell Culture Media
1. ADCF-MAb™ media without L-glutamine (HyClone) plus Lglutamine (200
mM) with LS-250 or LS-1000 lipid supplement (HyClone), or (Alternative)
SyntheChol™ cholesterol supplement (Sigma) and fatty acid supplement (Sigma).
2. (Alternative) EX-CELL® NS0 Serum-Free Medium (Sigma) plus L-glutamine
(200 mM).
3. (Alternative) CDM4NS0® Medium (Hyclone).
Cell culture reagents, plasticware, and glassware
1. T-75 (75 cm2) Flasks (e.g. Nunc).
2. One or two 250 mL spinner flask (Kontes Cytostir or similar).
3. Four or five 1 L spinner flasks (Kontes Cytostir or similar).
4. Orbital Shaker Platform/Multiple Purpose Rotator (e.g. Barnstead Lab-Line).
5. Stir Plate with at least 4 places for 1L spinner flasks
6. 5 M NH4Cl stock (in Milli-Q water) (e.g. Sigma).
7. 5 M NaCl stock (in Milli-Q water) (e.g. Sigma).
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8. 5 M Proline stock (in Milli-Q water) (e.g. Sigma).
9. (Alternative/Additional) Computer-controlled fermenter system (e.g. Sartorius
BiostatB Plus).
Cell counting
1. Scepter™ 2.0 Handheld Automated Cell Counter (Millipore).
2. (Alternative) Trypan Blue (e.g. Invitrogen), Microscope (e.g. Olympia), and
Hemocytometer.
3. (Alternative) Coulter counter (e.g. Beckman).
Glucose analysis
1. HemoCue® B-Glucose Analyzer (HemoCue).
2. (Alternative) YSI 2300 STAT Plus™ Glucose & Lactate Analyzer
(Yellow Springs Instruments).
3. (Alternative) NOVA BioProfile® Basic analyzer (NOVA Biomedical).
RNA stabilization
1. Ice bath to quickly cool cells.
2. (Optional) RNAlater® (Ambion).
3. (Optional) RNAProtect® (Qiagen).
RNA isolation and purification
1. RNAqueous-Midi®kits (Ambion).
2. (Alternative) PureYield™ RNA Midiprep System (Promega).
3. (Alternative) RNeasy® Midi Kit (Qiagen).
RNA clean-up (optional)
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1. RNeasy® Mini Kit (Qiagen).
2. RiboPure™ Kit (Ambion).
3. (Optional) RNase-Free DNase Set (Qiagen).
RNA quantification
1. Agilent 2100 Bioanalyzer (Agilent Technologies).
2. (Alternative) Ribogreen® RNA Quantification kit (e.g. Molecular Probes).
3. (Alternative) Spectrophotometer with 280 and 260 nm filters (e.g. TECAN).
4. (Alternative) Gel electrophoresis apparatus (e.g. Nunc).
DNA microarray
1. GLYCOv4 GeneChip® (Affymetrix), not available for commercial use.
2. (Alternative) Custom Nimblegen DNA microarray.
3. (Altenative) Custom spotted DNA microarray.
Gene expression analysis
1. GeneSpring® (Agilent).
2. (Alternative) ArrayStar® (DNASTAR).
3. (Alternative) ORIOGEN v3, not for commercial use
.(http://www.niehs.nih.gov/research/resources/software/oriogen/index.cfm),
Real-time qRT-PCR validation
1. Access RT-PCR kit (Promega, WI).
2. SYBR®Green I dye chemistry (Molecular Probes, Eugene, OR).
3. Primer Express® (Applied Biosystems, Foster City, CA).
4. Smart Cycler® (Cepheid, Sunnyvale, CA).
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2.4 Methods
Overview
This article will cover the key elements of the procedures needed to assess gene
expression changes under bioreactor conditions with particular focus on protein
glycosylation and other posttranslational modification genes. The factors that should be
considered when planning such experiments will be discussed. Although DNA
microarrays are central to assessing gene expression levels, much of the experimental
procedures described here – including experimental setup and sampling procedures – are
independent of the selected DNA microarray platform. Additionally, most DNA
microarray scanning software can generate multiple types of specialized files (such as
CEL for Affymetrix) as well as tab-delimited text files, and gene expression software
programs can read a variety of file types. Due to this flexibility, the experimental
procedures mentioned here can be performed fairly independent of the DNA microarray
platform to be used. A flow diagram outlining the basic procedure can be found in Figure
2.1. The details of the experimental design and set up will be discussed in more detail and
the reader will be informed of potential options.

Experimental design and set-up
As a means to demonstrate how to set up and run an experiment focused on
quantifying expression changes in genes associated with glycosylation and post-
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Figure 2.1 Flow diagram for the collection and analysis of gene expression data. The
process begins with the experimental design. Next, the experiments are conducted in
triplicate for each condition. From each condition, the samples are harvested and the
cells obtained. In order to analyze gene expression, the total RNA is separated from the
cells and purified. Depending on the DNA microarray platform, the researcher will
convert the mRNA to cDNA, or send the total RNA to the DNA microarray contract
facility for processing. The cDNA is then hybridized with DNA microarray, the DNA
microarray is scanned and the data is processed. At this point the process data will be
returned to the researcher for analysis. The processed data is usually imported into a
DNA microarray analysis software tool, where the data is normalized. Once the data is
normalized, statistical analysis is conducted to identify genes with differential expression
between the replicates. A variety of tools can be used to determine underlying gene
regulation principles. In order to publish the research results, the data is then submitted
to a public database.
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translation modification, a step-by-step procedure will be described for a model system.
The model system will be NS0 cells exposed to conditions known to affect protein
glycosylation, including elevated ammonium (Valley et al., 1999; Gawlitzek et al., 2000;
Gawlitzek et al., 1998) as well as three other conditions. Specifically, the experimental
procedure to set up ammonium-stressed, salt-stressed, ammonium-stressed with proline,
and control cultures will be described. The salt-stressed will provide a control for
osmolarity. The ammonium-stressed with proline will examine the ability of proline to
mitigate the negative effects of ammonium (Chen and Harcum, 2006). Additionally, a
control will normalize volumes, nutrients, and osmolarity. Biological triplicates for each
condition will be needed, thus requiring 12 individual culture vessels.
Since the anticipated gene expression changes are likely to be small, relative to
the large magnitude changes observed due to a heat-shock, it is important to synchronize
the control and ‘‘stressed’’ cultures as much as possible to reduce the growth-associated
differences. The use of a common inoculum for the control and stressed conditions
synchronizes the culture behavior, which should reduce the noise-to-signal ratio. In
Figure 2.2, a scale-up plan is shown for using a common inoculum to seed four 1 L
spinner flasks. These four spinner flasks represent only one-third of the experiment and
one complete set of the conditions. This process would need to be repeated two more
times to generate the biological triplicates (12 experimental vessels total). Since most
CO2 incubators can only hold one multi-place stirrer with four 1 L spinner positions, the
procedure outlined in this article runs biological triplicates from three separate inocula,
sequentially. It is possible to reduce the overall time by staggering the T-75 flasks and
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Figure 2.2 Expansion timeline for NS0 cells to be used in parallel 1 L spinner flasks.
NS0 cells are inoculated into a T-75 flask and allowed to expand to 1.5 x 105 cells/mL,
which takes 4 to 5 days. The T-75 flask cells (25 mL) are used to inoculate one 250 mL
spinner flask with 225 mL fresh media added. If the desired volume in the four 1 L
spinners is only 500 mL each, the cells from one 250 mL spinner flask can be used to
inoculate all four 1 L spinners. However, if a higher volume is required in the 1 L
spinners, an additional 1 L spinner can be used. Inoculate the extra 1 L spinner with the
entire contents of the 250 mL spinner flask and add up to 750 mL fresh media. Inoculate
the Control and Condition spinner flasks with the same volume of cells from either the
250 mL spinner or the extra 1 L spinner flasks (50 mL to 250 mL depending on desired
timeframe).
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recycling the 250 mL spinner with a one-day delay. This would stagger the four
experimental 1 L spinner flasks by one day, allowing sufficient time to harvest, wash, and
sterilize the spinner flasks.
For stresses sufficiently mild as to not alter the growth significantly, inoculating
the cells directly into the vessels containing the control and ‘‘stressed’’ media allows for
synchronization. An example set of growth profiles are shown in Figure 2.3A where the
stresses were mild, as indicated by the parallel growth profiles. An alternative approach is
required if the stresses to be investigated cause significant growth rate changes. In this
case, it is best to inoculate all the vessels with cells in control media. This will allow the
cells to grow sufficiently to obtain a baseline growth rate and confirm that cultures are
not different, and then the stresses can be applied. An example set of growth profiles are
shown in Figure 2.3B that highlights this approach, where the stresses were added at 40h. The growth profiles were similar prior to the stress at 40-h, and divergent after 40-h.
The sampling frequency and types needed for analysis will directly determine the
minimum volumes needed in the experimental vessels. In the model system, 500 mL
media was used in 1 L spinner flasks to assure sufficient material throughout the entire
experiment. The volume reduction due to sampling should not significantly alter the
culture characteristics, such as the mixing dynamics. For the model case, samples would
be taken for cell density, cell viability, glucose, lactate, osmolarity, and total RNA. If the
cell line of interest expressed a therapeutic recombinant protein, samples analyzing the
product quality should be taken periodically. The cell density, cell viability, glucose, and
lactate samples would be taken approximately every 12-h (see Figure 2.3A). For
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Figure 2.3 Example growth profiles for biological triplicate conditions. A) The
conditions being examined did not significantly affect the growth rate; however, the final
cell densities were significantly different. In this case, obtaining gene expression analysis
data from one time point, late in culture (around 90 hours) would not have high noise in
the data due to a growth effect. B) The conditions being examined significantly affect the
growth rate. In this case, the stress was applied at 40 hours. Sampling throughout the
culture’s growth (before and after the stress) would be desirable, such that gene
expression changes due to growth effect could be identified.
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mammalian cells, the sampling frequency can vary from 10 to 16-h without missing the
culture dynamics; however, it is important that the time intervals used be the same for all
replicates such that error bars in time are not needed. In the model case, the sample
interval was initially 16-h, and then alternated between 10 and 14-h to accommodate
more user-friendly work hours (see Figure 2.3). The volumes withdrawn for these
samples should be 5 mL per time point with 10 time points (50 mL total). The frequency
of these sample types would be the same for the growth inhibitory stress conditions (see
Figure 2.3B).
For DNA microarrays, a minimum of 10 µg total RNA is usually required. Thus,
it is critical that the cell pellet samples for total RNA to be sufficiently large enough to
assure sufficient material is obtained. Cultured cells typically have much lower total
RNA levels than tissue sample, consequently 1 x 107 cells are a minimum target of cells
to assure that 10 µg total RNA is obtained at the necessary concentration (1 µg/µL). For
beginning cultures with cell densities in the 2 x 105 cell/mL range, harvesting 50 mL
culture media per sample is sufficient. Once the cell densities are greater than 3 x 105
cell/mL, the harvest volumes can be decreased to 15 mL. The recommended RNA
isolation kits can handle up to 100 µg total RNA and associated cell debris, so it is
unlikely that a kit will be saturated with cell debris. For the non-growth altering stresses,
a single, late-stage exponential-phase total RNA sample from each condition would be
sufficient to capture gene expression changes due to the stress, which was indicated by
the vertical line in Figure 2.3A. Taken together with the other sample volumes (50 mL),
the total anticipated volume change in the vessel is only approximately 65 mL out of 500
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mL. For the growth altering stresses, multiple total RNA samples from each condition
would be needed to capture gene expression changes due to the stress. For the model
experiment shown in Figure 2.3B as vertical lines, total RNA samples should be taken at
40, 45, 50, 60, 70, 90, and 110-h to fully capture the potential culture gene expression
dynamics. Taken together with the other sample volumes (50 mL), the total anticipated
volume change in the vessel would be 155 mL. The similarity of mixing dynamics can be
assessed using culture media and tracer dyes at the various anticipated volumes to
confirm minimal effects. So, depending on the placement of the stirring paddles, the
initial culture volume for the growth altering stressed cultures may need to be increased
to between 750 and 1000 mL.

Culturing NS0 cells
Standard cell culture techniques should be used to thaw and expand the NS0 cells.

Standard media preparation
The ADCF-MAb media requires a cholesterol supplement, since NS0 cells are
cholesterol auxotrophs. ADCF-MAb media was designed to be used with the LS 250
lipid supplement (4 mL per liter media; Hyclone) or LS 1000 (1 mL per liter media;
HyClone). Alternatively, the cholesterol supplement SyntheChol™ (2 mL per liter,
Sigma) and the fatty acid supplement (0.5 mL per liter, Sigma) can be used as well. As
needed, add L-glutamine (25 mL of 200 mM L-glutamine stock per liter) to the ADCFMAb media. If other cell lines or media are used, prepare media appropriately.
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The NS0 cells will be inoculated into fresh media at approximately 2 x 105
cells/mL and allowed to reach 1.5 x 106 cells/mL prior to subsequent inoculation.
Preparation of the first spinner flask requires a cell density in the T-75 flask greater than
1.0 x 106 cells/mL. For example, 25 mL of 1.0 x 106 cells/mL added to 225 mL of fresh
media will result in an initial cell density of 1 x 105 cells/mL in the 250 mL spinner flask.
The 250 mL spinner flask will reach approximately 1.0 x 106 cells/mL in about 3–
4 days. Since the complete ADCF-MAb media supports cell densities of approximately 2
x 106 cells/mL, the cells should be transferred to fresh media in the exponential phase
(<1.5 x 106 cells/mL) to reduce the potential of a growth lag. For NS0 cells, a lead-time
of 8–12 days is needed for each replicate set. These lead-times can be shortened if the
cell line to be examined has faster doubling times than NS0 cells. For example, the higher
growth rate of CHO cells compared to NS0 cells results in less time required to expand
the cells.
If the phenomenon to be investigated requires high cell density cultures,
computer-controlled fermenters operated in a fed-batch manner will be required. The
description of fed-batch operation of mammalian cell cultures will not be described;
however, there are several research papers that describe fed-batch operation (Zhou et al.,
1997; Lee et al., 2003; Wong et al., 2005). The inoculum for the fermenters will be
generated in spinner flasks, as described above. Depending on the number of fermenters
available, the conditions to be examined may need to be run sequentially. If sequential
operation is required, it is very important to have standardized expansion trains.
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Media preparation
For the model case, three stressed conditions were compared to the control,
representing cells cultured in the standard media. In order to minimize osmolarity and
nutrient concentration differences, the final volumes in the experimental spinner flasks
were kept constant by water additions to the control and other stressed conditions as
required (see Table 2.1). For example, for the ammonium- stressed condition (Condition
1), 2 mL of the 5 M NH4Cl stock was added to the media and 4 mL of Milli-Q water. For
the salt-stressed condition (Condition 2), 2 mL of the 5 M NaCl stock was added and 4
mL of Milli-Q water. For the ammonium-stressed plus proline condition (Condition 3), 2
mL of the 5 M NH4Cl stock was added and 4 mL of the 5 M proline stock. For the
control culture (Control), 6 mL of Milli-Q water was added. To reduce any potential
osmolarity shocks, the salts, proline, ammonia, and water should be added to the medias
prior to the addition of cells. If the stresses significantly affect growth after the stress is
added, the control culture should have a water addition of equal volume to any chemical
addition.

Initial sampling
Once the vessels are inoculated, the initial cell density should be determined. A
Scepter™ 2.0 Handheld Automated Cell Counter or a similar device can be used to
obtain the initial cell densities and if cell viability is desired, the Trypan Blue exclusion
method can be used. Additionally, samples should be taken for glucose and lactate
analysis using a NOVA BioProfile Basic analyzer or the YSI 2300 STAT Plus™
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Table 2.1. Experimental media formulations. Media additions to induce the stressful
condition, while normalizing the nutrient concentrations and osmolality. Amounts listed
are per liter of the final media.
Control

Condition 1
(10 mM
Ammonium)

5 M NH4Cl

0

2 mL

0

2 mL

5 M NaCl

0

0

2 mL

0

5 M Proline

0

0

0

4 mL

6 mL

4 mL

4 mL

0

Additions

Milli-Q
Water
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Condition 2
Condition 3
(10 mM
(10 mM Ammonium
Salt)
+ 20 mM Proline)

Glucose & Lactate Analyzer. Procedures for the NOVA BioProfile Basic analyzer or
the YSI 2300 STAT Plus™ Glucose & Lactate Analyzer can be found from the
manufacturers.

Sampling
The cultures should be monitored periodically for 110 h with sampling every 10–
14 h. Samples for every time point should minimally include cell density and glucose
concentrations. Cell viability and lactate may provide additionally information on cell
health. The cell pellets for total RNA samples should be taken as per the experimental
design. Protein quality assessment samples should also be taken for systems that express
a therapeutic recombinant protein.

RNA isolation and purification
Sampling for total RNA isolation requires some type of stabilization. One method
simply rapidly cools the cell broth on ice water (4°C), then centrifuges at 4°C. The cell
pellet is then stored at -80° C. Alternatively, a stabilization agent can be added directly to
the cell broth for storage. Usually an equal volume of the stabilization agent is needed.
Commercially available stabilization agents include RNAlater Stabilization Solution
(Ambion) and RNAprotect cell reagent (Qiagen). The stabilized cell broth is then either
stored at -20 or -80°C depending on the manufacturer
Although the RNA extraction kits are designed to inactivate RNAses and other
degradative compounds, it is essential that proper sterile practices be used, and that no
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part of the kits be touched with bare hands, as RNAses are especially abundant on human
skin, and could affect reagents and samples. Also, all water and pipette tips used in
conjunction with these kits must be nuclease-free. It is best to process all the RNA from
all samples together.

RNA isolation
The RNAqueous Midi Kit can be used to extract and isolate the total RNA,
although many other kits, such as RNeasy Mini Kits, are also effective. These
procedures can be found at http://www.ambion.com and http://www.qiagen.com. Also,
the phenol–chloroform extraction method can be utilized. It is sold under the name TRI
Reagent (Sigma) and TRIzol (Invitrogen). Essentially, these procedures all have steps
to lyse the cells, remove cellular debris including lipids, proteins and DNA, followed by
binding and eluting the total RNA in nuclease-free water.

RNA purification
Many DNA microarray contract facilities require an additional RNA purification.
The RNeasy Mini Kits can be used for all RNA purifications procedures. Other
companies, such as Norgen Biotek offer alternatives; however, one should confirm the
compatibility with the DNA microarray contract facility beforehand. Normally, RNA
purification kits efficiently remove the majority of DNA without DNAse treatment;
however, if any of the mRNA transcripts of interest are in low abundance, an additional
DNAse digestion step should be performed. An RNase-Free DNAse Set should be used.
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The

procedure

for

Qiagen’s

DNAse

digestion

can

be

found

at

www.qiagen.com/hb/rnasefreednaseset. In the model case, the DNAse digestion step was
not needed; however, the additional Qiagen RNA clean-up was required by the
Consortium for Function Genomics DNA microarray facility.

RNA quantification
The Ribogreen RNA Quantification Kit (Molecular Probes) was used to
quantify the concentration of all RNA samples, although other alternatives include the
Agilent 2100 Bioanalyzer, UV/VIS spectrophotometer, or gel electrophoresis apparatus.
The

Ribogreen®

Quantification

Kit

procedure

can

be

found

at

http://hcgs.unh.edu/protocol/realtime/RiboGreen.pdf.

DNA microarray
There are several existing DNA microarray technologies; however, for this article,
the descriptions will focus on the usage of a high-density oligonucleotide DNA
microarray synthesized in situ using photolithography, a method developed by
Affymetrix. Other DNA microarray platforms that could be used with the glycosylation
and post-translational modification genes include pin-based fluid transfer systems, piezobased inkjet dispenser systems, and electronic-based addressing systems (Heller et al.,
2002). Selection of a DNA microarray platform depends on the experimental design,
gene sequences available, processing facility availability, and cost. Muyal et al. provides
a good review of the different platform technologies (Muyal et al., 2008). Further, Larkin
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et al. demonstrated that results obtained obtain from Affymetrix and two-color DNA
microarray platforms agreed, as long as reliable and consistent methods of identifying
genes were used. This makes sense when one considers that the biological and procedural
variation exerts a greater effect than platform variation (Larkin et al., 2005).
The specific DNA microarray that will be described is the GLYCOv4 GeneChip
DNA microarrays. The GLYCOv4 GeneChips are Affymetrix-manufactured DNA
microarrays that contain the known glycosylation-related genes for human and mouse.
The GLYCOv4 DNA microarrays were constructed for the Consortium for Functional
Glycomics with funding from the National Institutes of Health (NIH). The GLYCOv4
GeneChips are only available through a proposal process to academic researchers from
the Consortium for Function Genomics. Alternatively, a researcher could have a custom
DNA microarray manufactured containing these glycosylation genes using any platform
technology, as all the gene sequences are publicly available.
The GLYCOv4 GeneChip DNA microarray contains 25 perfect match and
mismatch (PM-MM) probes for each of the 1127 mouse glycosylation-related genes and
the 119 housekeeping genes. The list of all the included genes and probe sequences can
be found at
http://www.functionalglycomics.org/static/consortium/resources/resourcecoree.shtml.
The gene types include:
•

Glycosyltransferases

•

Glycan degradation proteins

•

Intercellular protein transport proteins
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•

Nucleotide sugar synthesis and transporter proteins

•

N-glycan biosynthesis-related proteins

•

Interleukins and receptors

•

Growth factors and receptors

•

Cytokines

Affymetrix DNA microarrays also include numerous control probes on the array.
Details of the Affymetrix Eukaryotic Hybridization Controls can be found at
http://www.affymetrix.com. Briefly, the GeneChip_ Eukaryotic Hybridization Controls
contains a mixture of four biotin-labeled cRNA controls with staggered concentrations.
The controls provides alignment signals used by the scanning software to provide
calibrated intensities that determine ‘‘present’’ and ‘‘absent’’ calls for a gene as well as
confirm hybridization and chip integrity.

RNA sample preparation for DNA microarray
The total RNA samples need to be very concentrated (1 µg/µL) for DNA
microarray analysis. Therefore, it may be necessary to precipitate the total RNA after the
purification step. For the model case, a vacuum concentrator was used to dry the 10 µg
samples, which then were re-suspended in 10 µL. Theses samples were sent to the
Consortium for Function Genomics. As typical of contract DNA microarray facilities, the
total RNA quality and concentration were determined upon arrival with an Agilent 2100
Bioanalyzer. This quality assurance step, allows the contractor to avoid expense of
labeling total RNA that has degraded in transit. Alternatively, some contract DNA
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microarray facilities require the researcher to reverse transcribe the RNA to cDNA, as
shipping the more stable cDNA is less problematic. If required to reverse transcribe the
RNA on-site, make sure to budget the cost of the reserve transcriptase (~$100 per
sample).
At the contract DNA microarray facilities, the RNA will be reverse transcribed in
the presence of the fluorescently-labeled dNTP analogues to obtain biotinylated cRNA.
The labeled RNA will be hybridized to a DNA microarray, such as the GLYCOv4
GeneChip, including Affymetrix’s GeneChip Eukaryotic Hybridization Controls. The
GLYCOv4 GeneChips will be scanned using the Hewlett– Packard GeneArray Scanner
G2500A and a processed image file with calculated signal intensities assigned to each
oligonucleotide spot on the GLYCOv4 GeneChip will be created. The data will be
reviewed for quality control at the contract DNA microarray facilities. The data files are
processed and returned as CEL files (for Affymetrix) to the researcher. Additionally, data
regarding the probes is provided. An example of the probe data provide in shown in
Table 2.2 for a GLYCOv4 GeneChip. Only data for the first 10 probes is shown in
Table 2.2 for brevity. Muyal et al. provides a good overview description of the DNA
microarray process from RNA sample preparation to data acquisition (imaging) (Muyal
et al., 2008). Additionally, the GeneChip Expression Analysis Technical Manual
provides details of the RNA preparation through imaging steps for Affymetrix DNA
microarrays.

Statistical analysis of gene expression data
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Table 2.2 Example probe set data information for the GLYCOv4 GeneChip.
Information for only the first 10 genes is listed. The GLYCOv4 GeneChip contains 25
probes per accession number. The accession numbers are sufficient information to create
a custom DNA microarray.
Subcategory

Probeset ID

Category

NM_013630.
2_psr1
NM_029686.
2_psr1
NM_181415.
3_psr1
NM_009730.
2_psr1
NM_008920.
4_psr1
NM_016914.
2_psr1

CBP: C-Type
Lectin
CBP: C-Type
Lectin
CBP: C-Type
Lectin
CBP: C-Type
Lectin
CBP: C-Type
Lectin

10Polycystin
10Polycystin

CBP: C-Type
Lectin

12-CTLD +
acidic neck

NM_010048.
3_psr1
NM_054042.
2_psr1
NM_010740.
3_psr1_s
NM_009378.
2_psr1

CBP: C-Type
Lectin
CBP: C-Type
Lectin
CBP: C-Type
Lectin
CBP: C-Type
Lectin

12-CTLD +
acidic neck

11-Attractin
11-Attractin
12-CTLD +
acidic neck

13-IDD
14Endosialin
14Endosialin

Pkd1 [Polycystin]

NM_013630

Probe
Set
Score
10.6

Pkd1l2 [Polycystin 1like protein 2]
Atrnl1 [Attractin
homolog]
Attractin

NM_029686

12.6

NM_181415

10.5

NM_009730

10.8

Prg2 [proteoglycan 2
bone marrow]
Prg3 [proteoglycan 3;
Eosinophil major basic
protein homolog]
DGCR2 DiGeorge
syndrome protein C
Cd248 [CD248 antigen
endosialin]
CD93 [C1q receptor;
Cd93 antigen]
Thbd
[Thrombomodulin]

NM_008920

12.3

NM_016914

12.1

NM_010048

11.1

NM_054042

11.7

NM_010740

10.5

NM_009378

11.6

Common name
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Accession
Number

In order to interpret the DNA microarray data, the raw DNA microarray data files
must be imported into a statistical analysis software program. Microsoft Excel is the
simplest program that could be used, but has limited function. In the model case,
GeneSpring was used; however, there are many commercial programs (e.g.
ArrayStar) and one public domain program (ORIOGEN) available. These programs
provide multiple statistical and post hoc tests, visualization and clustering tools, and often
pathway mapping. GeneSpring can directly import the CEL data generated by the
Affymetrix compatible scanner. Many gene expression analysis software tools can also
import gene expression data from tab-delimited text files. A portion of a tab-delimited
text file from the GLYCOv4 GeneChip is shown in Table 2.3. In this case, the data
from three biological replicates were combined into a single file.
The first step once the data has been imported into the software package is to
normalize the raw data between the DNA microarrays. Normalization adjusts for the
effects that are due to DNA microarray processing (Wit and McClure, 2004). For
example, with two-color DNA microarrays, imbalances in the red and green dyes can
occur due to labeling efficiency differences (Smyth and Speed, 2003). In GeneSpring,
the researcher needs to select a normalized protocol for the data. GeneSpring also
performs a quality check on the Affymetrix Hybridization Controls, which check for
minimum detection levels and titration of concentrations. The default normalization is
quartile and it is commonly normalized to the total intensity of the chip, which is often
set to the arbitrary value of 500. This method assumes that on average the total RNA
level in a cell is constant. Alternatively, one can normalize to the median chip intensity or

30

Table 2.3 Example gene expression data outputs for one condition.

The gene

expression signal, call, and p-values for 10 Probesets are shown for only the first 10
genes. Genes that are assigned as present (P) have p ≤ 0.04, whereas the genes assigned
as absent (A) have p ≥ 0.06 and low signals. Genes with p-values in-between are assigned
marginal (M) calls.
Probeset
ID
NM_0136
30.2_psr1
NM_0296
86.2_psr1
NM_1814
15.3_psr1
NM_0097
30.2_psr1
NM_0089
20.4_psr1
NM_0169
14.2_psr1
NM_0100
48.3_psr1
NM_0540
42.2_psr1
NM_0107
40.3_psr1
_s
NM_0093
78.2_psr1

Replicate 1

Replicate 2

Replicate 3

Signal

Call

P-value

Signal

Call

P-value

Signal

Call

P-value

64

P

0.00148

73.6

P

0.001049

100.4

P

0.000451

37.5

A

0.160942

16.4

M

0.056885

25.1

A

0.122135

7.8

A

0.493067

1.7

A

0.629375

14.9

A

0.227444

566.8

P

0.00003

428.9

P

0.00003

404.8

P

0.00003

32.8

A

0.129317

30.9

P

0.009484

31.9

P

0.007135

6.2

A

0.728492

3

A

0.728492

6.9

A

0.58937

9.5

A

0.424197

10.3

A

0.090421

1.6

A

0.655316

316.8

P

0.00003

304.5

P

0.00003

308.4

P

0.00003

3.3

A

0.990516

1.5

A

0.870683

11

A

0.197229

5.4

A

0.728492

2

A

0.79298

3.7

A

0.772556
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a particular set of housekeeping genes. Bahr et al. identified over 100 potential
housekeeping genes for CHO cells after reviewing multiple DNA microarray studies
(Bahr et al., 2009). Normalization methods also include linear models, global
normalization, LOESS normalization, and subset quantile normalization (Khoo et al.,
2007; Wu and Aryee, 2010; Yang et al., 2002). For Affymetrix CEL files, the steps used
are summarization, log transformation, and baseline transformation as described in the
Gene-Spring GX Manual.
After data normalization, differentially expressed genes can be identified from the
replicates and between the conditions of interest. In the model case, there are three
biological replicates for the four conditions, thus data from 12 DNA microarrays was
analyzed. Experiment groupings are used to identify sample parameters and the
replicates. For example, in the model case ammonium would be a parameter, as well as
proline and salt. Also, a principle component analysis is used by GeneSpring to check
data quality per DNA microarray. DNA microarray data that is of low quality can be
discarded if necessary at this step; however, then all the quality control checks are
repeated on the new experimental groupings (GeneSpring GX Manual).
An ANOVA analysis is used to detect differential expression. The Welch
ANOVA test using a Benjamini and Hochberg false discovery rate correction is a fairly
robust tool for multiple comparisons (p ≤ 0.05) (Benjamini and Hochberg, 1995). Many
software packages can also conduct numerous types of post hoc tests on the data
(pairwise comparisons). A Tukey Honestly Significant Difference (HSD) post hoc test is
one example that can identify genes that are significantly different between a pair of
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conditions (GeneSpring GX Manual). Table 2.4 shows an example Tukey post hoc for
an experiment with four conditions. Analyzing these differentially expressed genes for
biological relevant comparisons is crucial. For example, in the model case, a direct
comparison of the salt-stressed cultures to the ammonium with proline-stressed cultures
may not provide any meaningful biological information. However, the other pairwise
comparisons are more likely to result in biologically meaningful information.
Specifically, comparing the control and ammonium-stressed cultures would provide
information on the effects of ammonium on glycosylation genes. Comparing the control
and salt-stressed cultures would identify glycosylation genes sensitive to a low salt
addition (a mild osmolarity change). Comparing the ammonium-stressed and ammoniumstressed with proline cultures would identify genes sensitive to the proline addition.
Identifying differentially expressed genes and establishing links between these
changes and altered biological activity in response to stressful conditions is crucial.
Functional annotation can be used to assist with identifying underlying principles.
Several databases can be accessed to provide functional annotation such as the Gene
Ontology Consortium (GO), Metacyc, and the Kyoto Encyclopedia of Genes and
Genomes (KEGG). The Gene Ontology Consortium maintains a database of controlled
vocabularies for the description of molecular functions, biological processes and cellular
components of gene products, which can be accessed directly from Gene-Spring_.
Metacyc is a database of non-redundant, experimentally elucidated metabolic pathways.
The Metacyc Pathway Tools Omics Viewers allows for gene expression data to be
overlaid onto the metabolic pathway. KEGG is collection of manually drawn pathway
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Table 2.4 Example pairwise comparison of the culture conditions (Tukey post-hoc) –
hypothetical data.

The ANOVA analysis (p ≤ 0.05) identified 310 of the 952-

glycosylation genes as regulated across the four conditions. The diagonal represents selfcomparisons. Values above the diagonal represent the genes that have significantly
different expression levels between the two conditions. Values below the diagonal
represent the genes that are not significantly different between the two conditions.

Conditions

Control

Condition 1

Condition 2

Condition 3

Control

X

230

180

110

Condition 1

722

X

150

165

Condition 2

772

787

X

155

Condition 3

842

802

797

X
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maps representing the current knowledge of molecular interaction networks, including
glycan biosynthesis and metabolism. Additionally, tools like the MAPPFinder software
have been used to identify gene ontology with a higher-than-expected proportion in the
differentially expressed data (Kantardjieff et al., 2010).
Many different approaches can be taken to identify the biological significance for
an observed set of gene expression changes. Cluster analysis, principle component
analysis, heat-maps, k-means clustering, and self-organizing maps (SOM) are all
common tools (Wit and McClure, 2004; Landgrebe at al., 2002; Kantardjieff et al., 2009).
Hierarchical clustering was used to identify cell-cycle genes that were differentially
expressed due to hyperosmolarity (Shen et al., 2010) and principal components analysis
was used to condense the dimensionality for butyrate-treated culture gene expression data
(Kantardjieff et al., 2010). Wit and McClure reviewed these various tools and provides
examples of how each compares (Wit and McClure, 2004).
DNA microarray gene expression data is customarily validated using an
orthogonal method, with real-time qRT-PCR being the most commonly employed tool. In
the recent cell culture DNA microarray literature, the number of gene expression changes
that have been validated by real-time qRT-PCR varies from none to six genes (Gatti et
al., 2007; Kantardjieff et al., 2010; Shen et al., 2010; Khoo et al., 2007; Wlaschin and Hu,
2007). Work by Canales et al. demonstrated excellent concordance between real-time
qRT-PCR and DNA microarray fold change results using the three common real-time
qRT-PCR chemistries; calling into question the need for this validation step (Canales et
al., 2006). However, real-time RT-qPCR does provide lower thresholds of detection and
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larger assay ranges, which can be used to complement DNAmicroarray analysis for both
highly and rarely expressed mRNA species (Canales et al., 2006).
Real-time qRT-PCR uses primers to hybridize the mRNA species and amplify a
portion of the mRNA, in which either the DNA product or probes fluoresce
proportionally to the amount of mRNA in the sample. Gasparic et al. recently reviewed
nine real-time qRTPCR technologies and provides a description of the mechanism of
each (Gasparic et al., 2010). As with DNA microarrays, it is necessary to normalize the
gene expression data. For real-time qRT-PCR, housekeeping genes are used to provide
this normalization. Often actin, glyceraldehyde-3-phospahte dehydrogenase (GAPDH),
and 18S rRNA are used as normalizers for mammalian mRNA (Canales et al., 2006;
Gasparic et al., 2010). Using many DNA microarray data sets, Bahr et al. identified over
100 housekeeping gene targets for CHO cells due to consistent expression among a
variety of culture stresses (Bahr et al., 2009).
To validate DNA microarray gene expression results by real-time qRT-PCR, one
must select a real-time qRT-PCR chemistry, design primers to the target mRNA and
housekeeping genes, run the reactions, process the data, then compare to the DNA
microarray data. Schefe et al. provide a comprehensive guide to real-time qRT-PCR
methods and data analysis (Schefe et al., 2006). Canales et al. provides details for
comparing DNA microarray and real-time qRT-PCR results (Canales et al., 2006).
In the model case, gene expression levels were quantified using SYBR Green I
dye chemistry (Molecular Probes, Eugene, OR) (Richards et al., 2004; Hein et al., 2001).
Primers for each of the mRNA targets were designed using Primer Express (Applied
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Biosystems, Foster City, CA). Conventional reverse transcription polymerase chain
reactions (RT-PCR) and 2.0% agarose gels were used to confirm primer design, after
which visible products on the gels were sequenced to confirm primer specificity. A one
step RT-PCR kit (Promega, WI) was used for both conventional RT-PCR and real-time
qRT-PCR. The conventional RTPCR should be performed, as per kit instructions. The
real-time qRT-PCR can be performed using a Smart Cycler (Cepheid, Sunnyvale, CA).
For the model case, CT values were calculated using the Gene Expression’s CT
Difference (GED) method (Schefe et al., 2006). Alternatively, a second derivative
analysis CT method (Luu-The et al., 2005) outlined by Schwarz et al. and Peters et al.
(Schwarz et al., 2004; Peters et al., 2003) and normalized as per Pfaffl (Pfaffl et al., 2001)
can be used. The normalized gene expression levels for the control, ammonium-stressed,
salt-stressed, and ammonium-stressed with proline cultures were assessed using
Statistical Analysis Software (SAS). An ANOVA analysis (p ≤ 0.05) was used to identify
gene expression differences.

Data dissemination
Researchers are often required by journals to submit gene expression data to
public databases. Gene Expression Omnibus (GEO) at the National Institutes of Health
(NIH) in the United States and ArrayExpress at the European Bioinformatics Institute
(EBI) part of the European Molecular Biology Laboratory (EMBL) in the United
Kingdom, are two well-recognized public gene expression repositories. These public
databases offer great opportunities to compare data to other experimental results as well
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as learn from results of other experiments. Both GEO and ArrayExpress use the
Minimum Information About a Microarray Experiment (MIAME) guidelines that specify
the minimum information that should be included when describing a microarray
experiment. For GEO submission, the types of data input are categorized – including
metadata, raw data files, matrix tables, and the platform. The metadata comprises the
descriptive information and protocols used. The raw data files are the original, softwaregenerated quantitative results files. For Affymetrix DNA microarray data, the raw data is
contained in the CEL files. The matrix table is a spreadsheet that contains the normalized
data. The platform is a description of the DNA microarray architecture and probe
sequences. Many commercial platforms have already been submitted to GEO; however,
if a new platform has been used, the researcher will have to provide this information. As
more data becomes available and accessible through these databases, existing models can
be updated and improved. The procedure for GEO submission using MIAME can be
found online at http://www.ncbi.nlm.nih.gov/geo/info/MIAME.html (Barrett et al., 2011).
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2.5 Conclusion
DNA microarray technologies are extremely useful tools for evaluating how cells
respond at the gene expression level to stresses in their culture environment. It is known
that the culture environment can greatly impact protein quality, but so far, there has been
limited research devoted to evaluating the gene expression levels in response to these
culture conditions. While the lack of sequenced genomes hindered previous research, as
more genomes continue to be sequenced, the potential for gene expressional analysis
using DNA microarrays continues to grow. With DNA microarrays’ ability to look at
many different genes at once, researchers can now evaluate a larger scope of cellular
responses to specific stresses. This allows for the discovery of more comprehensive
patterns, involving not only the genes responsible for the enzymes in the glycosylation
pathway but also genes associated with other cellular functions that indirectly influence
the protein quality. Additionally, data collections from gene expression studies are now
publicly available online, providing researchers with even more data with which to
formulate models. With these deeper insights, more effective strategies can be designed
to take advantage of various culture parameters known to positively affect glycosylation
and other post-translational modifications in an effort to develop methods to improve
both the quality and quantity of therapeutic protein yields.
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CHAPTER THREE: GLYCOSYLATION-RELATED GENES IN
NS0 CELLS ARE INSENSITIVE TO MODERATELY
ELEVATED AMMONIUM CONCENTRATIONS

3.1 Abstract
NS0 and Chinese hamster ovary (CHO) cell lines are used to produce
recombinant proteins for human therapeutics; however, ammonium accumulation hinders
cell growth, recombinant protein production, and protein glycosylation. To improve
product quality and decrease costs, the link between ammonium and protein
glycosylation must be resolved. While ammonium is known to disrupt glycosylationrelated gene expression in CHO cells, NS0 studies have not been performed. This study
examined if NS0 cells were ammonium-sensitive at the gene expression level. The effects
of various culture conditions – ammonium, salt, and ammonium with proline - on gene
expression were assessed by DNA microarrays with mouse glycosylation-related and
housekeeping genes. Surprisingly, no significant differences in gene expression levels
were observed between the control and these conditions. Further, the elevated ammonium
condition was analyzed using real-time quantitative reverse transcriptase PCR (qRTPCR) for key glycosylation genes, and the qRT-PCR results corroborated the microarray
results, showing NS0 cells to be ammonium-insensitive at the gene expression level.
Thus, this study suggests that for NS0 cells, the observed ammonium-induced effects on
protein glycosylation and sugar nucleotide pools are due to translational or enzymatic
changes rather than transcriptional changes.
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3.2 Introduction
Mammalian cells are increasingly being used to produce glycoproteins for human
clinical therapies. The extent of glycosylation – or the addition of sugar groups to
proteins – plays an important role in the effectiveness of treatments, which makes protein
glycosylation quality a top priority (Butler, 2006; Butler and Meneses-Acosta, 2012;
Hudak and Bertozzi; Jenkins et al., 1996; Lingg et al., 2012; Ozturk, 1992). The culture
environment, in which ammonia and ammonium ions accumulate, plays a significant role
in determining cell growth rates, recombinant protein production, and protein
glycosylation quality (Berlec and Strukelj, 2013; Butler, 2006; Chen and Harcum, 2005;
deZengotita et al., 2002; Gawlitzek et al., 1999; Hansen and Emborg, 1994; Jenkins,
1996; Jenkins et al., 1996; Miller et al., 1988; Quek et al., 2010; Reuveny et al., 1986;
Schneider et al., 1997; Yang and Butler, 2000a). Specifically, elevated ammonium levels
reduce protein glycosylation quality, by decreasing terminal sialylation levels as well as
both the tetraantennary and tetrasialylated oligosaccharide structures, while increasing
molecular heterogeneity (Baker et al., 2001; Chen and Harcum, 2005; Yang and Butler,
2000b, 2002). All of these factors lower the efficacy of a therapeutic glycoprotein and
having to remove these isoforms increases costs (Jenkins et al., 1996).
Interestingly, elevated ammonium has been shown to lead to higher intracellular
nucleotide sugar pools, which serve as precursors for many glycosylation reactions, in
NS0 cells (Ryll, 1994; Valley et al., 1999). Additionally, when cells are supplemented
with

glycosylation

precursors,

such

as

N-acetylmannosamine

and

galactose,

glycosylation was not significantly increased, despite increased nucleotide sugar pools
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(Baker et al., 2001; Clark et al., 2005; Gu and Wang, 1998). Furthermore, cloning
additional copies of two genes encoding important glycosylation enzymes –
sialyltransferase and galactosyltransferase – produced only modest improvements in
protein glycosylation (Weikert et al., 1999).
In this research, we sought to expand our limited understanding of protein
glycosylation control, by investigating how elevated ammonium levels influence
glycosylation at the gene expression level. To this end, an Affymetrix-platform DNA
microarray was employed, that contains the known mouse glycosylation-related
nucleotide sequences and numerous housekeeping genes for mouse, the host organism of
the NS0 cell line. Elevated ammonium is known to significantly decrease protein
sialylation in NS0 cells (Baker et al., 2001), and the sialyltransferase gene has been
observed to be ammonium-sensitive in Chinese hamster ovary (CHO) cells (Chen and
Harcum, 2006), altered gene expression was expected in NS0 cells, as well. Additionally,
both CHO and NS0 cell lines are used to manufacture recombinant glycoproteins for
clinical therapies and can be cultured in defined media in suspension cultures (Gatti et al.,
2007). Initially, four culture conditions were compared – control, elevated ammonium,
elevated salt as an osmolarity control, and elevated ammonium with a proline addition, as
proline had been observed to reduce the negative effects of ammonium on product quality
for CHO cells. Additionally, the orthogonal gene expression quantification method realtime qRT-PCR was used to confirm the results observed for the elevated ammonium
culture condition using a newer media formulation.
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3.3 Materials and Methods
The NS0 cells (ECACC 85110503) for the DNA microarray studies were donated
to Clemson University by Merck, Inc, and originally from the European Collection of
Cell Cultures. The NS0 cells for the real-time qRT-PCR studies were purchased from
Sigma (catalog no. 03061601— ECACC 85110503), where Sigma is the official US
distributor ECACC. NS0 cells are a mouse myeloma cell line with lymphoblast
morphology, non-secreting clone, and cholesterol auxotroph (Whitford, 2003). The NS0
cell lines used in these studies do not express a recombinant protein and represent the
host strain or the fusion partner for generation of hybridomas. For the DNA microarray
studies, an animal-derived protein-free media, HyQ ADCF-Mab (Hyclone) (firstgeneration media), was used and supplemented with 5 mM glutamine (Hyclone) and LS250 cholesterol supplement (4 mL per L media; Hyclone) in 1000 mL spinner flasks with
100 rpm agitation. For the cultures analyzed by real-time qRT-PCR, a second-generation
ADCF-Mab media (Thermo Hyclone) was used with a LS-1000 cholesterol supplement
(1 mL per L media; Hyclone) in 250 mL spinner flasks with 60 rpm agitation. Both
studies cultured the cells in humidified incubators at 37°C and 5% CO2. A common seed
culture was used to inoculate the control and treatment cultures, which were then cultured
in parallel. Biological triplicates were used for each condition examined. The ammonium,
salt, and proline stock solutions (all 5000 mM) were prepared in Milli-Q water and added
to the fresh media prior to the addition of cells. Milli-Q water was added to the control
and treatment cultures to normalize culture volumes and media concentrations (1 to 6 mL
per L). For initial growth studies, the culture conditions were basal media (control), and
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basal media supplemented with either 10 mM NH4Cl (ammonium), 10 mM NaCl (salt),
or 10 mM NH4Cl and 20 mM proline (proline). For the DNA microarray studies, the
culture conditions were basal media (control), and basal media supplemented with either
5 mM NH4Cl (ammonium), 5 mM NaCl (salt), or 5 mM NH4Cl and 10 mM proline
(proline). Osmolality of the media was measured using the freezing point method
(Schmelzer et al., 2000). The 5 mM additions increased osmolality by approximately 30
mOsm/kg, or only approximately 10%. Cell concentrations and viabilities were
determined by the Trypan blue exclusion method. Glucose was measured using a Blood
Glucose Analyzer (Hemacue). For the real-time qRT-PCR studies, the control and
elevated ammonium (5 mM) conditions were investigated. Cell concentrations were
quantified using the Scepter 2.0 Handheld Automated Cell Counter (Millipore). Glucose
and lactate were quantified using a Yellow Springs Instruments (Yellow Springs, OH)
2900 Biochemistry Analyzer.

RNA isolation
Cells were harvested by centrifugation at 3000 g for 5 min at 4°C in order to
obtain total RNA. The supernatant and pellets were saved at –20°C and –80°C,
respectively. Total RNA was isolated from the pellet using the RNAqueous-MidiTM kits
(Ambion), except the DNase treatment was increased to 2 μl of DNase and 1 hour. The
total RNA was further purified using the RNeasy Qaigen kit. RNA concentrations were
determined using a Ribogreen RNA quantification kit (Molecular Probes).
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DNA microarray analysis
Ten micrograms of total RNA (1 μg/μl) per sample was sent to the Consortium
for Functional Genomics for gene expression analysis on the GLYCOv3 Chip. The
Affymetrix-platform and data discussed in this publication have been deposited in
NCBI's Gene Expression Omnibus (Barrett et al., 2013) and are accessible through GEO
Platform

accession

GPL11096:

http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?

acc=GPL11096. The GLYCOv3 Chip Mouse Gene List can also be found at
http://www.functionalglycomics.org/static/consortium/resources/resourcecoree.shtml
(accessed April 10, 2014). These Glyco-Gene Chips are available to academic
researchers through a proposal process. The GLYCOv3 Chip contains 952 mouse
glycosylation-related

probes,

including

probes

for

the

sialyltransferase,

galactosyltransferase, sialidase, and fucosyltransferase genes. All 14 of the genes
(including the two housekeeping genes), previously investigated in CHO cells under
elevated ammonium by qRT-PCR, were on GLYCOv3 Chip (Aebi et al., 2000).
Biological triplicates for each condition were analyzed for a total of 12 DNA
microarrays.
Briefly, upon arrival of the total RNA, the Consortium for Functional Genomics
staff assessed the RNA quality using a Bioanalyzer (Agilent). Then, the RNA was reverse
transcribed in the presence of the fluorescently-labeled dNTP analogues. The labeled
RNA was then hybridized to the GLYCOv3 Chip, including the GeneChip Eukaryotic
Hybridization Controls, Bacteriophage Controls, and GC Controls (Affymetrix). The
GeneChip Eukaryotic Hybridization Controls contains a mixture of four biotin-labeled
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cRNA controls with staggered concentrations. The Bacteriophage Controls contains four
bacteriophage P1 oligonucleotides, and the GC Control contains 44 random and specific
GC oligonucleotides that provide titrated fluorescent signals. These controls provide
calibrated intensities that are used to confirm hybridization and chip integrity. These
controls are used to determine the “Present” and “Absent” calls for a gene. Additionally,
there are 104 housekeeping mouse gene controls on the chip as probes. The GLYCOv3
Chips were scanned with a confocal scanner, which calculated the signal intensities
associated with each oligonucleotide on the GLYCOv3 chip into image files viewable by
researchers. The data was reviewed for quality control at the Consortium for Functional
Genomics, where the data files were processed and returned as .CEL files. GeneSpring®
imported the .CEL data, and each gene was then normalized to the total intensity of the
chip. The data discussed in this publication have been deposited in NCBI's Gene
Expression Omnibus (Barrett et al., 2013) and are accessible through GEO Series
accession number GSE28920
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28920).

Real-time qRT-PCR analysis
The cDNA was synthesized using 1 μg of total RNA from each sample as
template using Retroscript Kit (Life Technologies). Real-time RT-PCR was performed
with Quantitect SYBR Green PCR Kit (Qiagen) using primers designed for five
glycosylation-related genes: solute carrier family 35 (CMP-sialic acid transporter)
[Slc35a1], ST3 β-galactoside α-2,3-sialyltransferase 3 [St3gal3], ST3 β-galactoside α-
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2,3-sialyltransferase 4 [St3gal4], ST3 β-galactoside α-2,3-sialyltransferase 6 [St3gal6],
β(1,4)-galactosyltransferase [B4galt1], and two endogenous control genes: Actin, beta
(Actb) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) in a Rotor-Gene 3000
Real-Time Thermal Cycler (Qiagen). Primer sequences are listed in Table 3.1. Relative
∆∆C

gene expression levels were calculated using the 2-

T

method with Gapdh as an internal

standard (Livak and Schmittgen, 2001).

Statistical analysis
For the DNA microarray data, a Welch ANOVA test using a Benjamini and
Hochberg false discovery rate correction was used for the multiple comparisons (p ≤
0.05, p ≤ 0.10, and p ≤ 0.99) with Tukey Post-Hoc tests. ANOVA analysis was used to
analyze the effect of ammonium on cell densities and growth rates (p ≤ 0.05). For real
time qRT-PCR, a student’s two-tailed t-test was employed to determine the significant
differences between groups, with p ≤ 0.05 being considered as statistically different.
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Table 3.1 PCR primer sequences for analysis of NS0 cells. M. musculus primer
sequences used for qRT-PCR analysis of elevated ammonium for NS0 cultures.
Gene

Actb
B4galt1
Gapdh
Slc35a1
St3gal3
St3gal4
St3gal6

Forward Primer Sequence

5'- GGT GTG ATG GTG GGA ATG G -3'
5' TGT CTC TCC TCA CAA GGT GG 3
5'- GCA AAT TCA ACG GCA CAG TC -3'
5'- TCT ACA CGT CAG TGG TGG TG -3'
5' CTG TGA TGA AGT GGC AGT CG 3'
5'- GAG TGA TAA GAA GCG GGT GC -3'
5' CCC AAA CAC CCT ACA ACA GG 3'
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Reverse Primer Sequence

5'- TCT CCA TGT CGT CCC AGT TG -3'
5' TGG TGT CTC CAG CCT GAT TG 3'
5'- ATA CTC AGC ACC GGC CTC AC -3'
5'- AGC TCC CAG TGC AAA TGA AAG -3'
5' CTC TCG CTG GAT GTT GTG TG 3'
5'- GCT TGT CTG CTG CAA TCT CC -3'
5' ACA TGG TGG CAT TCC CGT AG 3'

3.4 Results
To study the impact of elevated ammonium on gene expression using a DNA
microarray, NS0 cells were cultured under four conditions: normal (control), elevated
ammonium, elevated salt, and elevated ammonium with proline. The elevated salt
treatment provided an osmolality control, while the proline-addition cultures were
included because previous elevated ammonium studies in CHO cells showed that a
proline-addition could reduce ammonium-induced growth inhibition and restore some
protein glycosylation (Chen and Harcum, 2005). Initially, NS0 were cultured under 10
mM ammonium, 10 mM salt, 10 mM ammonium with 20 mM proline; however, the
growth rates of the ammonium-stressed cultures (with and without proline) were only
approximately one-fifth of the control culture, while the salt-stressed culture growth rate
was only approximately one-third of the control culture (data not shown). These very
different growth rates were unquestionably too great to allow for meaningful gene
expression comparisons, as samples would have to be taken at different culture ages to
obtain similar cell densities, and the cells would be in very different growth phases.
Interpretation of data from cultures with multiple growth rate and cell densities
differences would have required significantly more samples than were available due to
the high cost of DNA microarrays. Thus, cell growth rates were examined at 5 mM
ammonium, 5 mM salt, and 5 mM ammonium with 10 mM proline. Previous studies have
shown that ammonium levels as low as 2 mM can negatively impact glycosylation, thus a
5 mM ammonium treatment was deemed to have the characteristics representative of
elevated ammonium (Andersen et al., 1994; Andersen and Goochee, 1995). The growth
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profiles for NS0 cells cultured under 5 mM ammonium, 5 mM salt, and 5 mM
ammonium with 10 mM proline are shown in Figure 3.1 for the control and treated
cultures shown as the average of triplicates with 95% confidence intervals. The ANOVA
analysis of the growth rates and final cell densities indicated that the culture treatment
was a significant factor. Further post hoc testing using paired t-tests showed no
differences for growth rates between the control and treated cultures (p > 0.05); however,
the paired t-tests did indicate that the final cell densities were different (p ≤ 0.05). The
final cell densities for the control, 5 mM ammonium, and 5 mM ammonium/10 mM
proline cultures were all different from each other; however, the final cell densities for
salt cultures were not different from the control cultures (p > 0.05), and were not different
from 5 mM ammonium cultures (p > 0.05). The final cell densities for salt cultures were
also different from the 5 mM ammonium/10 mM proline cultures (p ≤ 0.05). These
profiles and statistical analysis indicate that the culture conditions were very similar, such
that growth rate differences would not be a contributing factor in any gene expression
differences that might be identified and the final cell densities would only be a minor
factor.
For the DNA microarray experiments, the 90-h time point (indicated by a vertical
line in Figure 3.1) was selected for RNA isolation and DNA microarray analysis to
identify genes sensitive to ammonium in the exponentially growing cultures. The gene
expression analysis was performed at the 90 h time point to balance several experimental
constraints. The cultures needed to be in the same growth phase and at similar cell
densities, where mid-exponential growth was desired. The cell density needed to be
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Figure 3.1. Growth profiles for NS0 cells. NS0 cells were cultured under control,
elevated ammonium, elevated salt, and elevated ammonium with proline conditions in a
first-generation HyQ ADCF-Mab media with LS-250 cholesterol. RNA samples were
taken at 90-h for gene expression analysis by DNA microarrays as shown by the vertical
line. Error bars represent 95% confidence intervals.
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sufficiently high to obtain enough total RNA from a single sample (50 mL). And,
exponential growth after sampling needed to verifiable after sampling, at least another 12
hours of growth possible in the media. Additionally, due the cost of DNA microarrays,
only 12 DNA microarrays were available to the project from the Scripps Institute. Thus,
for four culture conditions to be sampled in triplicate, the experiment was limited to one
time point. As shown in Figure 3.1, all cultures continued to grow exponentially for at
least another 12 hours. GeneSpring® was used to analyze the gene expression levels
using a Welch ANOVA test with a Benjamini and Hochberg false discovery rate
correction for the four conditions, where each chip was normalized to total intensity.
Initially, the p-value cut-off was set to p ≤ 0.05; however, at this level no genes were
determined to be significantly different. Due to the high levels of noise commonly
observed in biological systems, the p-value cut-off was increased to p ≤ 0.10 and the data
re-examined; however, even at this level no genes were identified as being significantly
different between the conditions. In order to better understand why the ANOVA analysis
was not identifying any significant genes, the p-value was increased to p ≤ 0.99, and all
genes passed, as expected. The gene with the lowest p-value had a p-value of p = 0.964,
which indicates no significant difference in gene expression levels between the four
conditions examined, when gene intensities were normalized to the total chip intensity.
This means that none of the glycosylation genes had different gene expression levels
between any of the four conditions.
Further analysis of the DNA microarray data demonstrated that the Affymetrix
titrated controls had the expected dynamic range, indicating the gene chips were
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responsive to sample-level changes. It was also determined that noise was not the reason
for the high p-values as shown in Figure 3.2 by the high-level of reproducibility of the
biological replicates and low noise to signal ratio. Figure 3.2 only shows the gene
expression levels for the twelve glycosylation and two housekeeping genes previously
examined for CHO cells, as a graph of all 952 unchanged genes would be unreadable
(Chen and Harcum, 2006). Table 3.2 includes these selected genes with official Mus
musculus gene names, abbreviations, and Genbank accession number on the GLYCOv3
DNA microarray and the CHO cell (Cricetulus griseus) homolog, common name, and
GenBank accession number. The gene expression levels for the NS0 cell culture
conditions are connected between the conditions only to improve visualization. The
standard error bars for each condition and gene are shown (and are barely visible for
some genes). These very small standard error bars support that there are “no significant
difference” due to the underlying behaviour of the biological system, and not due to a
high signal-to-noise ratio in the data. Note: the Fut4 and Neu2 genes were identified as
“Absent”, not expressed, under these conditions in NS0 cells. These two genes are only
shown to highlight the range of magnitude for gene expression and because these are the
homologs of the CHO genes previously reported to be sensitive to ammonium. At the
other extreme are the housekeeping genes, which are commonly among the mostly highly
expressed genes within an organism. These gene expression data for these glycosylation
and housekeeping genes demonstrate the well-distributed dynamic range of gene
expression levels within the study and detected by the DNA microarrays. Thus, as further
shown in Figure 3.2, no glycosylation-related genes had significantly different gene
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Figure 3.2. Gene expression levels for 12 key glycosylation genes and two
housekeeping genes in NS0 cells. The NS0 cells were cultured under control, elevated
ammonium, elevated salt, and elevated ammonium with proline conditions in a firstgeneration HyQ ADCF-Mab media with LS-250 cholesterol. Data points between the
culture conditions are connected to assist with visualization only. The Fut4 and Neu2
genes were “Absent”, i.e., not expressed, under these conditions. Abbreviations are listed
in Table 3.2. Standard error bars are shown.
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Table 3.2 Selected M. musculus and Cricetulus griseus glycosylation and
housekeeping genes.
Abbreviation

Official Name

Actb

Actin, beta
UDP-Gal:betaGlcNAc
beta 1,4-galactosyl
transferase, polypeptide 1

B4galt1

GenBank
Accession #
(GLYCOv3)
M12481
NM_022305.2

Dpm1

dolichol-phosphate (betaD) mannosyltransferase 1

NM_010072.2

Fut4a

fucosyltransferase 4

NM_010242

Gapdh

glyceraldehyde-3phosphate dehydrogenase

M32599

Gnpda1

glucosamine-6-phosphate
deaminase 1

NM_011937

Gnpnat1

glucosamine-phosphate
Nacetyltransferase 1

NM_019425

Gp1

glucose phosphate
isomerase 1

NM_008155

Mgat1

mannosideacetylglucosam
inyltransferase 1

NM_010794.2

Neu2 a
Slc35a1
Slc35a2
St3gal3b
St3gal4
St3gal6 a,b
Ugp2

neuraminidase 2
solute carrier family 35
(CMP sialic acid
transporter), member 1
solute carrier family 35
(UDPgalactose
transporter), member A2
ST3 beta-galactoside
alpha-2,3sialyltransferase 3
ST3 beta-galactoside
alpha-2,3sialyltransferase 4
ST3 beta-galactoside
alpha-2,3sialyltransferase 6
UDP-glucose
pyrophosphorylase 2

NM_015750

Gene Name (From Chen
and Harcum, 2006)

GenBank
Accession #

Actin
β(1,4)Galactosyltransferase
(β(1,4)-GT)
Dolicholphosphate
mannose
synthase (DPMS)
α(1,3)-Fucosyltransferase
(α(1,3)-FT)
Glyceraldehyde-3phosphate
dehydrogenase (GAPDH)
Glucosamine-6-phosphate
isomerase Mesocricetus
auratus (G6PI)
UDP-GlcNAc:UDP Nacetyl-Dglucosamine-1phosphate transferase
(UDP-NAG)
Glucose phosphate
isomerase (GPI)
N-acetylglucosaminyltransferase
(NAGAT)
Sialidase

U20114.1
AF318896.1
AF121895.1
AF090449
X52123.1
X94699.1

U09453.1
Z37977.1
U65791
U06143.1

NM_011895

CMP-sialic acid
transporter (CMPSiaT)

Y12074.1

AB027147

UDP-galactose
transporter (UDPGalT)

AF299335.1

NM_009176.2

NA

NM_009178.2

Gal(β -1,3/4)-GlcNAcα(2,3)-sialyltransferase
IV (α(2,3)-ST)

AY266675.1

NM_018784

NA

NA

AF424698

UDP-glucosepyrop
hosphorylase (UDP-GPP)

AF004368.1
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NA

Table 3.2 (Continued): Selected M. musculus and Cricetulus griseus glycosylation
and housekeeping genes. Also listed are gene abbreviations, official names, and
Genbank accession numbers.

a Fut4 , Neu2, and St3gal6 were "Absent", i.e., not expressed as assessed by DNA microarray under the
condition studied.

b St3gal3 and St3gal6 are only shown quantitatively by real time qRT-PCR

NA – Not Applicable: Gene was not examined in Chen and Harcum, 2006.
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expression levels between the four conditions examined using the DNA microarray for
the NS0 cultures.
As DNA microarrays are not sensitive to small gene expression changes, and to
confirm these surprising gene expression results, the control and elevated ammonium
conditions of the experiment were repeated and the gene expression changes were
analyzed using real-time qRTPCR, an orthogonal and more sensitive gene expression
quantification method (Canales et al., 2006; Provenano and Mocellin, 2007; Schefe et al.,
2006; Wurmbach, 2009). For the real-time qRT-PCR experimental repeats, several minor
changes were necessary. Specifically, the protein-free, animal-free media originally used
for the microarray experiments was no longer available, so the next generation of that
media was used. The LS-1000 cholesterol supplement was used instead, since the
previous LS-250 supplement was unavailable. The culture volume was decreased from
1000 mL to 250 mL, since less total RNA is needed to perform real-time qRT-PCR
analysis. New NS0 cells were purchased from the European Collection of Cell Cultures
via Sigma. The second-generation media and LS-1000 supplement resulted in higher
growth rates and higher final cell concentration for both the control and elevated
ammonium cultures. Figure 3.3 shows the cell growth profiles for the control and
elevated ammonium cultures as the average of triplicates with 95% confidence intervals.
As with the DNA microarray experiment, the control NS0 cultures achieved higher final
cell concentration than the ammonium-stressed cultures. Three different time points
during the exponential growth phase were selected for RNA harvesting: 63-h, 66-h, and
72-h. These time points were chosen to obtain similar cell densities as the NS0 cultures
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Figure 3.3 Growth profiles for NS0 cells cultured under control and elevated
ammonium conditions. NS0 cells were grown in a second-generation ADCF-MAb
Media with LS-1000 cholesterol. RNA samples for real-time qRT-PCR were taken at 63h, 66-h, and 72-h for gene expression analysis as shown by the vertical lines. Error bars
represent 95% confidence intervals.
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harvested for the DNA microarray study to allow for more appropriate comparisons. The
real-time qRT-PCR analysis examined five glycosylation and two housekeeping genes:
Slc35a1, B4galt1, St3gal3, St3gal4, and St3gal6, where Actb and Gapdh served as
housekeeping genes for quantification. These five glycosylation genes were selected
because these genes represent key control reactions that significantly impact a
biopharmaceuticals efficacy (Damiani et al., 2009; Zhang et al., 1998). Additionally,
St3gal4 and B4galt1 gene expression was sensitive to ammonium for CHO cells (Chen
and Harcum, 2006), thus these two genes were thought to be more likely to have
detectable changes in NS0 than genes that were insensitive to ammonium in CHO cells.
The Slc35a1 gene product is a membrane protein responsible for nucleotide sugar
transport into the Golgi (Bill et al., 1998). The B4galt1 gene product catalyses the linkage
of a galactose onto N-acetylglucosamine on a glycoprotein (Kotani et al., 2001). The
product of the St3gal3, St3gal4, and St3gal6 genes catalyse the addition of a sialic acid
on the terminal galactose of a glycoprotein, which increases the efficacy of many
therapeutic glycoproteins (Bill et al., 1998; Butler and Meneses-Acosta, 2012). The M.
musculus primer sequences for these seven genes can be found in Table 3.1.
The normalized gene expression levels for Slc35a1, B4galt1, St3gal3, St3gal4,
and St3gal6 are shown in Figure 3.4 normalized to Gapdh of the time 63-h control
cultures. Both Gapdh and Actb did not changed throughout the study (ANOVA, p >
0.05), as expected. Additionally, there was no statistical difference between the control
and ammonium cultures at any time point for the five-glycosylation genes, and these gene
expression levels did not change across the nine hours examined (p > 0.05). To highlight
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Figure 3.4 Gene expression for Slc35a1, B4galt1, St3gal3, St3gal4, and St3gal6.
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Figure 3.4 (Continued). Gene expression for Slc35a1, B4galt1, St3gal3, St3gal4, and
St3gal6. NS0 cells were cultured under control and elevated ammonium conditions in a
second generation ADCF-MAb Media with LS-1000 cholesterol. The normalized gene
expression levels for the glycosylation genes A) Slc35a1, B) B4galt1, C) St3gal3, D)
St3gal4, and E) St3gal6 assessed by real-time qRT-PCR. Gene expression levels were
analyzed at 63-h, 66-h, and 72-h, and were normalized to the 63-h time point and Gapdh.
Error bars represent 95% confidence intervals. The dark gray bars represent control
cultures, while the white bars represent the elevated ammonium cultures.
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Table 3.3 Statistics on gene expression levels. The t-tests between the control and
ammonium-treated cultures for the five genes determined that the gene expression levels
were not different (p > 0.05). The p-values are listed for each pairs for the three time
points examined, which correspond to the error bars shown in Figure 3.4.
Gene
B4galt1
Slc35a1
St3gal3
St3gal4
St3gal6

63-h
0.89
0.89
0.33
0.62
0.97

Significance level (p-value)
66-h
0.33
0.16
0.60
0.85
0.85
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72-h
0.26
0.51
0.37
0.96
0.87

that these gene expression levels were not different, Table 3.3 lists the p-values for the
paired t-test p-valves for each time point. Additionally, the relative expression levels of
the St3gal3, St3gal4, and St3gal6 genes real-time qRT-PCR was consist with the relative
levels observed by DNA microarrays, where the expression levels were St3gal4 >
St3gal3 >> St3gal6. Thus, real-time qRT-PCR analysis demonstrates that NS0 cells are
not sensitive to 5 mM ammonium with respect to these five glycosylation-related genes.
And, the real-time qRT-PCR results confirm the DNA microarray results as accurate,
where the DNA microarray analysis demonstrated that none of the known glycosylationrelated genes were sensitive in NS0 cells at 5 mM ammonium.
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3.5 Discussion
Gene expression studies have been conducted on both NS0 and hybridoma cells
lines under hyperosmotic pressure (Gao et al., 2004; Shen and Sharfstein, 2006). Wu et
al. (2004) examined antibody production in NS0 cells, while Shen and Sharfstein (2006)
investigated gene expression changes in OKT3 cells, a hybridoma line, due to
hyperosmolality (Shen and Sharfstein, 2006; Wu et al., 2004). Wu et al. (2004) focused
their analysis on the cell physiology, thus providing few specific gene details; however,
they did report that three carbohydrate genes were upregulated while one carbohydrate
gene was down-regulated. Shen and Sharfstein (2006) used the Affymetrix Gene Chip
MOE430A, which contains over 14,000 genes and 4000 EST probe sets. The GLYCOv3
and MOE430A Chips have 482 genes in common. Of these, only two of the incommon
genes were identified as sensitive to hyperosmolality in OKT3 cells (glucosamine-6phosphate deaminase, and hexokinase 1, GenBank accession nos. NM_011937 and
NM_010438, respectively). If the responses were proportional to the stress introduced,
then the much lower osmotic level used in this NS0 cell study was unlikely to cause
changes in gene expression that were significant enough to detect, as these genes only
changed 2-fold under the hyperosmotic stress.
The NS0 cells used in this study did not produce a recombinant protein. A study
that compared non-producing (parental) and producing (monoclonal antibody) strains of
NS0 cells using DNA microarrays identified 104 genes with differential gene expression
(Khoo et al., 2007). The functional annotation of these genes determined that the
differentially expressed genes were involved in protein synthesis, lipid metabolism, and
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cell cycle regulation; however, none of these affected genes were glycosylation-related.
The absence of glycosylation-related genes sensitive to ammonium in the current study
cannot be entirely attributed to the non-producing status of the strain; however, it is
recognized that any genetic modifications could influence the cells’ response to elevated
ammonium. Consequently, the current study provides a baseline for future quantification
of the effects of elevated ammonium on recombinant NS0 cells. Sodium butyrate is cell
culture media additive than increases productivity, yet has been observed to have variable
effects on protein glycosylation where most studies have been conducted only with CHO
cells (Chen et al., 2011; Chung et al., 2001; Cost et al., 2010; Crowell et al., 2008;
Etchevarry and Ryll, 1998; Hong et al., 2011; Hossler et al., 2009; Lee et al., 2014; Liu et
al., 2014; Mohan and Lee, 2009; Sung and Lee, 2005; Sunley and Butler, 2010; Yee et
al., 2008a; Yee et al., 2008b). The effects of sodium butyrate on gene expression have
been examined in both CHO and NS0 cell using two CHO cell and mouse DNA
microarrays developed in-house (Gatti et al., 2007). Both CHO and NS0 cells were
studied with cross-species DNA microarray hybridization, in addition to the speciesspecific DNA microarray hybridization. These studies were conducted to corroborate
physiology and gene expression observations (Gatti et al., 2007). Both in-house DNA
microarrays contained glycosylation-related genes (Korke et al., 2004; Wlaschin et al.,
2005); however, which is unknown. Interestingly, their gene expression analysis did not
identify any glycosylation-related genes with significant expression changes due to
sodium butyrate in the CHO and NS0 cell lines (Gatti et al., 2007). More recently, 52
glycosylation-related gene expression levels have been quantified in recombinant CHO
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cells under sodium butyrate (Lee et al., 2014). Despite several biosynthetic genes having
slightly higher levels under sodium butyrate, the glycoprotein most likely had poorer
quality due to increased sialidase (Neu1) gene expression levels and lower b4galt2 and
st3gal3 levels, both critical sialic acid biosynthesis genes (Lee et al., 2014). These
differences in gene expression responses might be attributable to the nature of these cells.
NS0 cells are a cancer cell line, while CHO cells, despite being immortal are not a
cancerous cell line (Wlaschin et al., 2006).
The detrimental effects of ammonium on cell growth, protein productivity, and
protein glycosylation has results in studies to reduce the major source of ammonium, the
glutamine. Early studies that controlled glutamine with fed-batch techniques, reported
decreased protein glycosylation quality (Wong et al., 2005). These early results selected
the target glucose and glutamine levels arbitrary, where is possible, their early targets in
the ground breaking approach were just too low, but their approach was correct (Young,
2013). Other research groups have replaced the glutamine with alternative sources
concurrent with reducing the levels in CHO cell cultures with improved results or
adapted cells to growth in glutamine-free media (Kim et al., 2013; Taschwer et al., 2012).
And more recently, three different TCA cycle intermediates, α-ketoglutarate, citric acid,
and succinic acid, were examined for recombinant CHO cells to reduced ammonia
accumulation in culture medium (Ha and Lee, 2014). The α-ketoglutarate replacement
decreased the growth rate, but also increased sialylation and decrease ammonium
accumulation. The observed sialylation increase was correlated with increased ST3gal
and decreased Neu enzyme activity (Ha and Lee, 2014). Interestingly, the relative
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abundance of the Neu1, Neu2, and Neu3 genes shown in Kim et al., 2013 are
significantly different than the relevant abundance of the Neu1, Neu2, and Neu3 proteins
shown in Ha and Lee, 2014 for the control cultures, albeit the studies are from the same
laboratory with different CHO cell host cell lines. These results demonstrate that gene
expression and protein levels are not always proportional. Taken together, the gene
expression results for NS0 cells and the glutamine substitution outcomes for CHO cells
suggest that enzyme or substrate-level control is likely a very significant factor with
respect to ammonium affects on protein glycosylation in NS0 cells.

81

3.6 Conclusion
Sialyltransferase gene expression was anticipated to be significantly different
between the control and elevated ammonium cultures for the NS0 cells (Chen and
Harcum, 2006), since previous NS0 cell culture experiments observed elevated
intracellular nucleotide sugar pools in NS0 cells compared to CHO cells (Baker et al.,
2001). Also, it was anticipated that other glycosylation genes would be identified as
ammonium-sensitive by the NS0 cell experiments, since ammonium adversely affects
protein glycosylation. However, the results of this work indicate that the ammoniumsensitivity in NS0 cells for protein glycosylation is not at the gene expression level. Thus,
the further studies should focus on translational and substrate-level control as the
mechanism by which elevated ammonium impacts protein glycosylation changes in NS0
cells.
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CHAPTER FOUR: EXPANSION OF MESENCHYMAL STEM CELLS
UNDER ATMOSPHERIC CARBON DIOXIDE

4.1 Abstract
Stem cells are needed for an increasing number of scientific applications,
including both fundamental research and clinical disease treatment. To meet this rising
demand, improved expansion methods to generate high quantities of high quality stem
cells must be developed. Unfortunately, the bicarbonate buffering system – which relies
upon an elevated CO2 environment – typically used to maintain pH in stem cell cultures
introduces several unnecessary limitations in bioreactor systems. In addition to artificially
high dissolved CO2 levels negatively affecting cell growth, but more importantly, the
need to sparge CO2 into the system complicates the ability to control culture parameters.
This control is especially important for stem cells, whose behavior and phenotype is
highly sensitive to changes in culture conditions such as dissolved oxygen and pH. As a
first step, this study developed a buffer to support expansion of mesenchymal stem cells
(MSC) under an atmospheric CO2 environment in static cultures. MSC expanded under
atmospheric CO2 with this buffer achieved equivalent growth rates without adaptation
compared to those grown in standard conditions and also maintained a stem cell
phenotype, self-renewal properties, and the ability to differentiate into multiple lineages
after expansion.
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4.2 Introduction
Stem cells offer much potential for scientific applications. In addition to enabling
insights into developmental biology, pathology, and toxicology, stem cells also show
promise in treating human ailments such as spinal cord injuries, myocardial infarction,
Parkinson’s, type I diabetes, and sickle cell anemia (Berry et al., 2006; Hanna et al.,
2007; Ashton et al., 2011; Fernandes Platzgummer et al., 2011; Kinney et al., 2011;
Olmer et al., 2012; Serra et al., 2012; Alfred et al., 2011; Rodrigues et al., 2011). Many
treatments require large quantities of stem cells, but currently there are no readily
available sources that can meet these high demands (Fernandes Platzgummer et al., 2011;
Kinney et al., 2011; Zweigerdt, 2009; Shafa et al., 2011; Ratcliffe et al., 2012).
Consequently, in vitro expansion methods must be developed to generate high numbers
of stem cells (Kinney et al., 2011; Serra et al., 2012; Alfred et al., 2011; Shafa et al.,
2011; Yeatts et al., 2013; King and Miller 2007; Grolms et al., 2011). In addition to high
quantities, maintaining high quality in stem cell yields is equally important to maximize
treatment responses (Serra et al., 2012; King and Miller, 2007). The stem cell niche —
consisting of factors such as oxygen tension, pH, and mechanical forces — influences the
behavior of stem cells and dictates whether the stem cells will proliferate, differentiate, or
undergo apoptosis (Ashton et al., 2011; Serra et al., 2012; Yeatts et al., 2013; Grolms et
al., 2011; Papoutsakis, 2009; Wuertz et al., 2009; Frith et al., 2009; dos Santos et al.,
2010). Learning how these various factors regulate stem cell fate in vivo, and then
constructing systems that can replicate the desired conditions in vitro will be crucial
(Ashton et al., 2011; Yeatts et al., 2013). Through development of cost-efficient methods
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that allow maintenance of optimal culture parameters during in vitro expansion, it may be
possible to more effectively direct stem cell yields and enhance the clinical success of
stem cell-based therapies (Rodrigues et al., 2011; Shafa et al., 2011; Yeatts et al., 2013).
Stirred systems—in particular fed-batch, computer-controlled bioreactors—are
capably equipped to deliver high quantities of high quality mammalian cells due to
operational flexibility (Fernandes Platzgummer et al., 2011; Olmer et al., 2012; Ratcliffe
et al., 2012; Yeatts et al., 2013; King and Miller 2007; Grolms et al., 2011; Schroeder et
al., 2005). Bioreactors, where CO2 sparging is used for pH control, support the expansion
of mammalian cells in suspension (Fernandes Platzgummer et al., 2011; Rodrigues et al.,
2009). Expansion of anchorage-dependent cells, such as mesenchymal stem cells (MSC),
can also be achieved with the use of microcarriers in stirred bioreactors (Serra et al.,
2012; Alfred et al., 2011; Rodrigues et al., 2011; Sart et al., 2011). Through dynamic
monitoring and online control of parameters, stirred bioreactors can enable culture
conditions to be maintained within a desired range (Fernandes Platzgummer et al., 2011;
Olmer et al., 2012; Rodrigues et al., 2011; Ratcliffe et al., 2012; Grolms et al., 2011;
Schroeder et al., 2005). Additionally, bioreactors allow for scalability that is simply not
possible with other culture formats, potentially paving the way for delivery of the large
numbers of stem cells required for widespread clinical use (Olmer et al., 2012; Ratcliffe
et al., 2012; Grolms et al., 2009). However, the bicarbonate buffering system used to
regulate pH appears to be limiting the potential of stem cell expansion as it can hinder the
ability of stirred bioreactors to provide a highly consistent culture pH environment
(Rodrigues et al., 2011; Rodrigues et al., 2009; Goudar et al., 2006). The bicarbonate
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buffering system relies on the equilibrium between the CO2 gas sparged into the
bioreactor and the dissolved CO2 (dCO2) in the medium, which is maintained well above
physiological levels and can negatively affect cell growth and behavior (Rodrigues et al.,
2009; Goudar et al., 2006; Pattison et al., 2000; Zhang et al., 2010). This situation is
compounded by the production of CO2 by metabolically active cells (Goudar et al.,
2006). Previous efforts have been undertaken to remove excess dCO2 from the bioreactor
by adjusting the sparging profile; however, the coupling of the CO2 supply to the oxygen
supply complicates both dissolved oxygen and pH control (Goudar et al., 2006; Hu et al.,
2011). This mutual dependency leads to recurring cyclic fluctuations of both dissolved
oxygen and pH in bioreactors as efforts to regulate one inadvertently affects the other
(Olmer et al., 2012; Rodrigues et al., 2011; Grolms et al., 2009; Rodrigues et al., 2009;
Zhang et al., 2010; Yang et al., 2007; Osman et al., 2001). Other approaches to remove
dCO2 have modified the size of sparged bubbles, but this can compromise oxygen
transfer (Hu et al., 2011). Thus, methods to independently control dissolved oxygen and
pH may enable bioreactor systems to improve stem cell expansion as stem cells are
extremely sensitive to fluctuations in both dissolved oxygen and pH (Ashton et al., 2011;
Rodrigues et al., 2011; Grolms et al., 2009; Wuertz et al., 2009; dos Santos et al., 2010).
One simple method to reduce the dependence between dissolved oxygen and pH control
in mammalian cell culture is to decrease or eliminate the bicarbonate buffer’s role in pH
buffering. This would allow atmospheric CO2 levels to be used in the air/oxygen sparging
supplies. Several groups have developed media to support mammalian cell lines under an
atmospheric CO2 environment. Leibovitz (1963) developed the L-15 medium, which uses
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an amino acid buffer in addition to substituting galactose for glucose, for use in
mammalian cell culture (Leibovitz, 1963). Battista and Weiss (1991) developed a
medium for Chinese hamster ovary cells and baby hamster kidney (BHK) cells; however,
it is not appropriate for undifferentiated stem cell expansion, due to the presence of βglycerophosphate, which induces osteogenesis (Battista and Weiss, 1991; Fiorentini et
al., 2011). Goudar et al. (2006) developed a 3-(N-morpholino) propanesulfonic acid
(MOPS)-histidine buffer for BHK cells; however, the low pH of 6.8 makes it too acidic
for stem cells (Goudar et al., 2006). Swain and Pool (2009) investigated the use of
various nonbicarbonate buffers in Tyrode’s solution, composed of salt and glucose, for
potential use with in vitro fertilization, although they did not culture cells in their
proposed buffer (Swain and Pool, 2009). To our knowledge, attempts to expand stem
cells under an atmospheric CO2 environment have not been conducted.
The overall aim of this study was to develop a buffer system for a stem cell
medium that de-emphasized CO2-dependent pH buffering and to ensure that MSC
expanded in this medium under atmospheric CO2 behaved similarly to those expanded
under standard conditions. These initial studies were conducted in static cultures;
however, by eliminating the need for elevated CO2 sparging, large-scale stem cell
expansion could potentially be improved by preventing excessive dCO2 levels, as well as
enabling simpler controls to increase batch-to-batch reproducibility. The first goal of this
study was to determine whether MSC could be effectively expanded under atmospheric
CO2 levels as this has not yet been investigated. L-15 medium and various combinations
of MOPS-4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered media
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were examined to select a medium buffer that maintained growth rates and final cell
densities comparable to the standard buffer conditions without any prior adaptation
period. One MOPS-HEPES buffered medium was selected to address the subsequent
goals, where the second goal was to determine whether MSC maintained an
undifferentiated state and self-renewal ability when cultured in the MOPS-HEPES
buffered medium under atmospheric CO2 without prior adaptation. Histological staining
and stem cell-associated gene expression markers were compared for the undifferentiated
MSC cultured under the standard conditions and the MOPS-HEPES buffered medium
under atmospheric CO2. The third goal of the study was to assess the differentiation
potential of the MSC expanded under atmospheric CO2. Histological staining and
multiple lineage gene expression markers were compared for differentiated MSC that
were previously expanded under the standard conditions or in the MOPS-HEPES
buffered medium under atmospheric CO2. Finally, the fourth goal was to determine
whether MSC growth rates and stemness were maintained through multiple passages in
the MOPS-HEPES buffer under atmospheric CO2.
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4.3 Materials and Methods
MSC Expansion
Undifferentiated mouse MSC (Gibco) were maintained as anchorage-dependent
monolayers in T-75 flasks (Nunc) under 5% CO2 at 37°C in minimal essential medium-a
(MEM-α) (Gibco), which was supplemented with 10% fetal bovine serum (FBS)
(Gibco). For our custom compositions developed for atmospheric CO2 conditions, MOPS
and HEPES were added as buffering components, while sodium hydroxide was used to
adjust the initial pH. Leibovitz L-15 medium was also supplemented with 10% FBS. For
growth rate comparisons, undifferentiated MSC were initially seeded into 6-well plates
(Nunc) at 3.8 x 104 cells/well, corresponding to 4.0 x 103 cells/cm2. Warmed medium was
added to the wells (1.5 x 103 cells/mL). Plates were incubated under 5% CO2 or
atmospheric CO2 at 37°C. Cell growth in all three media was measured at five time
points over 57 h. Five parallel sets of cultures were grown for each condition. One set of
cultures was harvested at each time point. Each data point represents distinct independent
cultures in triplicate. Cell densities were quantified using the Scepter 2.0 Handheld
Automated Cell Counter (Millipore).

MSC Differentiation
For the differentiation experiments, undifferentiated MSC were grown for 48 h in
T-75 flasks at 37°C. The undifferentiated MSC were seeded at 4.0 x 103 cells/cm2 in
either the standard medium or MOPS-HEPES buffered medium. The standard medium
cultures were incubated under 5% CO2, while the MOPS-HEPES buffered medium
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cultures were incubated under atmospheric CO2. The undifferentiated MSC were
harvested and used to examine differentiation along the adipogenic, osteogenic, and
chondrogenic lineages. The StemPro Differentiation kits (Gibco) were used following the
manufacturer protocols. All differentiation cultures were incubated under 5% CO2 and
harvested at 16 days for analysis by histological staining and gene expression. The MSC
differentiation cultures were conducted in four triplicate sets, one set for each of the
histological staining and qRT-PCR analysis.

Extended MSC Expansion
Undifferentiated MSC were seeded at 4.0 x 103 cells/cm2 in either the standard
growth medium under 5% CO2 or the MOPS-HEPES buffered growth medium under
atmospheric CO2. One T-75 flask was used to seed 3 six-well plates in parallel for endpoint cell density analysis and a single T-75 flask for subsequent passages. MSC were
passaged every 60 h for five passages, which corresponds to approximately 75%
confluent and a 6.25-fold expansion at the end of each passage.

Histological Staining
Osteogenic activity was measured using the Alkaline Phosphatase Detection Kit
(Milipore). HCS LipidTox Green neutral lipid stain (Molecular Probes) was used to
detect the presence of lipids in the adipogenic cultures. The adipocyte samples were
mounted in SlowFade Gold Antifade reagent with DAPI (Molecular Probes), and imaged
using an Eclipse Ti Confocal microscope. Alcian Blue (Poly Scientific) was used to stain
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glycosaminoglycans in the chondrogenic cultures. Chondrogenic and osteogenic samples
were mounted using Permount (Fisher Scientific) and imaged using the Nikon AZ 100
Multizoom microscope.

Real time qRT-PCR
Total RNA was extracted from triplicate undifferentiated T-75 flask cultures or
triplicate differentiated T-25 flask cultures. The RNeasy Mini Kit (Qiagen) was used
following manufacturer’s protocol. cDNA was synthesized by Super-Script III FirstStrand Synthesis System for RT-PCR (Invitrogen) with 200 ng total RNA. RT2 SYBR®
Green qPCR Mastermix (SABiosciences) was used for qPCR analysis with MyiQ Optical
System Software Version 1.0 (Bio-Rad). Further data analysis was conducted using Realtime PCR Miner software (UC Berkeley). Normalized gene expression values were
obtained using the method previously outlined (Chen and Harcum, 2006). The primer
sequences are listed in Table 4.1.

Statistical Analysis
Statistical analysis of the growth rates, final cell densities, and gene expression
data was performed with SAS 9.3 using the general linear model procedure for the final
cell densities and gene expression levels (p ≤ 0.05) and the regression procedure for the
growth rate data (p ≤ 0.05).
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Table 4.1 PCR primer sequences for analysis of MSC.
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4.4 Results and Discussion
Formulation of a CO2-independent medium
Initially, the growth rate of undifferentiated MSC was evaluated in MEM-α
buffered with various concentrations of MOPS and HEPES under atmospheric CO2 by
endpoint assessment of cell densities. The range of MOPS and HEPES investigated were
12 to 18 mM. The cell densities using MOPS and HEPES were compared to the cell
densities obtained from the standard conditions using a common seed culture. Many of
the MOPS and HEPES combinations could achieve cell densities equal to that attained in
the standard medium under 5% CO2 (data not shown). The MOPS-HEPES buffered
medium selected to be examined further contained 12 mM MOPS, 12 mM HEPES, and 5
mM sodium bicarbonate (NaHCO3). This formulation was selected to minimize the
potential cytotoxic effects associated with HEPES buffer (Zigler et al., 1985). A low level
(5 mM) of NaHCO3 was added to the MOPS-HEPES buffered medium, because
bicarbonate is reported to be an essential cell nutrient for mammalian cells (Swim and
Parker, 1958).
There are several considerations when formulating a buffer for MSC expansion
under atmospheric CO2. Due to the multipotency of MSC, it is crucial that none of the
buffering components interfere with the normal behavior of undifferentiated MSC during
expansion. For instance, the β-glycerophosphate in Invitrogen’s CO2 independentmedium can induce osteogenesis, and therefore does not promote maintenance of an
undifferentiated MSC phenotype (Battista and Weiss, 1991; Fiorentini et al., 2011). At
the same time, the behavior of MSC is highly pH-dependent, so the buffering
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components must have sufficient buffering capacity within the desired pH range (Wuertz
et al., 2009). As Swain and Pool (2009) pointed out, pH buffering must also be
accomplished with buffer concentrations that are low enough to avoid cytotoxicity
(Swain and Pool, 2009). Their work demonstrated that buffers used in combination allow
for lower concentrations without compromising buffering capacity, a principle that was
used in our work. In short, the buffering components to be substituted for bicarbonate
must maintain pH effectively within a precise range while not altering the health or
phenotype of the MSC.

Undifferentiated MSC can be effectively expanded under an atmospheric CO2
environment while retaining stem cell characteristics
To evaluate the growth rates and final cell densities, undifferentiated
MSC were first expanded in standard MEM-α medium under 5% CO2 and this common
stock was used to seed subsequent cultures. The undifferentiated MSC were then grown
in the standard MEM-α medium and the MOPS-HEPES buffered MEM-α medium under
both 5% and atmospheric CO2 environments without prior adaptation. Additionally, the
undifferentiated MSC were grown under atmospheric CO2 in Leibovitz L-15 medium.
The L-15 medium was designed to support CO2-independent growth of mammalian cells,
but is now mainly used to grow specific cancer cell lines and buffer solutions while
performing analysis of cells under atmospheric conditions (Leibovitz, 1963; Maffia et al.,
2007; Mantegazza et al., 2008). To date, Leibovitz L-15 medium has not been
investigated for stem cell expansion. As expected, the cultures grown in the standard
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MEM-α medium under 5% CO2 had exponential growth without a lag phase, and the
cultures grown in the MEM-a standard medium under atmospheric CO2 failed to grow
(Figure 4.1A). In contrast, cultures grown in Leibovitz L-15 medium under atmospheric
CO2 had observable growth, albeit at a lower rate. The lower growth rate in the L-15
medium was most likely due to the medium’s buffering system and carbon energy source.
The L-15 medium relied on high amino acid concentrations to provide buffering capacity.
Elevated amino acids are not always problematic, but it has been observed that some
amino acids in elevated concentrations reduce growth rates in mammalian cells (Chen
and Harcum, 2005; Xing et al., 2011). Specifically, the L-15 medium contained 225 mM
alanine compared to 25 mM in the standard MEM-a medium (Leibovitz, 1963). The L-15
medium also substitutes galactose for glucose. Galactose has been implicated in shifting
cell metabolism from a predominantly glycolytic state to one relying more on oxidative
phosphorylation in several cell lines (Higuera et al., 2011; Aguer et al., 2011). Actively
growing cells appear to rely more heavily on glycolysis than oxidative phosphorylation
for energy production (Kinney et al., 2011; dos Santos et al., 2010; Pattappa et al., 2011),
which means galactose may not be a suitable primary carbon source for maintaining high
growth rates. Thus, the lower growth rates associated with MSC in the L-15 medium is
hypothesized to be due to the presence of high amino acid levels and the use of galactose
instead of glucose.
The undifferentiated MSC cultures grown in the MOPS-HEPES buffered medium
under 5% CO2 grew better than in Leibovitz L-15 medium (p ≤ 0.05), but still at a
suboptimal rate. The decreased growth rate in the MOPS-HEPES buffered medium under
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Figure 4.1 Proliferation of MSC. A: Growth profiles for MSC cultured in a standard
medium, a MOPS-HEPES buffered medium under both 5% and atmospheric CO2
conditions as well as the Leibovitz L-15 medium under atmospheric CO2. B: Negative
control staining for lineage-specific markers in undifferentiated MSCs cultured in MOPSHEPES buffered medium for 48-h. C: Oct4 normalized gene expression levels for
undifferentiated MSCs cultured in the standard medium in 5% CO2 (Std) and the MOPSHEPES buffered medium in atmospheric CO2 (M-H) for 48-h as indicated in panel A.
Error bars represent 95% confidence intervals.
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5% CO2 can be attributed to the low culture pH. More importantly, the undifferentiated
MSC cultures grown in the MOPS-HEPES buffered medium under atmospheric CO2 had
exponential growth without a lag phase. The observed growth rates for the
undifferentiated MSC in standard medium under 5% CO2 and the MOPS-HEPES
buffered MEM-α medium under atmospheric CO2 were not significantly different (p >
0.05) with observed growth rates of 0.033 h-1; which corresponds to a doubling time of
21-h. These results indicate that undifferentiated MSC can be expanded in MOPSHEPES buffered MEM-α medium under atmospheric CO2 at an equivalent rate to
undifferentiated MSC in standard MEM-α medium under a 5% CO2 environment, and
also achieve final cell densities that are not significantly different.
While growth rates were equivalent for the undifferentiated MSC cultured in the
standard MEM-α medium under 5% CO2 and the MOPS-HEPES buffered MEM-α
medium under atmospheric CO2, equally important is that the MSC maintained an
undifferentiated state and self-renewal abilities. The phenotype and multipotency of
undifferentiated MSC were assessed for MSC expanded for 48 h in the standard MEM-α
medium under 5% CO2 and the MOPS-HEPES buffered MEM-α medium under
atmospheric CO2. First, undifferentiated MSC were stained for markers of adipogenic,
osteogenic, and chondrogenic differentiation after expansion as negative controls. The
histological staining of the undifferentiated MSC showed absence of lineage markers
(Figure 4.1B), as expected, suggesting no gross signs of differentiation for both
conditions. Only the MSC cultured in the MOPS-HEPES buffered MEM-α medium
under atmospheric CO2 negative control stainings are shown (Figure 4.1B), as the MSC
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cultured in the standard MEM-a medium under 5% CO2 were not significantly different
from negative control the images provided in the standard staining protocol. The negative
control stainings for the undifferentiated MSC cultured in the MOPS-HEPES buffered
MEM-a medium under atmospheric CO2 can be compared with the positive control
stainings shown in Figure 4.2A, 4.3A, and 4.4A. Second, the MSC were analyzed for a
gene marker indicative of an undifferentiated stem cell state after expansion. Gene
expression levels for Oct4 (p = 0.75) (Figure 4.1C) were not significantly different
between undifferentiated MSC cultured in either the standard MEM-α medium under 5%
CO2 and the MOPS-HEPES buffered MEM-a medium under atmospheric CO2,
representing a similar extent of stemness.
These results indicate that undifferentiated MSC can be expanded under
atmospheric CO2 without compromising growth rates or the stem cell phenotype as
determined by gene expression markers, and supported by the undifferentiated appear
under histological staining. This is important because many MSC-based treatments rely
on undifferentiated MSC. Even in applications where the differentiated progeny of MSC
are desired, differentiation is typically induced after initial expansion generates a
sufficient quantity of undifferentiated MSC (Sart et al., 2011). These results indicate that
MSC can be effectively expanded without prior adaptation to the MOPS-HEPES buffer
and atmospheric CO2 conditions. The lack of an adaptation phase would allow for easier
translation to clinical applications.
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MSC retain multilineage differentiation potential after prior expansion under
atmospheric CO2
In order to characterize the differentiation potential of MSC cultured under
atmospheric CO2, cells were obtained from T-75 flasks that had been cultured for 48 h in
either the standard MEM-α medium under 5% CO2 or the MOPS-HEPES buffered
MEM-a medium under atmospheric CO2. These MSC were then differentiated along the
adipogenic, osteogenic, and chondrogenic lineages under 5% CO2 to assess multipotency.
As shown in Figure 4.2A, staining for lipid vesicle formation indicated a similar extent of
adipogenic differentiation between the two conditions. Also, adipogenic gene expression
levels for lipoprotein lipase (p = 0.095), PPARγ2 (p = 0.86), and C/EBPα (p = 0.47) were
not significantly different between the two conditions (Figure 4.2B). As shown in Figure
4.3A, staining for alkaline phosphatase activity indicated a similar extent of osteogenic
differentiation between the two conditions. Also, osteogenic gene expression levels for
collagen I (p = 0.89), osteonectin (p = 0.088), and CBFα1 (p = 0.99) were not
significantly different between the two conditions (Figure 4.3B). As shown in Figure
4.4A, staining for glycosaminoglycan production indicated a similar extent of
chondrogenic differentiation between the two conditions. Also, chondrogenic gene
expression levels for collagen II (p = 0.22), aggrecan (p = 0.55), and Sox9 (p = 0.94)
were not significantly different between the two conditions (Figure 4.4B). These results
demonstrate that the tri-lineage differentiation potential of undifferentiated MSC along
the adipogenic, osteogenic, and chondrogenic lineages were not impacted by prior
expansion
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Figure 4.2. Adipogenic differentiation of MSC. A: Histological staining of MSC
cultured in a standard medium under 5% CO2 (Std) and in a MOPS-HEPES buffered
medium under atmospheric CO2 (M-H). The stain HCS LipidTox was used to visualize
lipids (green) and DAPI was used to visualize the nuclei (blue). B: Lipoprotein lipase,
PPARγ2, and C/EBPα normalized gene expression levels in adipogenically differentiated
MSC. Error bars represent 95% confidence intervals.
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Figure 4.3 Osteogenic differentiation of MSC. A: Histological staining of MSC
cultured in a standard medium under 5% CO2 (Std) and in a MOPS-HEPES buffered
medium under atmospheric CO2 (M-H). The stains FRV and Napthol Phosphate were
used to visualize alkaline phosphatase activity in pink. B: Collagen I, Osteonectin, and
CBFα1 normalized gene expression levels in osteogenically differentiated MSC. Error
bars represent 95% confidence.
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Figure 4.4 Chondrogenic differentiation of MSC. A: Histological staining of MSC
cultured in a standard medium under 5% CO2 (Std) and in a MOPS-HEPES buffered
medium under atmospheric CO2 (M-H). The stain Alcian Blue was used to visualize
glycosaminoglycans in blue. B: Collagen II, Aggrecan, and SOX9 normalized gene
expression levels in chondrogenically differentiated MSC. Error bars represent 95%
confidenceintervals.
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Undifferentiated MSC retain expansion potential and stem cell characteristics after
multiple passages under atmospheric CO2
While expanding MSC effectively without prior adaptation to the MOPS-HEPES
buffer and atmospheric CO2 enables easier translation to clinical applications, prolonged
expansion may be required to generate larger quantities of undifferentiated stem cells. To
this end, serial passages of undifferentiated MSC were conducted. Both the standard
medium under 5% CO2 and the MOPS-HEPES buffered medium under atmospheric CO2
were examined for five passages. To ensure that growth rates were maintained in the
exponential phase, the cultures were only expanded to approximately 75% confluent at
the 60-h time point representing a potential fold-expansion in each passage of 6.25-fold.
The final cell densities for all five passages were not significantly different between MSC
expanded in the standard medium under 5% CO2 and the MOPS-HEPES buffered
medium under atmospheric CO2 (p > 0.05) (Figure 4.5A). Additionally, the final cell
densities were not different between the passages (p > 0.05). These end-point cell
densities correspond to an overall growth rate of 0.031 h-1 over 60-h, which is not
statistically different (p > 0.05) from the 57-h overall growth rates observed for the
passage 1 MSC cultured in the standard medium under 5% CO2 and the MOPS-HEPES
buffered medium under atmospheric CO2 (Figure 4.1A). Gene expression levels for Oct4
were not significantly different for the undifferentiated MSC expanded in the standard
medium under 5% CO2 and the MOPS-HEPES buffered medium under atmospheric CO2
after passage five (p > 0.05) (Figure 4.5B). It has been previously shown that MSC
growth rates change in vitro after only five passages (Wall et al., 2007), thus maintenance

118

Figure 4.5

Extended MSC expansion. A: End-point cell density analysis for

undifferentiated MSC through five passages cultured in a standard medium under 5%
CO2 (Std) and in a MOPS-HEPES buffered medium under atmospheric CO2 (M-H). B:
Oct4 normalized gene expression for undifferentiated MSC after passage 5. Error bars
represent 95% confidence intervals.
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of growth rate in the MOPS-HEPES buffer under atmospheric CO2 for this duration
would meet current expected outcomes. Additionally, in vitro MSC growth rates are a
highly sensitive indicator of stemness and were shown to decrease prior to changes in
differentiation markers (Wall et al., 2007). It has been previously shown that Oct4 gene
expression levels are highly correlated with a more primitive stem cell-like state capable
of extended proliferation, increased colony forming potential, and multilineage
differentiation. For example, hypoxia increased MSC stemness as determined by the
potential for proliferation, colony formation, and differentiation and coincided with the
upregulation of Oct4 and Rex-1 gene expression (Grayson et al., 2006). In addition,
overexpression of Oct4 and Nanog were shown to enhance stem cell properties in MSC
as determined by proliferation and differentiation potential, while knockdown of Oct4
and Nanog decreased proliferation and differentiation potential (Tsai et al., 2012).
Therefore, the similar Oct4 expression levels and similar growth patterns that were
observed indicate similar levels of stemness between the MSC grown in 5% CO2 and
those MSC grown in atmospheric CO2.

Potential impacts of CO2 independence on large-scale stem cell expansion in stirred
bioreactors
Stirred bioreactors—with unmatched scalability—represent a very promising
culture format for delivering high yields of either suspension or anchorage-dependent
stem cells with uniform properties (Fernandes Platzgummer et al., 2011; Serra et al.,
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2012; King and Miller, 2007; Grolms et al., 2009). The online monitoring and control
capabilities allow culture parameters to be adjusted throughout the duration of expansion,
which can provide crucial batch-to-batch reproducibility (Shafa et al. 2011). The
biopharmaceutical industry has long taken significant advantage of these systems, but
stem cell expansion techniques have lagged behind and not yet transitioned into truly
large-scale vessels (Olmer et al., 2012; Zweigerdt, 2009). Many stem cell-based
treatments require large quantities of stem cells, and because native stem cells are
relatively scarce in adult tissues, sufficient quantities of stem cells must be expanded in a
timely manner in vitro for use in treatments. Additionally, adult stem cells decline in
quantity and quality over time in a person, thus reducing the ability to harvest autologous
supplies (dos Santos et al., 2010). These considerations have led some to suggest that
establishing stem cell banks may be a more practical solution (Serra et al., 2012).
Allogenic stem cell stocks would allow patients access to stem cells on demand, in much
the same way that blood banks currently work. These stem cell banks would further
necessitate large-scale cultivation at optimal growth rates to produce sufficient quantities
of cells. The MSC cultured in the MOPS-HEPES buffer under atmospheric CO2 were
able to maintain high/optimal growth rates for five passages, which would allow for
large-scale cultivation.
As stem cell expansion moves toward large-scale, issues similar to those currently
encountered in other large-scale mammalian cell cultures will likely be encountered.
Many of these problems result from the widespread use of the bicarbonate buffering
system to regulate culture pH. In contrast to pH buffer redundancies in the body, the
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bicarbonate buffering system essentially functions alone in typical mammalian cell
culture. In cell culture media, elevated levels of NaHCO3 are added, which necessitates
the use of high CO2 levels in the gas phase that are significantly higher than physiological
levels (See Figure 4.6) (Goudar et al., 2006; Pattison et al., 2000). The indirect
equilibrium between the CO2 from the gas phase and the NaHCO3 added to the medium
maintains pH, via H+ concentration. Due to the nonpolar nature of CO2, it can freely
diffuse across cell membranes. At high concentrations, it can lower intracellular pH.
(Goudar et al., 2006; Pattison et al., 2000) In addition to affecting growth rates, these
elevated dCO2 levels can also alter the metabolism, productivity, and glycosylation
profiles in other mammalian cell lines, although this has not yet been reported in stem
cells (Goudar et al., 2006; Pattison et al., 2000; Hu et al., 2011). As cell densities increase
in large-scale cultures, additional CO2 is produced by the actively growing cells, which
causes a buildup of dCO2 and gas phase CO2 levels (Goudar et al., 2006). This dCO2
buildup can negatively impact cells grown in stirred bioreactors, and the effects increase
with vessel size (Goudar et al., 2006; Hu et al., 2011). The use of a nonbicarbonate buffer
would reduce dCO2 buildup and potentially improve growth.
In stirred bioreactors, oxygen and CO2 gases are sparged into the vessel as
bubbles, to increase mass transfer between the gas and liquid phases (King and Miller,
2007). The breakup of these bubbles at the gas–liquid interface is responsible for the
majority of cell death and damage during stirred bioreactor cultures (Rodrigues et al.,
2011; Papoutsakis, 2009; Zhang et al., 2010). Interestingly, managing the size of these
bubbles has been proposed as a solution to the problem of dCO2 buildup (Pattison et al.,
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Figure 4.6 Bicarbonate buffer equilibrium. NaHCO3 salt is commonly added to
mammalian cell culture medium to provide buffering in concert with elevated gas phase
CO2, which will equilibrate with dCO2.
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2000; Zhang et al., 2010; Hu et al., 2011). Larger bubbles are more effective in stripping
dCO2, while smaller bubbles are more effective at delivering oxygen to the culture (Hu et
al., 2011). With both oxygen and CO2 being supplied via the same sparged gas phase,
only one bubble size distribution can be supplied. As vessels are scaled-up, the dCO2
buildup becomes problematic, such that sparger designs allow for larger bubbles to strip
dCO2 at the expense of adequate oxygen supply (Hu et al., 2011). Hu et al. (2011)
proposed decoupling the oxygen and CO2 supplies by supplying pure oxygen via
microspargers into the bioreactor, and air via standard spargers; however, they were
concerned about the added control complexity (Hu et al., 2011). A nonbicarbonate buffer
would allow for a single gas supply (air/oxygen), thus decreasing controller complexity.
The coupling of the oxygen and CO2 supplies complicates control of culture
parameters and allows for pH and dissolved oxygen variability that is unacceptable,
particularly for stem cells (Serra et al., 2012; Rodrigues et al., 2011; Yeatts et al., 2013;
Wuertz et al., 2009; dos Santos et al., 2010). Several researchers have indicated that this
pH/CO2/O2 interdependence complicates bioreactor control and have gone on to quantify
the effects of pH, CO2, or dissolved oxygen variability on growth or productivity
(Rodrigues et al., 2009); however, few have suggested replacing the bicarbonate buffer
system as a means to improve pH control (Goudar et al., 2006). Yet it would appear far
simpler to use a nonbicarbonate buffer—such as the MOPS-HEPES combination used in
this study—that does not rely on elevated dCO2 levels for pH control. This work was the
first to demonstrate that the bicarbonate buffering system and an elevated CO2
environment are not required for effective expansion of undifferentiated MSC.
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Elimination of the bicarbonate buffer should lead to improved control of culture
conditions and enhanced stem cell expansion in bioreactors.
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4.5 Conclusion
Stem cells will be used in increasing numbers of scientific applications in the
future, ranging from basic research to clinical treatments. To provide stem cells for these
applications, new large-scale stem cell expansion methods must be developed. Stirred
bioreactors possess many advantages that allow for generation of large quantities of
uniform stem cells in a reproducible manner. Unfortunately, the bicarbonate buffer used
in mammalian cell culture, and the excessive CO2 sparging required by that system
hinder the ability to optimize process controls and generate stem cell yields of the highest
quality. This work developed a MOPS-HEPES buffering system that de-emphasized the
role of CO2 in pH buffering. Undifferentiated MSC were expanded without prior
adaptation under an atmospheric CO2 environment in the presence of the MOPS-HEPES
buffer at growth rates equal to those expanded under 5% CO2 in the presence of the
standard bicarbonate buffer. Additionally, the undifferentiated MSC expanded under an
atmospheric CO2 environment retained equivalent differentiation potential along the
adipogenic, osteogenic, and chondrogenic lineages compared to undifferentiated MSC
previously expanded under 5% CO2, as determined by histological staining and gene
expression markers. Furthermore, serial passaging of MSC in the MOPS-HEPES
buffered medium under atmospheric CO2 did not hinder MSC expansion or decrease
stemness gene expression markers as compared to MSC serially passaged under standard
conditions. Utilization of CO2-independent buffers, such as the MOPS-HEPES buffer
developed here, has the potential to improve stem cell bioreactor expansion by allowing
for tighter control of pH and dissolved oxygen.
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CHAPTER 5: IMPACT OF HIGH EXTRACELLULAR LACTATE
ON THE METABOLISM OF THREE BREAST CANCER CELL LINES:
MCF10A, MCF7, AND MDA-MB-231

5.1 Abstract
Metabolism is a crucial component of cancer’s malignant arsenal, and flexibility
with respect to nutrient sources allow it to survive harsh conditions as well as efforts to
treat it. Lactate, which accumulates in tumors and was long thought to be simply a waste
product that results from the Warburg Effect, is now becoming appreciated for its ability
to serve as a metabolic substrate for cancer cells to utilize. Additionally, lactate has also
been shown to promote metastasis, gene expression patterns consistent with the “cancer
stem cell” phenotype, and treatment resistance in tumors. Therefore, to better understand
the impact of extracellular lactate on the metabolism of cancer, three breast cancer cell
line – MCF-10A, MCF-7, and MDA-MB-231 - were analyzed using 13C-metabolic flux
analysis in response to being cultured in high-lactate conditions. Metabolic flux maps that
quantify individual pathway activity were generated for each cell line and each condition,
and compared between the control and high-lactate cultures, and between the cell lines.
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5.1 Introduction
Cell metabolism plays a pivotal role in cancer. Metabolism governs the energy
production, macromolecular synthesis, and intracellular redox balance necessary for cell
replication and other vital processes, and therefore when normal metabolism becomes
unbalanced it can enable malignant behaviors. The Warburg effect – defined as glucose
to lactate conversion rates even in the presence of adequate oxygen – has been witnessed
in many types of cancer since its discovery in the 1920s. Since then, additional metabolic
mechanisms have been discovered and have been shown to play a significant role in
cancer progressions and malignancy. One of these important alternative mechanisms
centers around lactate. Lactate accumulation in tumors is associated with increased
malignant activity and poor patient prognosis (Kennedy and Dewhirst, 2010). Secreted
from glycolytic cancer cells and autophagic carcinoma-associated fibroblasts, lactate can
be utilized metabolically by other cancer cell populations, a process known as the
Reverse Warburg effect (Kennedy and Dewhirst, 2010; Kennedy et al., 2013; MartinezOutschoorn et al., 2011; Pavlides et al., 2010; Sonveaux et al., 2008). For example, when
lactate was injected into mice with xenografts of the human breast cancer cell line MDAMB-231, metastasis increased ten-fold (Bonuccelli et al., 2010). Additionally, when the
human breast cancer cell line MCF-7 was exposed to lactate in vitro, genes associated
with “stemness” were upregulated and gene expression patterns consistent with the
“cancer stem cell” phenotype were observed (Martinez-Outschoorn et al., 2011). In
several other types of cancers, intratumoral lactate levels – which can sometimes rise to
as high as 40 mM – correlate with treatment resistance as well as poor patient prognosis
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(Kennedy and Dewhirst, 2010). It has been shown in xenotransplants and mouse cancer
models that inhibiting the ability of cancer cells to utilize lactate can force cells to
become glycolytic and retard tumor growth through glucose starvation, while rendering
the remaining cells more susceptible to radiation treatments (Sonveaux et al., 2008).
Since lactate accumulation and its subsequent utilization by surrounding cells appears to
negatively affect cancer patient outcomes, deciphering the role of lactate at the metabolic
level within central metabolism is crucial.
Metabolic flux analysis (MFA) is a tool that can be used to quantify metabolic
fluxes through individual metabolic pathways, and thus can be used to compare changes
in metabolic activity rates due to various factors. MFA uses extracellular uptake and
secretion rates of nutrients and waste products, and a discrete metabolic network model
of the relevant metabolic reactions (Hiller and Metallo, 2012). The use of stable isotopic
tracers, typically

13

C-labeled nutrients, and the resulting mass isotopomer distribution

(MID) data increases the resolution of individual fluxes within the defined metabolic
reaction network. Several mammalian systems have been characterized including Chinese
hamster ovary (CHO) cells at both stationary and exponential growth phases, MDA-MB231 cells under various nutrient considerations, and several other cancer cell lines under
hypoxia (Ahn and Antoniewicz, 2011; Ahn and Antoniewicz, 2013; Gaglio et al., 2011).
Several software tools – all relying upon regression analysis to solve the system of linear
equations specified by the metabolic network - exist to allow researchers to conduct MFA
without having to develop programming code, including Metran, OpenFLUX,
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CFlux2,

and FiatFlux (Ahn and ANtoniewicz 2011; Quek et al., 2009; Weitzel et al., 2013;
Zamboni et al., 2009).
The aim of this study was to determine the role of extracellular lactate on the
metabolism of proliferating breast cancer cells during exponential growth. Three human
breast cell lines were examined that represent three different stages of breast cancer.
MCF-10A cells are a non-tumorigenic breast cell line, MCF-7 cells are a tumorigenic,
luminal breast cancer cell line, and MDA-MB-231 cells are metastatic, basal breast
cancer cell line (Zancan et al., 2010). Each cell line was grown in both a control
condition without a lactate addition, as well as a high-lactate condition for which lactate
was added to the extracellular culture medium. The high-lactate concentration was
selected for each cell line to allow equivalent growth rates between the control and highlactate conditions. Three isotopic tracers were used individually, in parallel labeling
studies: [1,2-13C] glucose - as it has been shown to most accurately resolve fluxes in
glycolysis and the pentose-phosphate pathway (PPP) (Metallo et al., 2009); [U-13C] Lglutamine - as it has been shown to most accurately resolve fluxes in the mitochondrial
TCA cycle (Metallo et al., 2009); and [U-13C] sodium lactate - to elucidate lactate
metabolism. For the control cultures, only [1,2-13C] glucose and [U-13C] L-glutamine
tracers were used, since no extracellular lactate was added to these cultures. Metran was
used to solve the metabolic fluxes using the glucose and glutamine data. The lactate
tracer data for the high-lactate conditions was able to characterize the distribution of
labeled carbon within the intracellular metabolites. Metabolic flux maps for each cell line
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and each condition were generated, and compared between the control and high-lactate
cultures, and between the cell lines.
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5.2 Materials & Methods
Cell lines and media formulations
MCF-10A (ATCC® CRL-10317TM) and MCF-7 (ATCC® HTB-22TM) cells were
purchased from ATCC, while MDA-MB-231 (ATCC® CRL-10317TM) were kindly
provided to us by Dr. Brian Booth of Clemson University. Dulbecco’s modified Eagle
medium (DMEM) without glucose, glutamine, sodium pyruvate, and phenol red (Life
Technologies) was used as the growth media. The growth media was supplemented with
5 mM glucose (FIsher), 3 mM glutamine (Life Technologies), 10% dialyzed fetal bovine
serum (dFBS, Life Technologies) and 1% penicillin-streptomycin solution (Life
Technologies). High-lactate cultures were supplemented with 10 mM sodium L-lactate
(Sigma) for the MCF-10A cultures and 20 mM for the MCF-7 and MDA-MB-231
cultures. The isotopic tracers used in this study were [1,2-13C] glucose, [U-13C] Lglutamine, and [U-13C] sodium lactate. All isotopes were purchased from Sigma-Aldrich.

Cell growth and parallel labeling experiments
All cell lines were initially seeded at 2 x 104 cells/cm2 in the control growth media. Cells
were cultured at 37°C in a 5% CO2 humidified incubator. At 24-h, the media for the
MDA-MB-231 cultures was exchanged and the experimental conditions were introduced.
For MCF-10A and MCF-7 the media was replenished at 24-h, and at 48-h the media was
exchanged to introduce the experimental conditions. The later start point for the MCF10A and MCF-7 cultures was due to a reproducible longer lag phase. For clarity, the full
experimental setup is shown in Figure 5.1. Cell numbers and extracellular metabolite
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concentrations were measured at two time points, 24-h and 48-h after the media
exchange. Cell numbers and glucose and lactate concentrations were obtained from the
six-well plates, while the amino acid concentrations were obtained from the T-25 flasks.
The intracellular MIDs were obtained from the T-25s at 24-h after the media exchange.
The control condition had parallel cultures for both glucose (95% molar enriched [1,213

C] glucose) and glutamine tracers (95% molar enriched [U-13C] L-glutamine), whereas

the high-lactate cultures also had parallel replicates for the lactate tracer (50% molar
enriched [U-13C] sodium L-lactate). Six-well plates (Nunc) were used to obtain cell
numbers and glucose and lactate concentrations with six replicates for each time point. T25 flasks were used to obtain extracellular amino acid concentrations and intracellular
MID measurements in triplicate.

Cell numbers, and glucose and lactate concentrations
Cell numbers were obtained using the Scepter 2.0 Handheld Automated Cell
Counter (Millipore). Glucose and lactate concentrations were measured using a YSI 2700
Bioanalyzer.

Preparation of samples for GC-MS analysis
The methods used here for the extraction and derivatization of intracellular and
extracellular metabolites, as well as the specific metabolite fragments used for
identification, were performed according to the protocol outlined by Ahn and
Antoniewicz (2011), with a few minor alterations. Samples were incubated and allowed
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to derivatize for 60 min, and the sample volumes were increased to 1 mL after
derivatization. The injection volume used was 3 µL and samples were injected in splitless
mode. Amino acid standards were used .to calculate amino acid concentrations in the [U–
13

C] algal amino acid solution, which were then used to quantify the amino acid

concentrations in the extracellular medium.

Extracellular amino acid concentrations and intracellular MID measurements
GC-MS analysis was performed using a Hewlett Packard 7683 GC equipped with
an HP-5 (30 m x 0.32 mm i.d. x 0.25 µm; J&W Scientific) capillary column, interfaced
with a Hewlett Packard 5973 MS operating under ionization by electron impact as 2000
eV and 200°C ion source temperature. The injection port and interface temperatures were
both 250°C while helium flow was maintained at 1 mL/min. Mass spectra were recorded
in full scan mode for amino acid quantification and in single ion mode (SIM) for MIDs as
well as internal standards and standardization curves. MIDs were obtained by integration
of single ion chromatograms, and corrected for natural isotope abundances using the
Metran software (Fernandez et al., 1996; Yoo et al., 2008).

Determination of biomass specific consumption and production rates
Specific consumption and production rates for nutrients and waste metabolites in
the extracellular medium were determined based on cell growth rate and nutrient time
profiles using the previously described method of Meadows et al. (2008). Each sample
was independent, so average values were used to calculate fluxes. Prior to the flux
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Figure 5.1. Experimental setup for parallel labeling experiment for each of the three
breast cancer cell lines. Six-well plates and T-25 flasks were all seeded together. Times
indicate when the plates or flasks were harvested for analysis relative to the media
exchange. Isotopic labeling is graphically shown by shading. Clear for no isotope, gray
for glucose, blue for glutamine, and yellow for lactate. None of the six-well plates
contained isotopically-labeled media.
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calculations, statistical analysis of the amino acid concentration data was conducted using
jmp 10.0.0 (SAS Institute, Inc). The generalized linear model was used where cell line,
condition, and time were examined as effectors of the amino acid concentration (p ≤
0.05). Amino acid concentrations were averaged if determined not to be statistically
different with respect to the cell lines, condition, or time (p ≤ 0.05). All amino acid
concentrations were significantly affected by time (p ≤ 0.05). Several amino acid
concentrations were not significantly affected by cell line, condition, or both (p ≤ 0.05).
In those cases, the similar values were averaged to calculate fluxes. The spontaneous
glutamine degradation rate was accounted for in the glutamine flux calculation. The
lactate flux into the cells for the high-lactate cultures was estimated from the change in
the extracellular M3 labeled lactate species concentration between 24 and 48-h after the
media change.

Metabolic network model
To model central carbon metabolism for the three breast cancer cell lines, a
general mammalian cell model was used. This generalized mammalian cell model was
adapted from the previously developed framework by Ahn and Antoniewicz (2013). The
major reactions for glycolysis, PPP, the TCA cycle, amino acid metabolism, lactate
metabolism, and fatty acid metabolism were included in the mammalian cell model. Due
to the varying lipid content reported across the breast cancer cell lines and breast cancer
tissue (Abramczyk et al., 2015), a two-compartment biomass description was used, where
the Main Biomass includes proteins, nucleotides, and carbohydrates (Ahn and
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Antoniewicz, 2013). The protein amino acid composition appears to be relatively
consistent between the three cell lines by Raman spectra (Talari et al., 2015). Lipid
Biomass includes lipids and phospholipid (Bonarius et al., 1996). The two intracellular
compartments were modeled; cytosolic and mitochondrial, as well as a pyruvate sink to
account for reactions and pathways not explicitly included in the metabolic network
model (Ahn and Antoniewicz, 2013; Metallo et al., 2009; Metallo et al., 2012). Cofactor
balances, such as NADH and NADPH were not included in the model, as different
isoenzymes have varying cofactor requirements and the inclusion of these assumptions
can skew subsequent analysis (Ahn and Antoniewicz, 2011). Carbon dioxide was treated
as an unbalanced metabolite, and was not measured. Oxygen uptake was excluded from
the model and was also not measured. For the high-lactate cultures, an additional
extracellular reaction was included to account for the uptake of the labeled lactate tracer.
The control condition mammalian cell model has 73 reactions and the high-lactate
condition mammalian cell model has 74 reactions. The full metabolic network model
with atom transitions can be found in the Appendix A.

Metabolic flux analysis
13

C-Metabolic flux analysis was performed using the software package Metran

(Yoo et al. 2008), which utilizes the elementary metabolite unit (EMU) framework
(Antoniewicz et al., 2007b) Metabolic fluxes were estimated using experimentally
measured-values for consumption and production rates and from mass isotopomer
distributions for intracellular metabolites. In Metran, the metabolic fluxes were based on
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the quantities that minimized the variance-weighted sum of squared residuals (SSRes)
between the measured and simulated values. Metran can handle MID data from parallel
labeling experiments to be used simultaneously to generate a single flux map, per
condition and cell line, a capability that has been validated by MFA experiments for both
E. coli and CHO cells (Leighty and Antoniewicz, 2012; Ahn and Antoniewicz, 2013).
For this study, random initial fluxes were used and the MID error was 0.7 mol%. The
MIDs for each tracer were: glucose [3-phosphoglycerate (3PG), phosphoenolpyruvate
(PEP), dihydroxyacetone phosphate (DHAP), pyruvate, lactate, and alanine] and
glutamine [succinate, malate, α-oxoglutarate (AKG), glutamate, citrate, glutamine,
pyruvate, and lactate]. The MIDs from the lactate tracer for the high-lactate condition
were not included in the Metran simulations; however, the lactate tracer flux was
included. The fluxes for glucose, lactate, and glutamine were assigned 10% error, while
the other amino acid fluxes were assigned 50% error, due to the low concentration values
limiting precision. The main biomass and lipid biomass fluxes were assigned 25% error,
due to the imprecision of previous estimates of cancer cell lipid content (Abramczyk et
al., 2015). The lactate tracer flux was assigned 50% error, due to assumptions regarding
how the value was calculated. Namely, the M3 isotope was only an approximation of
total extracellular lactate, and the extracellular fluxes of M1 and M2 isotopes out of the
cells were not accounted for. The simulations were determined to have converged when a
global solution was achieved that satisfied the accepted SSRes criteria. This was
determined from analyzing the simulated fit results via a chi-square statistical test to
measure goodness-of-fit (Antoniewicz et al., 2006; Antoniewicz et al., 2007a). After
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convergence, 95% confidence intervals were generated for all parameters based on the
SSRes parameter (Antoniewicz et al., 2006).
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5.3 Results and Discussion
Cell growth
To determine the effects of high extracellular lactate on breast cancer metabolism,
three human breast cell lines, MCF-10A, MCF-7, and MDA-MB-231, were grown under
both control and high-lactate conditions. For MCF-10A, the high-lactate culture media
contained 10 mM lactate, while for MCF-7 and MDA-MB-231 the high-lactate culture
media contained 20 mM lactate. In order to have more control over the nutrient
conditions in the media and the isotopic labeling enrichment, the growth media used did
not contain sodium pyruvate, and glucose and glutamine had to be added. The dialyzed
FBS (dFBS) was also selected to minimize the carry over of glucose and other small
molecules. The high-lactate concentration selected for the high-lactate condition was
representative of lactate concentrations found within tumors that have been shown to
elicit the malignant effects associated with lactate accumulation (Kennedy and Dewhirst,
2010; Martinez-Outschoorn et al., 2011), yet also allowed for equivalent growth rates
between the control and high-lactate conditions. To characterize cell growth, cell counts
were taken every 24-h for several days and the resulting growth profiles for the three cell
lines are shown in Figure 5.2. All three cultures had significant lag phases; which were
reproducible and predictable for each cell line (48-h for MCF-10A and MCF-7 and 24-h
for MDA-MB-231). After the lag phase, the cultures were switched to the test conditions,
as indicated by the arrow in Figure 5.2. For control condition cultures the media
composition did not change, only isotopes were added; however, the cultures to be tested
under the high-lactate condition, the media was switched to the high-lactate media. All
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cultures exhibited exponential growth for 48-h after the media exchange, indicating that
the high-lactate condition did not significantly affect the overall growth rates for each cell
line (p > 0.05). The exponential growth rates were 0.017, 0.018, and 0.021 h-1,
respectively, for the MCF-10A, MCF-7, and MDA-MB-231 cell lines. In previous work
with mammalian cell lines, it has been shown that isotopic steady-state is reached for
glycolysis and the PPP metabolites with glucose labeling while TCA metabolites reach
close to isotopic steady-state with glutamine labeling within this time frame (Ahn and
Antoniewicz, 2013). Thus, samples for MID analysis were taken 24-h after the media
change, indicated by the black arrow, while all cultures were in the mid-exponential
phase (Figure 5.2).

Glucose, lactate, and amino acid metabolism
The glucose and lactate time profiles for each of the cell lines for each condition
are shown in Figure 5.3. The calculated flux rates are listed in Table 5.1, while the
concentrations for the 24-h and 48-h samples are listed in Appendix B. The three control
cultures had high glycolytic efficiency, or conversion of glucose into lactate, where the
theoretical maximum glycolytic efficiency is 2.0 mol lactate / mol glucose. Specifically,
the control condition cultures had glycolytic efficiencies of 1.7, 1.5, and 1.8, respectively,
for the MCF-10A, MCF-7, and MDA-MB-231 cell lines. The high-lactate condition
cultures had glycolytic efficiencies of 1.4, 0.8 and 1.3, respectively, for MCF-10A, MCF7, and MDA-MB-231 cell lines. The high extracellular lactate concentration caused all
three cell lines to have decreased glycolytic efficiencies.
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Figure 5.2. Growth profiles for the three breast cancer cell lines. A) The growth
profiles of MCF-10A shown in red, B) The growth profiles of MCF-7 shown in blue, and
C) The growth profiles of MDA-MB-231 shown in purple. The control cultures are
represented by solid markers, while the high-lactate cultures represented by hollow
markers. The media exchange occurred at the time point indiciated by the black arrow.
Error bars represent 95% confidence intervals.
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With respect to amino acid fluxes, the statistical analysis showed that several amino acid
concentrations between cell lines or condition were not different (p > 0.05); however,
they were different between 24-h and 48-h. Specifically, the glutamine, methionine,
phenylalanine, and tyrosine concentrations were not significantly different (p > 0.05)
between the cell lines or between conditions (p > 0.05). The concentrations of aspartate,
glutamate, glycine, and threonine were significantly different between cell lines (p ≤
0.05), but within the same cell line were not significantly different between the control
and high-lactate conditions (p > 0.05). Leucine concentrations were not significantly
different between cell lines (p > 0.05), but were significantly different between the
control and high-lactate conditions (p ≤ 0.05). The amino acid flux rates are listed in
Table 5.1, while the amino acid concentrations for the 24-h and 48-h samples are listed in
Appendix B.

Lactate tracer uptake rate
To calculate the lactate tracer flux for the high-lactate condition, the amount of
the M3 lactate isotope – corresponding to the [U-13C] lactate tracer – that was taken up by
the cells from the extracellular media was determined from the change in the M3 lactate
isotope concentration (after it was corrected for natural isotope abundance) from 24-h to
48-h. Specifically, the lactate flux was assumed to be double this change, since only 50%
of the initial extracellular lactate was labeled. It is possible that some of the M3 lactate
was secreted into the extracellular media unaltered; however, it was assumed that this
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was balanced by the M1/M2 lactate species secreted into the extracellular media. Table
5.1 lists the calculated lactate tracer uptake fluxes for the three cell lines.
To further understand the impact of the high extracellular lactate concentrations
on metabolism, the distribution of labeled intracellular metabolites in central metabolism
was examined. These MID values were obtained for intracellular metabolites cultured in
the high-lactate condition where 50% of the extracellular lactate was [U-13C] lactate. The
intracellular metabolites that were labeled included pyruvate, lactate, alanine, citrate,
AKG, glutamate, succinate, proline, aspartate, and malate. Though only intracellular
metabolites were measured in this study, the labeling is in agreement with a previous
labeling study where MCF-7 and MDA-MB-231 cells were incubated in a glucose-free
media with 10 mM 3-13C-lactate. In that glucose-free study, labeled alanine and
glutamate were observed, which could only have been generated if alanine and glutamate
were labeled intracellularly. In contrast, the labeling of the TCA metabolites and other
amino acids had significantly lower labeling, with an average carbon labeling of only
~1%.
One notable characteristic of the intracellular labeling due to the lactate tracer,
was the high fraction of M1 species relative to M2 species for both the intracellular
pyruvate, alanine, and lactate, as well as TCA metabolites. Since the lactate tracer was
[U-13C] labeled, one might expect to observe mostly M3, then M2, followed by M1, if
lactate were the sole carbon source and no lactate were being produced from the
metabolism of glucose and glutamine. In a case where lactate was the sole carbon source
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Figure 5.3 Glucose and lactate profiles for the three breast cancer cell lines. A) The
left graph shows the glucose concentrations over time for the three breast cancer cell
lines, while B) The right graph shows the net lactate concentrations over time adjusting
for the initial extracellular lactate in the high-lactate cultures. MCF-10A is represented in
red, MCF-7 in blue, and MDA-MB-231 in purple. The control cultures are represented by
solid markers, while the high-lactate cultures are represented by hollow markers. All
error bars represent 95% confidence intervals.

‘
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Table 5.1. Glucose, lactate, and amino acid fluxes for the three breast cancer cell
lines for the control and high-lactate conditions. Fluxes are given in nmol /106 cells/h,
and correspond to the measured flux between the 24-h and 48-h time points.

Flux (nmol/106 cells/h)

MCF10-A

MCF-7

MDA-MB-231

Metabolite

Control

HighLactate

Control

HighLactate

Control

HighLactate

Glucose
Lactate
Alanine
Aspartate
Glutamate
Glutamine
Glycine
Isoleucine
Leucine
Methionine
Phenylalanine
Proline
Serine
Threonine
Tyrosine
Valine

-222
379
10.6
4.9
12.1
-48
6.2
-8.3
-6.7
-2.6
-4.7
1.5
-18.7
-1.9
-3.6
-5.8

-181
252
10.7
3.7
10.2
-55
5.7
-8.4
-7.5
-1.5
-4.5
1.3
-20.3
-1.9
-3.7
-6.3

-210
318
13.7
6.6
11.5
-53
9.7
-9.5
-8.3
-3.1
-3.8
2.8
-19.7
-1.2
-4
-9.5

-159
132
11.7
5.4
11.6
-64
9.4
-9.2
-7.4
-2.2
-3.8
2.3
-22.5
-1.2
-3.8
-10.4

-337
606
10.2
3.5
8.6
-44
7.8
-4.7
-4.7
-1.4
-3.4
0.83
-15.8
-1.2
-3.5
-6.4

-268
344
8.2
4.5
10.4
-55
7
-8.4
-8.8
-2.2
-4
1.3
-19.8
-1.6
-3.8
-9.1
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and continuously consumed, labeled lactate would enter the cell and label pyruvate as M3
and the TCA metabolites as M2 after one turn of the TCA cycle, as shown in Figure
5.4A. If M3 lactate continued to enter the mitochondria as the primary source of acetylCoA, then the TCA metabolites would stay enriched with 13C. However, since the labeled
lactate flux into the cell and to pyruvate was relatively low compared to the unlabeled
glucose flux to pyruvate, the majority of the pyruvate becoming acetyl-CoA in the
mitochondria would be M0 labeled, as seen in Figure 5.4B. Therefore, when the M2labeled oxaloacetate from the first TCA cycle run, indicated by the blue box in Figure
5.4A and 5.4B, goes through the TCA cycle again, the majority of the time it combine
with an M0 acetyl-CoA, and will produce the M1-labeled the TCA metabolites from the
lactate tracer, as was seen in this study.
The MID data from the high-lactate conditions demonstrated that the labeled
lactate was consumed by the cells. Also, the presence of high extracellular lactate alters
intracellular metabolism for all three breast cancer cell lines. Specifically, the high
extracellular lactate concentration decreased glucose consumptions rates and decreased
lipid production rates.

Intracellular labeling from [1,2-13C] glucose
A [1,2-13C] glucose isotope was used for this study because previous studies have
shown it to be an optimal tracer for the glycolytic pathway for mammalian cells (Metallo
et al., 2009). The composition of the tracer in the extracellular medium was 95% molar
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enrichment, and 24-h has been shown to be sufficient to achieve isotopic steady-state for
intermediate metabolites in the glycolytic pathway for CHO cells, another mammalian
cell line with a similar growth rate (Ahn and Antoniewicz, 2013). The complete glucosederived MID measurements for all cell lines and conditions can be found in Appendix C.
All of the MID data was corrected for natural isotope abundances.
The average carbon labeling for PEP, 3PG, DHAP, pyruvate, alanine, and lactate
was at least 20% for all three cell lines, and the labeling concentrations did not drastically
change between the three cell lines, nor between the control and high-lactate conditions.
This reflects the consistently high flux through glycolysis for each of the three cell lines,
and makes sense considering that all three cell lines grew at an exponential rate for both
the control and high-lactate conditions.

Intracellular labeling from [U-13C] glutamine
The [U-13C] glutamine isotope was used for this study because previous studies
have shown it to be an optimal tracer for the TCA cycle pathway for mammalian cells
(Metallo et al., 2009). The composition of the tracer in the extracellular medium was 95%
molar enrichment, and the 24-h to be sufficient to nearly achieve isotopic steady-state for
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Figure 5.4 Generation of M1-labeled TCA metabolites from extracellular U-13C
lactate. A) Initial labeled lactate produces M2 TCA metabolites. B) M1 labeled
metabolites will form on the second run, where the M2 oxaloacetate (OAA) will most
likely encounter an M0 acetyl-CoA. For clarity, some reaction pathways were condensed.
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intermediate metabolites in the TCA cycle for CHO cells (Ahn and Antoniewicz 2013).
The complete glutamine-derived MID measurements for all cell lines and conditions can
be found in Appendix C. All of the MID data was corrected for natural isotope
abundances.
In all cell lines and conditions, glutamine, AKG, and glutamate were heavily
enriched from the glutamine tracer. Pyruvate and lactate were minimally enriched from
the glutamine isotope for all cell lines and conditions. In MCF-10A and MDA-MB-231,
the high-lactate condition led to a higher average carbon labeling in pyruvate and lactate
as compared to the control condition. In MCF-7, the trend seen in MCF-10A and MDAMB-231 was reversed: decreased labeling in pyruvate and lactate was observed under the
high-lactate condition compared to the control condition. The increased labeling of
pyruvate and lactate from glutamine in MCF-10A and MDA-MB-231 under the highlactate condition suggests that glutamine anaplerosis was enhanced to provide energy via
oxidative phosphorylation, and then secreted as alanine and lactate, in response to
decreased glucose consumption and decreased energy generation via glycolysis. While
glucose consumption (and hence energy generation via glycolysis) decreased in MCF-7
cells under the high-lactate condition, the decreased labeling in pyruvate and lactate from
glutamine suggests the glutamine-derived intermediates continued through the TCA cycle
rather than being secreted as alanine and lactate.
The TCA metabolites succinate, malate, and citrate also showed significant
labeling from the glutamine tracer. Succinate and malate had similar average carbon
labeling in all three cell lines for both conditions, whereas citrate labeling was relatively

159

similar between the different cell lines, but had some notable differences between the
control and high-lactate conditions. In response to the high-lactate conditions, all three
breast cancer cell lines showed a much greater proportion of M5 citrate compared to the
control condition, as can be seen in Figure 5.5. Increased M5 citrate was likely due to the
TCA cycle running in “reverse” through the reductive carboxylation pathway, as seen in
Figure 5.6. If correct, this labeling trend would be reflected – and it was - in the three cell
lines having higher exchange fluxes from AKG to citrate for the high-lactate condition
compared to the control. These results suggest that cancer cells continue to replenish
TCA intermediates through glutamine anaplerosis, and use glutamine for citrate synthesis
and fatty acid production via reductive carboxylation. Mammalian cells, including several
cancer cell lines, have been observed to increase reductive carboxylation of glutamine
under hypoxia (Metallo et al., 2012; Wise et al., 2011), but this is the first time it has
been observed in response to high-lactate levels.

Metabolic flux analysis
To quantify the metabolic activity, Metran was used to simulate the metabolite
flux rates, MIDs from parallel glucose and glutamine tracer labeling, and compare them
to the measured results for the model. A flux map was generated for each cell line for
each condition (Leighty and Antoniewicz, 2012; Ahn and Antoniewicz, 2013). Flux maps
for all cell lines and conditions are shown in Figures 5.6-5.11, and listed in Appendix D.
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Figure 5.5 MID labeling of citrate from [U-13C] glutamine. The fractional abundance
of the M0, M4, and M5 labeled forms of citrate for MCF-10A, MCF-7, and MDA-MB231 cultures for both control and high-lactate conditions.
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Figure 5.6 Reductive carboxylation of AKG to citrate. When AKG is oxidized through
the normal TCA pathway shown by the black arrows, the resulting citrate will be M4.
When AKG is carboxylated to isocitrate, the resulting citrate will be M5. For clarity,
some reaction pathways were condensed.
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Figure 5.7A Metabolic flux map for MCF-10A cells for the control condition. Line
thicknesses reflect relative flux values, which are in nmol/106 cells/h.
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Figure 5.7B Metabolic flux map for MCF-10A cells for the high-lactate condition.
Line thicknesses reflect relative flux values, which are in nmol/106 cells/h.
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Figure 5.7C Metabolic flux map for MCF-7 cells for the control condition. Line
thicknesses reflect relative flux values, which are in nmol/106 cells/h.
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Figure 5.7D Metabolic flux map for MCF-7 cells for the high-lactate condition. Line
thicknesses reflect relative flux values, which are in nmol/106 cells/h.
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Figure 5.7E Metabolic flux map for MDA-MB-231 cells for the control condition.
Line thicknesses reflect relative flux values, which are in nmol/106 cells/h.
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Figure 5.7F Metabolic flux map for MDA-MB-231 cells for the high-lactate
condition. Line thicknesses reflect relative flux values, which are in nmol/106 cells/h.
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For all three cell lines, the reactions in glycolysis had the highest fluxes in both
the control and high-lactate conditions. Compared to the control condition, all three cell
lines were characterized by decreased glucose consumption and decreased lactate
production when cultured in the high-lactate conditions. This agrees with previous studies
that showed lactate accumulation correlated with reduced entry of pyruvate into the TCA
cycle in leukemia cells (Samudio, et al., 2009). In the mitochondria, the high-lactate
condition resulted in decreased fluxes of acetyl-CoA into citrate for all three cell lines;
however, production of citrate from AKG via reductive carboxylation (characterized by
the exchange flux between AKG and citrate) increased for all three cell lines for the highlactate condition and likely compensated for the lack of citrate produced from acetylCoA. This is consistent with the increased M5 citrate labeling for all three cell lines for
the high-lactate condition shown in Figure 5.5, and in accordance with the behavior of
several other cancer cell lines when exposed to hypoxia, suggesting a possible link
between hypoxia and not only lactate accumulation but also consumption. The flux of
citrate from the mitochondria to the cytosol – and subsequent conversion into acetyl-CoA
for fatty acid synthesis – decreased for all three cell lines for the high-lactate condition
compared the control condition. This is surprising, considering that the decreased flux of
glucose into the mitochondria should make cells more dependent on glutamine-derived
citrate for fatty acid synthesis. Previous studies demonstrated that MDA-MB-231 cells
have a higher lipid content than MCF-7, which have a higher lipid content than MCF10A (Abramczyk et al., 2015). These lipid biomass content values were obtained form
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Raman spectra and staining. Without this data, the model would have assumed one lipid
content for all three cell lines; however, the lipid concentrations were not precise enough
to allow high confidence in the fatty acid lipid biomass fluxes.

Lactate’s effects on cancer cell metabolism and behavior
In this study, the metabolic responses of three breast cancer cell lines, MCF-10A,
MCF-7, and MDA-MB-231, to high lactate were examined using

13

C-MFA. MCF-10A

represents normal, precancerous breast cells, MCF-7 represents early-stage breast cancer,
and MDA-MB-231 represents a malignant and metastatic advanced breast cancer. Three
isotope tracers were used to aid resolution of central carbon metabolism and the resulting
fluxes and MID data sets were paired with a mammalian metabolic network model to
develop intracellular metabolic activity maps for each cell line under the control
condition, as well as the high-lactate condition. The three breast cancer cell lines cultured
in high-lactate conditions continued to grow exponentially at equivalent rates (p > 0.05),
despite having lower glucose consumption rates (p ≤ 0.05). While lactate was consumed
by MCF-10A, MCF-7, and MDA-MB-231 when exposed to high concentrations of
extracellular lactate, the lactate consumption might have even been reduced in these
conditions compared to in vivo conditions, due to the presence of glucose. MCF-7 and
MDA-MB-231 have been shown to utilize lactate as the main carbon source in the
absence of glucose (Kennedy et al., 2013). Most notably, all three cell lines exhibited
increased reductive carboxylation, as determined by increased M5 citrate labeling, which
can only occur if glutamine is metabolized through the reverse TCA cycle. Increased
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reductive carboxylation has previously been observed in several types of cancer cells in
response to hypoxia (Metallo et al., 2012; Wise et al., 2011). These results indicate that
there may be a link between hypoxia and lactate metabolism in tumor cells, even when
oxygen is sufficient, since oxygen was sufficient in the present experiments.
Interestingly, both hypoxia and elevated lactate correlate with resistance to treatments
that rely on induction of oxidative stress because lactate consumption allows cells to
utilize its antioxidant capacity to reduce oxidative stress and hypoxia limits formation of
reactive oxygen species (Groussard et al., 2000; Keith et al., 2007, Kennedy and
Dewhirst, 2010). Additionally, both exposure to elevated lactate, and hypoxia seem to
promote the “cancer stem cell” (CSC) phenotype independently (Heddleston et al., 2009,
Hill et al., 2009; Martinez-Outschoorn et al., 2011). Furthermore, upon injection of
lactate into mice with MDA-MB-231 xenografts, metastasis increased ten-fold
(Bonuccelli et al., 2010; Martinez-Outschoorn et al., 2011). Hypoxia has also been
implicated in increasing the metastatic potential of cancer cells (Hill et al., 2009; Pani et
al., 2010). All of these malignant behaviors – treatment resistance, stem cell gene
signatures, and increased metastasis – are correlated with tumor recurrence and poor
patient prognosis. All of these behaviors have also been shown to be promoted by both
hypoxia and elevated lactate. While cancer cells have long been known to produce high
levels of lactate, especially in hypoxic tumor regions, cancer cells can also consume and
metabolize lactate as a substrate (Kennedy et. al, 2013; Pavlides et al., 2009; Sonveaux et
al., 2008). The findings in this study highlight that elevated extracellular lactate
conditions can shift cancer cell metabolism towards a state normally thought to be
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characteristic of hypoxia, even in the presence of sufficient oxygen.
Metabolic flexibility appears to play an important role in enabling cancer to thrive
and survive in our bodies, against the harsh environmental factors encountered, including
inflammation, oxidative stress, and extreme nutrient and oxygen fluctuations (Dayem et
al., 2010; Pavlides, et al., 2010; Reuter et al., 2010). As a result, the ability to metabolize
lactate offers potential advantages to cancer cells. To gain a better understanding of
lactate uptake and metabolism, one study inhibited the main lactate transporter, MCT1, in
cervical cancer cells. This induced a switch from lactate-fueled respiration to glycolysis
(Sonveaux et al., 2008). In the same study, blocking MCT1 in a mouse lung cancer model
as well as a colorectal cancer xenotransplant slowed tumor growth by forcing the lactateconsuming cells to switch to glucose consumption. These cells were then more sensitive
to radiation treatment (Sonveaux et al., 2008). Even if the cancer cells that consume
lactate are not dependent on it – though it is believed to promote treatment resistance
through antioxidant effects – inhibiting lactate consumption can have downstream effects
on other tumor cells, and indeed compromise the tumor itself (Hirschhaeuser et al., 2011;
Kennedy and Dewhirst, 2010).
The findings of this study suggest that breast cancer cells adapt to high lactate
concentrations by increasing reductive carboxylation within the TCA cycle. Reductive
carboxylation is also observed to increase under hypoxia. In addition, both elevated
lactate and hypoxia have been linked to treatment resistance, metastasis, and the
promotion of the cancer stem cell phenotype. This suggests a potential connection
between these behaviors. Normally, oxygen is required for lactate to be used as the sole
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carbon source by tumors via oxidative phosphorylation in the TCA cycle (Kennedy et al.,
2013); however, lactate’s effect on TCA cycle activity – namely, increased reductive
carboxylation of glutamine - has thus far not been reported. If elevated lactate can indeed
mediate malignant behavior in cancer cells via this metabolic pathway as well as serve as
a substrate, approaches to prevent lactate-induced changes should be re-evaluated,
especially when targeting cancer cells residing in hypoxic niches.
13

C-MFA should continue to play an important role in future studies aimed at

precisely determining the effects of elevated lactate on cancer cell metabolism. In order
to increase resolution of the MIDs, the extracellular lactate should be entirely isotopically
labeled. Additionally, low glucose and low extracellular pH should be used to promote
lactate uptake. These results demonstrated that lactate plays an important role in changing
cancer cell metabolism, which might contribute to the increased metastasis, treatment
resistance, and patient death rates observed to be associated with elevated lactate
accumulation. Additionally, the surprising link to hypoxia should be further investigated.
Moving forward, there are several details that could be refined to `improve the
results of this MFA study. First, the metabolic network model contained two additional
pyruvate pools (pyr.snk and pyr.mII) to manage the multiple reactions at the pyruvate
node as well as to account for reactions not explicitly defined in the network (Ahn and
Antoniewicz, 2013). Due to the high flux of pyruvate into the sink under the high-lactate
conditions, it may be necessary to constrain or remove this pool. The additional pyruvate
mitochondrial pool (pyr.mII) was included to model potential pyruvate channeling (Ahn
and Antoniewicz, 2013); however, this assumption may not be supported by the cancer
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MID data. Additionally, the reversibility of several reactions, could be modified to allow
acetyl-CoA to re-enter the mitochondria via citrate, to account for fatty acid oxidation.
Second, the lipid composition used for the breast cancer cells was for cells cultured under
glucose with limited precision and only included the lipid droplets, and not the total lipid
content (Abramczyk et al., 2015). Furthermore, the effects of high extracellular lactate on
the lipid content of breast cancer cells was not obtained. Therefore, accurate estimates for
lipid biomass for each of the cell lines under each condition is needed to resolve the
intracellular fluxes. Finally, the lactate tracer used was only 50% enriched, which
significantly reduced the fractional abundance of the MIDs obtained for the high-lactate
cultures. In the future, using a higher enrichment for the lactate tracer would increase the
fractional abundances of the MIDs, such that the MID data could be used in the MFA
simulations to estimate intracellular fluxes.
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5.5 Conclusion
While cancer cells have long been known to exhibit excessive glycolytic behavior
resulting in the production of high levels of lactate, the role of lactate after its initial
secretion has only recently come to be appreciated and has focused mainly on gene
expression, metastatic potential, and correlations regarding treatment outcome and patient
prognosis. In this study, the effect of high concentrations of extracellular lactate on the
intracellular metabolic activity of three breast cancer cell lines was examined for the first
time. Under high-lactate conditions, all three cell lines reduced glucose consumption and
decreased lactate consumption. Additionally, the high-lactate condition resulted in lactate
consumption and incorporation into intracellular metabolites in all three cell lines, as well
as stimulation of the reverse TCA cycle via reductive carboxylation, activity that has
been associated with hypoxia and correlates with several malignant behaviors. There
remains much more to learn concerning lactate’s role in cancer – both metabolic and
otherwise – but MFA should serve as a valuable tool to decipher lactate’s role in cancer
metabolism, and along with inquiries from other angles, may allow us to further unravel
the complex web of factors that make cancer so difficult to treat.
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CHAPTER 6: FUTURE WORK

The research contained within this dissertation employed several complementary
tools to elucidate the inner workings of cells – from the expression of genes, to the
display of surface phenotype markers, to the intracellular fluxes in metabolic pathways.
The importance of examining cellular behavior from many independent angles cannot be
understated. With respect to the metabolism of breast cancer cells, MFA was used to
estimate the activity of internal metabolic pathways in response to high-lactate. While
metabolite levels and intracellular labeling patterns provide information regarding the
inputs, outputs, and direction of the substrates in central metabolism, examining the
cellular responses using orthogonal methods would improve the results, as well as
suggest possible refinements to the MFA framework, that could be used to inform and
improve future studies. For instance, using DNA microarrays to examine the expression
of genes that code for the enzymes involved in central carbon metabolism could provide
insight with regards to control in the MFA studies. Specifically, are the genes that encode
isocitrate dehydrogenase and aconitase – the enzymes that enable the reductive
carboxylation of α-ketoglutarate into citrate – upregulated by elevated lactate? If not, the
increased flux would be controlled at the substrate level. Histological staining could be
used to visualize the lipid content or highlight the activity of the mitochondria under
elevated lactate, thus confirming or rejecting the model simulation of lower lipid levels of
mitochondrial pathway activity, respectively.
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Furthermore, future work to decipher the specific roles that lactate plays in the
progression of cancer should mimic more closely the tumor microenvironment.
Specifically, tumors are known to have regions that are hypoxic. Using 3D cultures might
be one method to capture different microenvironments. Another approach might be to
have cultures that can allow the cells to communicate via paracrine secretions through a
porous membrane, but also keep the cells separated to allow for independent harvesting
of intracellular MIDs. Thus, an oxygen gradient could be established that exposes some
subpopulations of cancer cells to hypoxia, while others have access to sufficient oxygen.
Similar setups could also create chemogradients that expose different cancer cell
subpopulations to different levels of nutrients. These more complex models of tumor
compartmentalization would more accurately reflect the reality within tumors. Unlike
traditional 2D models, which assume all the cells consist of a single homogeneous
population, a 3D model would enable researchers to shed light on the dynamic interplay
between different subsets of tumor cells, which are known to be quite heterogeneous.
While the 2D culture results provide a necessary baseline, the results of 3D studies could
then be compared to these 2D culture results to determine if heterogeneity plays a role or
just the lactate concentration is the important factor.
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Appendix A
Reactions in the metabolic network used for 13C-MFA.

Table A.1 The metabolic network specified for use in 13C-MFA for the three breast
cancer cell lines. The cultures grown under the control conditions only used 73 reactions
for the model, while the high-lactate metabolic model contained an extra reaction, v74.
v1

Gluc.ext (abcdef) -> G6P.c (abcdef)

v2

G6P.c (abcdef) <=> F6P.c (abcdef)

v3

F6P.C (abcdef) -> FBP.C (abcdef)

v4

FBP.c (abcdef) <=>DHAP.c (cba) + GAP.c (def)

v5

DHAP.c (abc) <=> GAP.c (abc)

v6

GAP.c (abc) <=> 3PG.c (abc)

v7

3PG.c (abc)<=> PEP.c (abc)

v8

PEP.c (abc) -> Pyr.c (abc)

v9

G6P.c (abcdef) -> CO2 (a) + Ru5P.c (bcdef)

v10 Ru5P.c <=> R5P.c
v11 X5P.c (abcde) <=> EC2.c (ab) + GAP.c (cde)
v12 F6P.c (abcdef) <=> EC2.c (ab)+ E4P.c (cdef)
v13 S7P.c (abcdefg) <=> EC2.c (ab) + R5P.c (cdefg)
v14 F6P.c (abcdef) <=> EC3.c (abc) + GAP.c (def
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Table A.1 The metabolic network specified for use in 13C-MFA for the three breast
cancer cell lines. The cultures grown under the contol conditions only used 73 reactions
for the model, while the high-lactate metabolic model contained an extra reaction, v74.

v15 S7P.c (abcdefg) <=> EC3.c (abc) + E4P.c (defg)
v16 Pyr.c (abc) <=> Lact.c (abc)
v17 Pyr.c (abc) -> Pyr.snk (abc)
v18 Pyr.c (abc) -> Pyr.m (abc)
v19 Pyr.m (abc) -> CO2 (a) + AcCoA.m (bc)
v20 AcCoA.m (ab) + OAC.m (cdef) -> Cit.m (fedbac)
v21 Cit.m(abcdef) <=> AKG.m (abcde) + CO2 (f)
v22 AKG.m (abcde) -> CO2 (a)+ Suc.m (bcde)
v23 Suc.m (abcd) <=> Fum.m (abcd)
v24 Fum.m (abcd) <=> Mal.m (abcd)
v25 Mal.m (abcd) <=> OAC.m (abcd)
v26 Mal.m (abcd)-> Pyr.mII (abc)+ CO2 (d)
v27 Pyr.mII (abc) + CO2 (d) -> OAC.m (abcd)
v28 Pyr.m (abc) <=> Pyr.mII (abc)
v29 Mal.c (abcd) -> Pyr.c (abc) + CO2 (d)
v30 Mal.m (abcd) <=> Mal.c (abcd)
v31 Mal.c (abcd) <=> OAC.c (abcd)
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Table A.1 The metabolic network specificed for use in 13C-MFA for the three breast
cancer cell lines. The cultures grown under the control conditions only used 73 reactions
for the model, while the high-lactate metabolic model contained an extra reaction, v74.

v32 OAC.c (abcd) -> PEP.c (abc) + CO2 (d)
v33 Cit.m (abcdef) <=> Cit.c (abcdef)
v34 Cit.c (abcdef) -> AcCoA.c (ab) + OAC.c (cdef)
v35 AcCoA.c (ab) -> FA.c (ab)
v36 Gln.c (abcde) -> Glu.c (abcde)
v37 Glu.c (abcde) <=> AKG.m (abcde)
v38 Glu.c (abcde) <=> Pro.c (abcde)
v39 Asp.c (abcd) <=> OAC.c (abcd)
v40 Asp.c (abcd) -> Asn.c (abcd)
v41 Pyr.c (abc) <=> Ala.c (abc)
v42 Ser.c (abc) <=> Pyr.c (abc)
v43 Ser.c (abc) -> Gly.c (ab) + MEETHF (c)
v44 Thr.c (abcd)-> AcCoA.c (cd) + Gly.c (ab)
v45 Met.c (abcde) + CO2 (f) -> Suc.m (bcdf) + CO2 (a) + C1 (e)
v46 Val.c (abcde) + CO2 (f) -> Suc.m (dcef) + 2CO2 (a,b)
v47 Ile.c (abcdef) + CO2 (g) -> Suc.m (bcdg) + AcCoA.m (ef) + CO2 (a)
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Table A.1 (continued): The metabolic network specified for use in 13C-MFA for the
three breast cancer cell lines. The cultures grown under the control conditions only used
73 reactions for the model, while the high-lactate metabolic model contained an extra
reaction, v74.
v48 Phe.c (abcddefghi) -> Fum.m (defg) + 2 AcCoA.m (bc, hi) + CO2 (a)
v49 Tyr.c (abcdefghi) -> Fum.m (defg) + 2 AcCoA.m (bc, hi) + CO2 (a)
v50 Leu.c (abcdef) + CO2 (g) -> 3 AcCoA.m (bc, de, gf) + CO2 (a)
v51 Gln.ext (abcde) -> Gln.c (abcde)
v52 Asp.c (abcd) -> Asp.ext (abcd)
v53 Ile.ext (abcdef) -> Ile.c (abcdef)
v54 Leu.ext (abcdef) -> Leu.c (abcdef)
v55 Met.ext (abcde) -> Met.c (abcde)
v56 Phe.ext (abcdefghi) -> Phe.c (abcdefghi)
v57 Ser.ext (abc) -> Ser.c (abc)
v58 Tyr.ext (abcdefghi) -> Tyr.c (abcdefghi)
v59 Val.ext (abcde) -> Val.c (abcde)
v60 Thr.ext (abcd) -> Thr.c (abcd)
v61 Arg.ext (abcdef) -> Arg.c (abcdef)
v62 Cys.ext (abc) -> Cys.c (abc)
v63 His.ext (abcdef)-> His.c (abcdef)
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Table A.1 (continued): The metabolic network specified for use in 13C-MFA for the
three breast cancer cell lines. The cultures grown under the control conditions only used
73 reactions for the model, while the high-lactate metabolic model contained an extra
reaction, v74.

v64

Lys.ext (abcdef) -> Lys.c (abcdef)

v65

Trp.ext (abcdefghijk) -> Trp.c (abcdefghijk)

v66

Ala.c (abc) -> Ala.ext (abc)

v67

Gly.c (ab) -> Gly.ext (ab)

v68

Pro.c (abcde) -> Pro.ext (abcde)

v69

Glu.c (abcde) -> Glu.ext (abcde)

v70

Lact.c (abc) -> Lact.ext (abc)

v71

Ru5P.c (abcde) <=> X5P.c (abcde)
0.0862 Ala + 0.0519 Arg + 0.0495 Asp + 0.0397 Asn + 0.0200 Cys + 0.0444 Glu+
0.0532 Gln + 0.0742 Gly + 0.0197 His + 0.0446 Ile + 0.0777 Leu + 0.0785 Lys +
0.0191 Met + 0.0302 Phe + 0.0432 Pro + 0.0592 Ser + 0.0532 Thr + 0.0061 Trp + 0.025

v72

Tyr + 0.0573 Val + 0.0384 G6P + 0.0321 Ru5P -> Biomass

v73

FA.c -> Lipids

v74

Lact.tr (abc) -> Lact.c (abc)
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Appendix C
Measured and simulated MID values for
intracellular metabolites from glucose and glutamine tracers.

Figure C.1 MID values for intracellular metabolites from [1,2-13C] glucose for
MCF-10A for the control condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.2 MID values for intracellular metabolites from [1,2-13C] glucose for
MCF-10A for the high-lactate condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.3 MID values for intracellular metabolites from [1,2-13C] glucose for
MCF-7 for the control condition. All MIDs were corrected for natural isotope
abundances. All MIDs were corrected for natural isotope abundances.
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Figure C.4 MID values for intracellular metabolites from [1,2-13C] glucose for
MCF-7 for the high-lactate condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.5 MID values for intracellular metabolites from [1,2-13C] glucose for
MDA-MB-231 for the control condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.6 MID values for intracellular metabolites from [1,2-13C] glucose for
MDA-MB-231 for the high-lactate condition. All MIDs were corrected for natural
isotope abundances.
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Figure C.7 MID values for intracellular metabolites from [U-13C] glutamine for
MCF-10A for the control condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.8 MID values for intracellular metabolites from [U-13C] glutamine for
MCF-10A for the high-lactate condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.9 MID values for intracellular metabolites from [U-13C] glutamine for
MCF-7 for the control condition. All MIDs were corrected for natural isotope
abundances.
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Figure C.10 MID values for intracellular metabolites from [U-13C] glutamine for
MCF-7 for the high-lactate condition. All MIDs were corrected for natural isotope
abundances. All MIDs were corrected for natural isotope abundances.
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Figure C.11 MID values for intracellular metabolites from [U-13C] glutamine for
MDA-MB-231 for the control condition. All MIDs were corrected for natural isotope
abundances.

202

Figure C.12 MID values for intracellular metabolites from [U-13C] glutamine for
MDA-MB-231 for the high-lactate condition. All MIDs were corrected for natural
abundances.
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Appendix D
MFA results for the three breast cancer cell lines
Table D.1 MFA results for the MCF-10A cells for the control condition. Fluxes measured
in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

1. 216.087 ± 17.834

8.4 %

Gluc.ext -> G6P.c

( 186.31, 255.86)

2. 137.526 ± 11.225

8.4 %

G6P.c <=> F6P.c (net)

( 117.38, 161.16)

3. ( >1000, >1e4) ± >1000

>100 % G6P.c <=> F6P.c (exch)

( 148.72, >10000)

4. 187.450 ± 15.761

8.6 %

F6P.c -> FBP.c

( 161.20, 222.67)

5. 187.450 ± 15.761

8.6 %

FBP.c <=> DHAP.c + GAP.c (net)

( 161.20, 222.67)

6. ( 0.0, >1e4) ± >10000

>100 % FBP.c <=> DHAP.c + GAP.c (exch)

( 0.00, >10000)

7. 187.450 ± 15.761

8.6 %

DHAP.c <=> GAP.c (net)

( 161.20, 222.67)

8. 303.069 ± 29.134

9.9 %

DHAP.c <=> GAP.c (exch)

( 251.94, 365.56)

9. 399.862 ± 33.612

8.5 %

GAP.c <=> 3PG.c (net)

( 343.93, 475.02)

10. ( 0.0, >1000) ± >1000

>100 % GAP.c <=> 3PG.c (exch)

( 0.00, >10000)

11. 399.862 ± 33.612

8.5 %

( 343.93, 475.02)

12. ( 0.0, 3.7) ± 72.604

>100 % 3PG.c <=> PEP.c (exch)

( 0.00, 283.16)

13. 417.958 ± 35.917

8.8 %

( 357.76, 497.83)

14. 76.565 ± 8.307

11.0 % G6P.c -> CO2 + Ru5P.c

( 61.29, 93.69)

15. 24.962 ± 2.782

11.3 % Ru5P.c <=> R5P.c (net)

( 19.86, 30.72)

16. ( 102.2, >1e4) ± >1000

>100 % Ru5P.c <=> R5P.c (exch)

( 0.00, >10000)

17. 49.924 ± 5.565

11.3 %

( 39.73, 61.43)

3PG.c <=> PEP.c (net)

PEP.c -> Pyr.c

X5P.c <=> EC2.c + GAP.c (net)
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

18. ( 39.4, >1e4) ± >1000

>100 % X5P.c <=> EC2.c + GAP.c (exch)

( 0.00, >10000)

19. -24.962 ± 2.782

10.8 % F6P.c <=> EC2.c + E4P.c (net)

( -30.72, -19.86)

20. 0.000 ± 2.452

>100 % F6P.c <=> EC2.c + E4P.c (exch)

( 0.00, 9.56)

21. -24.962 ± 2.782

10.8 % S7P.c <=> EC2.c + R5P.c (net)

( -30.72, -19.86)

22. ( 1.9, >1e4) ± >1000

>100 % S7P.c <=> EC2.c + R5P.c (exch)

( 0.00, >10000)

23. -24.962 ± 2.782

10.8 % F6P.c <=> EC3.c + GAP.c (net)

( -30.72, -19.86)

24. ( 466.6, >1e4) ± >1000

>100 % F6P.c <=> EC3.c + GAP.c (exch)

( 0.00, >10000)

25. 24.962 ± 2.782

11.3 % S7P.c <=> EC3.c + E4P.c (net)

( 19.86, 30.72)

26. ( 1.8, >1e4) ± >1000

>100 % S7P.c <=> EC3.c + E4P.c (exch)

( 0.00, >10000)

27. 385.000 ± 35.901

9.6 %

( 309.95, 449.96)

28. ( 0.0, >1e4) ± >1000

>100 % Pyr.c <=> Lact.c (exch)

( 0.00, >10000)

29. 18.413 ± 35.396

>100 % Pyr.c -> Pyr.snk

( 0.00, 138.04)

30. 42.283 ± 11.652

28.5 % Pyr.c -> Pyr.m

( 23.67, 69.12)

31. 42.284 ± 10.069

24.9 % Pyr.m -> CO2 + AcCoA.m

( 23.08, 62.35)

32. 66.073 ± 8.056

12.5 % AcCoA.m + OAC.m -> Cit.m

( 50.89, 82.31)

33. 40.537 ± 4.792

12.0 %

( 32.39, 51.08)

34. 0.000 ± 0.410

>100 % Cit.m <=> AKG.m + CO2 (exch)

( 0.00, 1.60)

35. 64.128 ± 5.258

8.3 %

( 55.36, 75.87)

36. 75.803 ± 8.363

11.2 % Suc.m <=> Fum.m (net)

( 61.08, 93.70)

37. ( 0.0, >1e4) ± >1000

>100 % Suc.m <=> Fum.m (exch)

( 0.00, >10000)

Pyr.c <=> Lact.c (net)

Cit.m <=> AKG.m + CO2 (net)

AKG.m -> CO2 + Suc.m
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

38. 82.509 ± 9.134

11.2 % Fum.m <=> Mal.m (net)

( 66.38, 102.00)

39. ( 0.0, 7.5) ± >1000

>100 % Fum.m <=> Mal.m (exch)

( 0.00, >10000)

40. 54.364 ± 7.749

14.6 % Mal.m <=> OAC.m (net)

( 39.54, 69.76)

41. 85.624 ± 88.638

>100 % Mal.m <=> OAC.m (exch)

( 17.51, 363.20)

42. 11.710 ± 2.205

20.3 %

Mal.m -> Pyr.mII + CO2

( 8.19, 16.79)

43. 11.709 ± 4.273

37.9 %

Pyr.mII + CO2 -> OAC.m

( 8.55, 25.22)

44. -0.000 ± 3.316

>100 % Pyr.m <=> Pyr.mII (net)

( -0.62, 12.31)

45. 0.000 ± 3.157

>100 % Pyr.m <=> Pyr.mII (exch)

( 0.00, 12.31)

46. 14.658 ± 8.418

59.1 %

Mal.c -> Pyr.c + CO2

( 0.00, 32.83)

47. 16.435 ± 8.707

56.8 % Mal.m <=> Mal.c (net)

( 1.34, 35.29)

48. ( 0.0, >1e4) ± >1000

>100 % Mal.m <=> Mal.c (exch)

( 0.00, >10000)

49. 1.778 ± 10.088

>100 % Mal.c <=> OAC.c (net)

( -18.01, 21.34)

50. ( 158.8, >1e4) ± >1000

>100 % Mal.c <=> OAC.c (exch)

( 0.00, >10000)

51. 18.096 ± 7.548

46.9 % OAC.c -> PEP.c + CO2

( 4.01, 33.45)

52. 25.536 ± 6.810

28.6 % Cit.m <=> Cit.c (net)

( 12.41, 38.97)

53. ( 0.0, >1e4) ± >10000

>100 % Cit.m <=> Cit.c (exch)

( 0.00, >10000)

54. 25.536 ± 6.810

28.6 % Cit.c -> AcCoA.c + OAC.c

( 12.41, 38.97)

55. 25.536 ± 6.810

28.6 % AcCoA.c -> FA.c

( 12.41, 38.97)

56. 44.627 ± 3.866

8.7 %

Gln.c -> Glu.c

( 37.73, 52.81)

57. 23.591 ± 3.424

14.6 % Glu.c <=> AKG.m (net)

( 17.62, 30.98)
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

58. 467.362 ± >100

46.3 %

Glu.c <=> AKG.m (exch)

59. 3.306 ± 0.663

21.4 % Glu.c <=> Pro.c (net)

( 1.98, 4.57)

60. ( 0.0, >1e4) ± >10000

>100 % Glu.c <=> Pro.c (exch)

( 0.00, >10000)

61. -9.218 ± 2.102

21.9 % Asp.c <=> OAC.c (net)

( -13.24, -5.04)

62. ( 0.0, >1e4) ± >1000

>100 % Asp.c <=> OAC.c (exch)

( 0.00, >10000)

63. 2.100 ± 0.426

21.6 %

( 1.22, 2.88)

64. 15.356 ± 5.541

40.9 % Pyr.c <=> Ala.c (net)

( 4.50, 26.11)

65. ( 0.0, >1e4) ± >1000

>100 % Pyr.c <=> Ala.c (exch)

( 0.00, >10000)

66. 28.436 ± 6.271

23.9 % Ser.c <=> Pyr.c (net)

( 15.27, 39.73)

67. ( 660.8, >1e4) ± >1000

>100 % Ser.c <=> Pyr.c (exch)

( 30.41, >10000)

68. 9.761 ± 3.088

35.1 %

( 3.71, 15.75)

69. 0.000 ± 0.393

>100 % Thr.c -> AcCoA.c + Gly.c

70. 1.026 ± 0.771

>100 % Met.c + CO2 -> Suc.m + CO2 + MEETHF ( 0.00, 3.01)

71. 3.210 ± 2.331

99.6 % Val.c + CO2 -> Suc.m + 2 CO2

( 0.00, 9.09)

72. 7.439 ± 3.811

60.4 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2

( 0.00, 14.86)

73. 3.216 ± 1.802

67.8 % Phe.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 7.03)

74. 3.490 ± 1.864

63.8 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 7.27)

75. 0.980 ± 1.284

>100 % Leu.c + CO2 -> 3 AcCoA.m + CO2

( 0.00, 5.01)

76. 46.937 ± 3.977

8.5 %

( 39.83, 55.33)

77. 4.546 ± 1.940

49.0 % Asp.c -> Asp.ext

Asp.c -> Asn.c

Ser.c -> Gly.c + MEETHF

Gln.ext -> Gln.c
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( 284.20, >1000)

( 0.00, 1.53)

( 0.74, 8.31)

Table D.1 (continued) MFA results for the MCF-10A cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

78. 9.801 ± 3.826

44.5 % Ile.ext -> Ile.c

( 2.19, 17.11)

79. 5.074 ± 1.514

34.1 %

Leu.ext -> Leu.c

( 2.75, 8.66)

80. 2.023 ± 0.839

49.1 % Met.ext -> Met.c

( 0.70, 3.97)

81. 4.791 ± 1.850

44.2 % Phe.ext -> Phe.c

( 1.30, 8.51)

82. 41.295 ± 5.609

14.2 %

( 29.48, 51.35)

83. 4.802 ± 1.892

45.1 % Tyr.ext -> Tyr.c

( 1.14, 8.51)

84. 6.203 ± 2.520

46.1 % Val.ext -> Val.c

( 2.12, 11.94)

85. 2.782 ± 0.644

24.6 % Thr.ext -> Thr.c

( 1.65, 4.16)

86. 2.730 ± 0.553

21.6 % Arg.ext -> Arg.c

( 1.59, 3.75)

87. 1.050 ± 0.213

21.6 % Cys.ext -> Cys.c

( 0.61, 1.44)

88. 1.050 ± 0.213

21.6 % His.ext -> His.c

( 0.61, 1.44)

89. 4.147 ± 0.841

21.6 %

( 2.42, 5.69)

90. 0.315 ± 0.064

21.5 % Trp.ext -> Trp.c

( 0.18, 0.43)

91. 10.999 ± 5.498

59.4 % Ala.c -> Ala.ext

( 0.28, 21.72)

92. 5.876 ± 3.002

60.4 %

Gly.c -> Gly.ext

( 0.07, 11.78)

93. 1.049 ± 0.497

55.9 %

Pro.c -> Pro.ext

( 0.07, 2.01)

94. 14.947 ± 4.066

29.1 % Glu.c -> Glu.ext

( 6.67, 22.53)

95. 385.000 ± 35.901

9.6 %

( 309.95, 449.96)

96. 49.924 ± 5.565

11.3 % Ru5P.c <=> X5P.c (net)

( 39.73, 61.43)

97. ( 39.4, >1e4) ± >1000

>100 % Ru5P.c <=> X5P.c (exch)

( 0.00, >10000) |

Ser.ext -> Ser.c

Lys.ext -> Lys.c

Lact.c -> Lact.ext
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98. 52.499 ± 10.639

Biomass Equation (v72)

( 30.59, 72.09)

99. 25.536 ± 6.810

28.6 % FA.c -> Lipids

( 12.41, 38.97)
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Table D.2 MFA results for the MCF-10A cells for the high-lactate condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

1. 178.106 ± 14.923

8.6 %

Gluc.ext -> G6P.c

( 148.54, 206.74)

2. 134.782 ± 11.032

8.4 %

G6P.c <=> F6P.c (net)

( 113.09, 156.11)

3. ( 145.6, >1e4) ± >1000

>100 % G6P.c <=> F6P.c (exch)

( 0.00, >10000)

4. 161.499 ± 13.478

8.6 %

( 134.76, 187.32)

5. 161.499 ± 13.478

8.6 % FBP.c <=> DHAP.c + GAP.c (net)

( 134.76, 187.32)

6. ( 0.0, >1e4) ± >10000

>100 % FBP.c <=> DHAP.c + GAP.c (exch)

( 0.00, >10000)

7. 161.499 ± 13.478

8.6 %

( 134.76, 187.32)

8. ( >1000, >1000) ± >1000

42.6 % DHAP.c <=> GAP.c (exch)

( >1000, >1000)

9. 336.355 ± 28.452

8.7 %

( 279.96, 390.93)

10. ( 0.0, >1000) ± >1000

>100 % GAP.c <=> 3PG.c (exch)

( 0.00, >10000)

11. 336.355 ± 28.452

8.7 %

( 279.96, 390.93)

12. ( 0.0, >1e4) ± >10000

>100 % 3PG.c <=> PEP.c (exch)

( 0.00, >10000)

13. 336.355 ± 28.452

8.7 %

( 279.96, 390.93)

14. 41.561 ± 7.107

18.1 % G6P.c -> CO2 + Ru5P.c

( 25.28, 53.00)

15. 13.358 ± 2.383

18.9 % Ru5P.c <=> R5P.c (net)

( 7.92, 17.22)

16. ( >1000, >1e4) ± >1000

>100 % Ru5P.c <=> R5P.c (exch)

( 0.00, >10000)

17. 26.717 ± 4.765

18.9 % X5P.c <=> EC2.c + GAP.c (net)

( 15.85, 34.43)

18. ( >1e4, >1e4) ± >10000

>100 % X5P.c <=> EC2.c + GAP.c (exch)

( 0.00, >10000)

19. -13.358 ± 2.383

17.1 %

( -17.22, -7.92)

20. 1.710 ± 3.513

>100 % F6P.c <=> EC2.c + E4P.c (exch)

F6P.c -> FBP.c

DHAP.c <=> GAP.c (net)

GAP.c <=> 3PG.c (net)

3PG.c <=> PEP.c (net)

PEP.c -> Pyr.c

F6P.c <=> EC2.c + E4P.c (net)
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( 0.00, 13.70)

Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD
21. -13.358 ± 2.383

%SD

Reaction

Confidence Interval

17.1 % S7P.c <=> EC2.c + R5P.c (net)

( -17.22, -7.92)

22. ( >1000, >1e4) ± >10000 >100 % S7P.c <=> EC2.c + R5P.c (exch)

( 0.00, >10000)

23. -13.358 ± 2.383

17.1 %

( -17.22, -7.92)

24. 1.096 ± 2.898

>100 % F6P.c <=> EC3.c + GAP.c (exch)

( 0.00, 11.30)

25. 13.358 ± 2.383

18.9 % S7P.c <=> EC3.c + E4P.c (net)

( 7.92, 17.22)

F6P.c <=> EC3.c + GAP.c (net)

26. ( >1000, >1e4) ± >10000 >100 % S7P.c <=> EC3.c + E4P.c (exch)

( 0.00, >10000)

27. 259.478 ± 28.071

11.2 % Pyr.c <=> Lact.c (net)

( 204.70, 314.18)

28. ( >1e4, >1e4) ± >10000

88.4 %

29. 112.236 ± 47.312

47.5 % Pyr.c -> Pyr.snk

( 19.28, 203.79)

30. 23.143 ± 12.503

69.2 % Pyr.c -> Pyr.m

( 0.01, 48.78)

31. 19.393 ± 9.948

58.9 % Pyr.m -> CO2 + AcCoA.m

( 0.00, 38.80)

32. 61.342 ± 6.497

11.0 % AcCoA.m + OAC.m -> Cit.m

( 46.02, 71.36)

33. 47.663 ± 4.754

10.3 % Cit.m <=> AKG.m + CO2 (net)

( 37.24, 55.78)

34. 21.424 ± 2.324

11.1 % Cit.m <=> AKG.m + CO2 (exch)

( 16.66, 25.73)

35. 81.418 ± 6.179

7.7 %

AKG.m -> CO2 + Suc.m

( 69.68, 93.78)

36. 96.201 ± 8.607

9.1 %

Suc.m <=> Fum.m (net)

( 78.87, 112.43)

37. ( 0.0, >1000) ± >1000

>100 % Suc.m <=> Fum.m (exch)

( 0.00, >10000)

38. 103.768 ± 9.163

9.0 %

( 85.12, 120.85)

39. ( >1000, >1e4) ± >1000

81.9 % Fum.m <=> Mal.m (exch)

( 26.33, >10000)

40. 57.591 ± 8.226

15.1 %

( 38.80, 70.89)

Pyr.c <=> Lact.c (exch)

Fum.m <=> Mal.m (net)

Mal.m <=> OAC.m (net)
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( 422.37, >10000)

Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

41. ( >1000, >1e4) ± >1000

45.7 %

Mal.m <=> OAC.m (exch)

42. 0.000 ± 1.531

>100 % Mal.m -> Pyr.mII + CO2

( 0.00, 5.97)

43. 3.750 ± 4.212

>100 % Pyr.mII + CO2 -> OAC.m

( 0.00, 16.43)

44. 3.750 ± 4.255

>100 % Pyr.m <=> Pyr.mII (net)

( -0.37, 16.23)

45. ( 0.0, >1e4) ± >10000

>100 % Pyr.m <=> Pyr.mII (exch)

( 0.00, >10000)

46. 51.461 ± 6.902

13.9 % Mal.c -> Pyr.c + CO2

( 35.59, 62.50)

47. 46.177 ± 7.135

16.3 % Mal.m <=> Mal.c (net)

( 33.11, 60.93)

48. ( >1000, >1e4) ± >1000

61.7 % Mal.m <=> Mal.c (exch)

( >1000, >10000)

49. -5.284 ± 5.685

90.0 % Mal.c <=> OAC.c (net)

( -13.03, 9.14)

50. ( >1000, >1e4) ± >1000

83.0 % Mal.c <=> OAC.c (exch)

( >1000, >10000)

51. -0.000 ± 2.754

>100 % OAC.c -> PEP.c + CO2

( 0.00, 10.74)

52. 13.679 ± 4.529

36.8 % Cit.m <=> Cit.c (net)

( 2.61, 20.28)

53. ( 0.0, >1e4) ± >10000

>100 % Cit.m <=> Cit.c (exch)

( 0.00, >10000)

54. 13.679 ± 4.529

36.8 % Cit.c -> AcCoA.c + OAC.c

( 2.61, 20.28)

55. 13.679 ± 4.568

37.1 % AcCoA.c -> FA.c

( 2.61, 20.43)

56. 51.080 ± 4.110

8.2 %

Gln.c -> Glu.c

( 43.44, 59.47)

57. 33.755 ± 3.913

12.0 % Glu.c <=> AKG.m (net)

( 26.65, 41.91)

58. ( 272.8, >1e4) ± >1000

>100 % Glu.c <=> AKG.m (exch)

59. 3.017 ± 0.703

24.8 % Glu.c <=> Pro.c (net)

( 1.60, 4.35)

60. ( 0.0, >1e4) ± >10000

>100 % Glu.c <=> Pro.c (exch)

( 0.00, >10000)
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Confidence Interval
( >1000, >10000)

( 247.06, >10000)

Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

61. -8.395 ± 2.196

24.5 % Asp.c <=> OAC.c (net)

( -12.66, -4.09)

62. ( 0.0, >1e4) ± >1000

>100 % Asp.c <=> OAC.c (exch)

( 0.00, >10000)

63. 1.857 ± 0.469

26.6 %

( 0.88, 2.71)

64. 13.849 ± 5.087

40.8 % Pyr.c <=> Ala.c (net)

( 3.93, 23.76)

65. ( 0.0, >1e4) ± >10000

>100 % Pyr.c <=> Ala.c (exch)

( 0.00, >10000)

66. 20.889 ± 7.360

39.8 % Ser.c <=> Pyr.c (net)

( 6.68, 35.38)

67. ( 754.3, >1e4) ± >1000

>100 % Ser.c <=> Pyr.c (exch)

( 0.00, >10000)

68. 9.442 ± 3.256

37.6 % Ser.c -> Gly.c + MEETHF

( 2.78, 15.48)

68. 9.442 ± 3.256

37.6 %

( 2.78, 15.48)

70. 1.243 ± 0.828

89.9 % Met.c + CO2 -> Suc.m + CO2 + MEETHF ( 0.00, 3.23)

71. 4.490 ± 2.614

71.1 % Val.c + CO2 -> Suc.m + 2 CO2

( 0.00, 10.20)

72. 9.050 ± 3.724

46.6 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2

( 1.54, 16.06)

73. 3.669 ± 1.916

62.2 % Phe.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 7.47)

74. 3.899 ± 1.948

58.6 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2

( 0.09, 7.69)

75. 5.921 ± 3.048

60.1 % Leu.c + CO2 -> 3 AcCoA.m + CO2

( 0.00, 11.89)

76. 53.122 ± 4.164

8.0 % Gln.ext -> Gln.c

( 45.38, 61.62)

77. 4.263 ± 1.959

53.7 % Asp.c -> Asp.ext

( 0.42, 8.06)

78. 11.139 ± 3.748

37.3 % Ile.ext -> Ile.c

( 3.63, 18.25)

79. 9.542 ± 3.039

34.8 % Leu.ext -> Leu.c

( 3.65, 15.50)

80. 2.125 ± 0.890

49.1 % Met.ext -> Met.c

( 0.60, 4.07)

Asp.c -> Asn.c

Ser.c -> Gly.c + MEETHF
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Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

81. 5.061 ± 1.932

43.0 % Phe.ext -> Phe.c

( 1.29, 8.82)

82. 33.070 ± 6.619

21.5 % Ser.ext -> Ser.c

( 20.33, 46.15)

83. 5.060 ± 1.941

43.2 % Tyr.ext -> Tyr.c

( 1.26, 8.82)

84. 7.136 ± 2.765

44.6 % Val.ext -> Val.c

( 2.02, 12.80)

85. 2.460 ± 0.743

31.9 % Thr.ext -> Thr.c

( 1.34, 4.24)

86. 2.414 ± 0.609

26.6 % Arg.ext -> Arg.c

( 1.15, 3.52)

87. 0.928 ± 0.234

26.6 % Cys.ext -> Cys.c

( 0.44, 1.36)

88. 0.928 ± 0.234

26.6 % His.ext -> His.c

( 0.44, 1.36)

89. 3.667 ± 0.925

26.6 % Lys.ext -> Lys.c

( 1.74, 5.35)

90. 0.279 ± 0.070

26.6 % Trp.ext -> Trp.c

( 0.13, 0.41)

91. 9.996 ± 4.998

59.4 % Ala.c -> Ala.ext

( 0.25, 19.75)

92. 6.007 ± 3.006

57.1 % Gly.c -> Gly.ext

( 0.13, 11.86)

93. 1.021 ± 0.499

55.9 % Pro.c -> Pro.ext

( 0.04, 1.99)

94. 11.847 ± 4.262

40.6 % Glu.c -> Glu.ext

( 3.30, 19.92)

95. 280.600 ± 28.088

10.3 % Lact.c -> Lact.ext

( 225.69, 335.24)

96. 21.122 ± 1.977

9.6 %

Lact.tr -> Lact.c

( 17.26, 24.97)

97. 26.717 ± 4.765

18.9 % Ru5P.c <=> X5P.c (net)

( 15.85, 34.43)

98. ( >1e4, >1e4) ± >10000

>100 % Ru5P.c <=> X5P.c (exch)

( 0.00, >10000)

99. 46.421 ± 11.713

Biomass Equation (v72)

( 22.07, 67.76)

100. 13.679 ± 4.568

37.1 % FA.c -> Lipids

( 2.61, 20.43)
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Table D.3 MFA results for the MCF-7 cells for the control condition. Fluxes measured in
nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

1. 205.809 ± 18.276

9.1 %

Gluc.ext -> G6P.c

( 171.39, 242.66)

2. 162.152 ± 14.524

9.2 %

G6P.c <=> F6P.c (net)

( 134.74, 191.39)

3. ( >1000, >1e4) ± >1000

>100 % G6P.c <=> F6P.c (exch)

( 0.00, >10000)

4. 189.819 ± 16.839

9.1 %

F6P.c -> FBP.c

( 158.01, 223.68)

5. 189.819 ± 16.839

9.1 %

FBP.c <=> DHAP.c + GAP.c (net)

( 158.01, 223.68)

6. ( 0.0, >1e4) ± >10000

>100 % FBP.c <=> DHAP.c + GAP.c (exch)

( 0.00, >10000)

7. 189.819 ± 16.839

9.1 %

( 158.01, 223.68)

8. ( >1000, >1000) ± >1000

57.6 % DHAP.c <=> GAP.c (exch)

( >1000, >10000)

9. 393.472 ± 35.037

9.1 %

( 327.30, 463.95)

10. ( 205.5, 646.5) ± >1000

>100 % GAP.c <=> 3PG.c (exch)

( 0.00, >10000)

11. 393.472 ± 35.037

9.1 %

( 327.30, 463.95)

12. ( >1000, >1e4) ± >1000

>100 % 3PG.c <=> PEP.c (exch)

13. 410.146 ± 36.903

9.3 %

14. 42.487 ± 7.252

17.9 % G6P.c -> CO2 + Ru5P.c

( 27.37, 55.65)

15. 13.834 ± 2.431

18.4 % Ru5P.c <=> R5P.c (net)

( 8.78, 18.26)

16. ( >1000, >1e4) ± >1000

>100 % Ru5P.c <=> R5P.c (exch)

( 0.00, >10000)

17. 27.667 ± 4.861

18.4 %

( 17.55, 36.51)

18. ( 402.5, >1e4) ± >1000

>100 % X5P.c <=> EC2.c + GAP.c (exch)

( 0.00, >10000)

19. -13.834 ± 2.431

16.9 % F6P.c <=> EC2.c + E4P.c (net)

( -18.26, -8.78)

20. 0.000 ± 2.752

>100 % F6P.c <=> EC2.c + E4P.c (exch)

( 0.00, 10.73)

DHAP.c <=> GAP.c (net)

GAP.c <=> 3PG.c (net)

3PG.c <=> PEP.c (net)

PEP.c -> Pyr.c

X5P.c <=> EC2.c + GAP.c (net)
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( 236.98, >10000)
( 340.60, 484.52)

Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

21. -13.834 ± 2.431

16.9 % S7P.c <=> EC2.c + R5P.c (net)

( -18.26, -8.78)

22. 4.655 ± 3.330

95.3 % S7P.c <=> EC2.c + R5P.c (exch)

( 0.00, 12.99)

23. -13.834 ± 2.431

16.9 %

( -18.26, -8.78)

24. ( 675.1, >1e4) ± >1000

>100 % F6P.c <=> EC3.c + GAP.c (exch)

( 0.00, >10000)

25. 13.834 ± 2.431

18.4 % S7P.c <=> EC3.c + E4P.c (net)

( 8.78, 18.26)

26. ( >1000, >1e4) ± >1000

>100 % S7P.c <=> EC3.c + E4P.c (exch)

( 0.00, >10000)

27. 331.000 ± 33.045

10.3 % Pyr.c <=> Lact.c (net)

( 266.48, 395.35)

28. ( 0.0, >1e4) ± >1000

>100 % Pyr.c <=> Lact.c (exch)

( 0.00, >10000)

29. 56.896 ± 44.056

>100 % Pyr.c -> Pyr.snk

( 0.00, 171.82)

30. 60.250 ± 17.573

32.2 % Pyr.c -> Pyr.m

( 25.72, 94.25)

31. 60.250 ± 17.573

32.2 %

( 25.72, 94.25)

32. 94.227 ± 14.882

16.4 % AcCoA.m + OAC.m -> Cit.m

( 65.05, 123.10)

33. 40.127 ± 5.041

13.1 % Cit.m <=> AKG.m + CO2 (net)

( 30.55, 50.21)

34. 3.967 ± 1.659

47.6 % Cit.m <=> AKG.m + CO2 (exch)

( 1.00, 7.47)

35. 69.094 ± 6.349

9.4 %

( 56.96, 81.72)

36. 87.333 ± 11.084

13.2 % Suc.m <=> Fum.m (net)

( 65.93, 109.16)

37. 10.895 ± 14.681

>100 % Suc.m <=> Fum.m (exch)

( 0.00, 57.26)

38. 94.976 ± 11.765

12.8 % Fum.m <=> Mal.m (net)

( 72.21, 118.09)

39. ( 0.0, >1e4) ± >1000

>100 % Fum.m <=> Mal.m (exch)

( 0.00, >10000)

40. 79.960 ± 15.910

21.0 % Mal.m <=> OAC.m (net)

( 48.57, 110.62)

F6P.c <=> EC3.c + GAP.c (net)

Pyr.m -> CO2 + AcCoA.m

AKG.m -> CO2 + Suc.m
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

41. ( 110.4, 182.5) ± >100

>100 % Mal.m <=> OAC.m (exch)

( 1.38, >1000)

42. 14.267 ± 3.536

26.8 % Mal.m -> Pyr.mII + CO2

( 7.63, 21.42)

43. 14.267 ± 4.837

36.7 % Pyr.mII + CO2 -> OAC.m

( 7.63, 26.50)

44. 0.000 ± 2.930

>100 % Pyr.m <=> Pyr.mII (net)

( -1.57, 9.86)

45. -0.000 ± 0.424

>100 % Pyr.m <=> Pyr.mII (exch)

( -0.00, 1.65)

46. 28.870 ± 8.750

33.6 %

( 12.22, 46.35)

47. 0.749 ± 17.414

>100 % Mal.m <=> Mal.c (net)

( -32.56, 35.36)

48. ( 413.7, >1e4) ± >1000

>100 % Mal.m <=> Mal.c (exch)

( 0.00, >10000)

49. -28.121 ± 15.864

48.8 % Mal.c <=> OAC.c (net)

( -59.10, 2.77)

50. ( >1000, >1e4) ± >1000

>100 % Mal.c <=> OAC.c (exch)

( >1000, >10000)

51. 16.673 ± 6.548

44.5 % OAC.c -> PEP.c + CO2

( 4.86, 30.40)

52. 54.100 ± 14.859

30.0 %

( 24.72, 82.67)

53. ( 0.0, >1e4) ± >10000

>100 % Cit.m <=> Cit.c (exch)

( 0.00, >10000)

54. 54.100 ± 14.859

30.0 % Cit.c -> AcCoA.c + OAC.c

( 24.72, 82.67)

55. 54.100 ± 14.859

30.0 %

AcCoA.c -> FA.c

( 24.72, 82.67)

56. 46.696 ± 4.090

8.9 %

Gln.c -> Glu.c

( 38.79, 54.74)

57. 28.967 ± 4.193

15.1 %

Glu.c <=> AKG.m (net)

( 20.86, 37.22)

Mal.c -> Pyr.c + CO2

Cit.m <=> Cit.c (net)

58. ( >1000, >1000) ± >1000 >100 % Glu.c <=> AKG.m (exch)

( 639.25, >10000)

59. 2.352 ± 0.605

27.8 % Glu.c <=> Pro.c (net)

( 1.17, 3.53)

60. ( 0.0, >1e4) ± >10000

>100 % Glu.c <=> Pro.c (exch)

( 0.00, >10000)
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

61. -9.306 ± 2.986

29.5 % Asp.c <=> OAC.c (net)

( -15.13, -3.49)

62. ( 0.0, >1e4) ± >10000

>100 % Asp.c <=> OAC.c (exch)

( 0.00, >10000)

63. 1.232 ± 0.320

28.2 % Asp.c -> Asn.c

( 0.60, 1.85)

64. 16.557 ± 7.028

49.0 % Pyr.c <=> Ala.c (net)

( 2.85, 30.26)

65. ( 0.0, >1e4) ± >10000

>100 % Pyr.c <=> Ala.c (exch)

( 0.00, >10000)

66. 25.688 ± 7.937

33.9 % Ser.c <=> Pyr.c (net)

( 10.32, 41.27)

67. ( >1000, >1e4) ± >1000

>100 % Ser.c <=> Pyr.c (exch)

( 17.54, >10000)

68. 11.241 ± 4.536

46.3 % Ser.c -> Gly.c + MEETHF

( 2.40, 20.09)

69. 0.000 ± 0.168

>100 % Thr.c -> AcCoA.c + Gly.c

( 0.00, 0.66)

70. 1.381 ± 0.859

80.8 % Met.c + CO2 -> Suc.m + CO2 + MEETHF ( 0.00, 3.35)

71. 6.572 ± 3.863

74.4 % Val.c + CO2 -> Suc.m + 2 CO2

( 0.00, 15.07)

72. 10.286 ± 4.894

53.8 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2

( 0.74, 19.82)

73. 3.744 ± 1.960

62.7 %

( 0.00, 7.64)

74. 3.900 ± 1.997

60.9 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 7.79)

75. 2.801 ± 1.748

80.1 %

Leu.c + CO2 -> 3 AcCoA.m + CO2

( 0.00, 6.82)

76. 48.051 ± 4.132

8.8 %

Gln.ext -> Gln.c

( 40.06, 56.17)

77. 6.564 ± 2.919

51.6 % Asp.c -> Asp.ext

( 0.88, 12.26)

78. 11.672 ± 4.866

46.6 %

( 2.18, 21.16)

79. 5.204 ± 1.848

40.4 % Leu.ext -> Leu.c

( 1.83, 9.04)

80. 1.967 ± 0.899

54.4 % Met.ext -> Met.c

( 0.41, 3.91)

Phe.c -> Fum.m + 2 AcCoA.m + CO2

Ile.ext -> Ile.c
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

81. 4.668 ± 1.974

49.0 %

Phe.ext -> Phe.c

82. 38.747 ± 6.530

17.7 % Ser.ext -> Ser.c

( 26.10, 51.57)

83. 4.670 ± 1.989

49.4 % Tyr.ext -> Tyr.c

( 0.79, 8.55)

84. 8.328 ± 3.983

54.9 % Val.ext -> Val.c

( 1.26, 16.80)

85. 1.633 ± 0.420

27.9 % Thr.ext -> Thr.c

( 0.81, 2.45)

86. 1.602 ± 0.416

28.2 % Arg.ext -> Arg.c

( 0.78, 2.40)

87. 0.616 ± 0.160

28.2 % Cys.ext -> Cys.c

( 0.30, 0.92)

88. 0.616 ± 0.160

28.2 % His.ext -> His.c

( 0.30, 0.92)

89. 2.433 ± 0.632

28.2 % Lys.ext -> Lys.c

( 1.19, 3.65)

90. 0.185 ± 0.048

28.2 % Trp.ext -> Trp.c

( 0.09, 0.28)

91. 14.001 ± 6.998

59.4 % Ala.c -> Ala.ext

( 0.35, 27.65)

92. 8.962 ± 4.498

59.7 % Gly.c -> Gly.ext

( 0.19, 17.73)

93. 1.028 ± 0.499

57.7 % Pro.c -> Pro.ext

( 0.05, 2.00)

94. 13.744 ± 4.607

37.5 % Glu.c -> Glu.ext

( 4.77, 22.74)

95. 331.000 ± 33.045

10.3 %

Lact.c -> Lact.ext

( 266.48, 395.35)

96. 27.667 ± 4.861

18.4 %

Ru5P.c <=> X5P.c (net)

( 17.55, 36.51)

97. ( 402.5, >1e4) ± >1000

>100 % Ru5P.c <=> X5P.c (exch)

( 0.00, >10000)

98. 30.802 ± 8.006

Biomass equation (v72)

( 15.02, 46.24)

99. 54.100 ± 14.859

30.0 % FA.c -> Lipids

( 24.72, 82.67)
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Confidence Interval
( 0.84, 8.55)

Table D.4 MFA results for the MCF-7 cells for the high-lactate condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

1. 169.893 ± 15.016

9.1 %

Gluc.ext -> G6P.c

2. 128.736 ± 12.726

10.2 % G6P.c <=> F6P.c (net)

( 104.37, 154.00)

3. ( 543.3, >1e4) ± >1000

>100 % G6P.c <=> F6P.c (exch)

( 0.00, >10000)

4. 154.467 ± 13.998

9.4 %

F6P.c -> FBP.c

( 126.57, 181.16)

5. 154.467 ± 13.998

9.4 %

FBP.c <=> DHAP.c + GAP.c (net)

( 126.57, 181.16)

6. ( 0.0, >1e4) ± >10000

>100 % FBP.c <=> DHAP.c + GAP.c (exch)

( 0.00, >10000)

7. 154.467 ± 13.998

9.4 %

( 126.57, 181.16)

8. 547.530 ± 75.292

14.3 % DHAP.c <=> GAP.c (exch)

( 424.97, 718.61)

9. 321.800 ± 29.029

9.3 %

( 263.96, 377.18)

10. ( 0.0, >1000) ± >1000

>100 % GAP.c <=> 3PG.c (exch)

( 0.00, >10000)

11. 321.800 ± 29.029

9.3 %

( 263.96, 377.18)

12. ( 1.8, 64.2) ± >100

>100 % 3PG.c <=> PEP.c (exch)

( 0.00, 744.14)

13. 340.597 ± 31.547

9.5 %

( 278.00, 401.03)

14. 39.767 ± 6.463

16.7 % G6P.c -> CO2 + Ru5P.c

( 25.04, 50.25)

15. 12.866 ± 2.141

17.1 % Ru5P.c <=> R5P.c (net)

( 8.00, 16.35)

16. ( 361.1, >1e4) ± >1000

>100 % Ru5P.c <=> R5P.c (exch)

( 0.00, >10000)

17. 25.731 ± 4.282

17.1 % X5P.c <=> EC2.c + GAP.c (net)

( 15.99, 32.69)

18. ( 54.9, >1e4) ± >1000

>100 % X5P.c <=> EC2.c + GAP.c (exch)

( 0.00, >10000)

19. -12.866 ± 2.141

15.9 % F6P.c <=> EC2.c + E4P.c (net)

( -16.35, -8.00)

20. 0.000 ± 2.052

>100 % F6P.c <=> EC2.c + E4P.c (exch)

( 0.00, 8.00)

DHAP.c <=> GAP.c (net)

GAP.c <=> 3PG.c (net)

3PG.c <=> PEP.c (net)

PEP.c -> Pyr.c
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( 139.99, 198.55 )

Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

21. -12.866 ± 2.141

15.9 % S7P.c <=> EC2.c + R5P.c (net)

( -16.35, -8.00)

22. ( 285.1, >1e4) ± >1000

>100 % S7P.c <=> EC2.c + R5P.c (exch)

( 0.00, >10000)

23. -12.866 ± 2.141

15.9 % F6P.c <=> EC3.c + GAP.c (net)

( -16.35, -8.00)

24. ( 0.0, >1e4) ± >1000

>100 % F6P.c <=> EC3.c + GAP.c (exch)

( 0.00, >10000)

25. 12.866 ± 2.141

17.1 % S7P.c <=> EC3.c + E4P.c (net)

( 8.00, 16.35)

26. ( 283.5, >1e4) ± >1000

>100 % S7P.c <=> EC3.c + E4P.c (exch)

( 0.00, >10000)

27. 133.279 ± 19.894

15.7 % Pyr.c <=> Lact.c (net)

( 91.83, 169.42)

28. 279.857 ± >100

67.1 % Pyr.c <=> Lact.c (exch)

( 64.65, 729.62)

29. 167.594 ± 40.602

24.8 %

( 92.44, 250.79)

30. 39.915 ± 13.667

38.8 % Pyr.c -> Pyr.m

( 13.31, 66.61)

31. 39.915 ± 12.927

36.7 % Pyr.m -> CO2 + AcCoA.m

( 13.31, 63.73)

32. 65.995 ± 8.067

12.6 % AcCoA.m + OAC.m -> Cit.m

( 48.02, 79.48)

33. 34.845 ± 4.598

13.7 %

( 25.28, 43.21)

34. 29.833 ± 3.822

13.3 % Cit.m <=> AKG.m + CO2 (exch)

( 21.85, 36.76)

35. 53.962 ± 5.337

10.3 % AKG.m -> CO2 + Suc.m

( 42.98, 63.79)

36. 66.222 ± 7.798

12.1 % Suc.m <=> Fum.m (net)

( 49.14, 79.55)

37. ( 58.5, >1e4) ± >1000

>100 % Suc.m <=> Fum.m (exch)

( 0.00, >10000)

38. 70.945 ± 7.927

11.4 % Fum.m <=> Mal.m (net)

( 53.79, 84.70)

39. ( 26.3, >1000) ± >1000

>100 % Fum.m <=> Mal.m (exch)

( 0.00, >10000)

40. 61.376 ± 7.827

12.9 % Mal.m <=> OAC.m (net)

( 44.79, 75.31)

Pyr.c -> Pyr.snk

Cit.m <=> AKG.m + CO2 (net)
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

41. ( 16.9, 37.2) ± >1000

>100 % Mal.m <=> OAC.m (exch)

( 0.00, >10000)

42. 4.618 ± 1.799

39.9 % Mal.m -> Pyr.mII + CO2

( 0.98, 7.99)

43. 4.618 ± 3.027

72.6 % Pyr.mII + CO2 -> OAC.m

( 0.81, 12.61)

44. 0.000 ± 2.500

>100 % Pyr.m <=> Pyr.mII (net)

( -1.17, 8.58)

45. 0.000 ± 0.300

>100 % Pyr.m <=> Pyr.mII (exch)

( 0.00, 1.17)

46. 4.951 ± 4.072

>100 % Mal.c -> Pyr.c + CO2

( 0.00, 15.88)

47. 4.951 ± 7.500

>100 % Mal.m <=> Mal.c (net)

( -5.06, 24.19)

48. ( 0.0, >1e4) ± >1000

>100 % Mal.m <=> Mal.c (exch)

( 0.00, >10000)

49. -0.000 ± 9.823

>100 % Mal.c <=> OAC.c (net)

( -14.02, 24.29)

50. ( 0.0, 1.0) ± >1000

>100 % Mal.c <=> OAC.c (exch)

( 0.00, >10000)

51. 18.797 ± 5.457

31.8 % OAC.c -> PEP.c + CO2

( 8.66, 29.94)

52. 31.150 ± 8.164

27.6 % Cit.m <=> Cit.c (net)

( 12.02, 43.86)

53. ( 0.0, >1e4) ± >10000

>100 % Cit.m <=> Cit.c (exch)

( 0.00, >10000)

54. 31.150 ± 8.164

27.6 % Cit.c -> AcCoA.c + OAC.c

( 12.02, 43.86)

55. 31.150 ± 7.203

24.3 % AcCoA.c -> FA.c

( 15.55, 43.64)

56. 43.820 ± 3.913

9.1 %

Gln.c -> Glu.c

( 36.04, 51.30)

57. 19.117 ± 3.432

18.4 % Glu.c <=> AKG.m (net)

( 12.23, 25.61)

58. 134.232 ± 18.456

14.3 % Glu.c <=> AKG.m (exch)

( 101.63, 173.61)

59. 3.803 ± 1.030

29.3 % Glu.c <=> Pro.c (net)

( 1.81, 5.83)

60. ( 0.0, >1e4) ± >10000

>100 % Glu.c <=> Pro.c (exch)

( 0.00, >10000)
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

61. -12.353 ± 2.846

21.8 % Asp.c <=> OAC.c (net)

( -17.97, -6.87)

62. ( 0.0, >1e4) ± >10000

>100 % Asp.c <=> OAC.c (exch)

( 0.00, >10000)

63. 1.463 ± 0.240

16.5 % Asp.c -> Asn.c

( 1.11, 2.04)

64. 13.999 ± 5.510

44.9 % Pyr.c <=> Ala.c (net)

( 3.24, 24.73)

65. ( 0.0, >1e4) ± >10000

>100 % Pyr.c <=> Ala.c (exch)

( 0.00, >10000)

66. 9.239 ± 10.787

>100 % Ser.c <=> Pyr.c (net)

( -11.46, 30.61)

67. ( 389.9, >1e4) ± >1000

>100 % Ser.c <=> Pyr.c (exch)

( 0.00, >10000)

68. 11.653 ± 4.513

44.0 % Ser.c -> Gly.c + MEETHF

( 2.85, 20.45)

69. 0.000 ± 0.124

>100 % Thr.c -> AcCoA.c + Gly.c

( 0.00, 0.48)

70. 1.221 ± 0.811

79.5 % Met.c + CO2 -> Suc.m + CO2 + MEETHF ( 0.00, 3.16)

71. 5.697 ± 3.255

61.6 % Val.c + CO2 -> Suc.m + 2 CO2

( 0.00, 12.70)

72. 5.342 ± 3.108

62.7 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2

( 0.00, 12.12)

73. 2.201 ± 1.602

83.9 % Phe.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 6.25)

74. 2.522 ± 1.645

74.2 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 6.42)

75. 3.764 ± 2.626

95.3 % Leu.c + CO2 -> 3 AcCoA.m + CO2

( 0.00, 10.24)

76. 45.429 ± 3.936

8.8 %

( 37.61, 52.96)

77. 9.099 ± 2.815

33.7 % Asp.c -> Asp.ext

( 3.70, 14.68)

78. 6.988 ± 3.171

48.0 % Ile.ext -> Ile.c

( 1.48, 13.85)

79. 6.616 ± 2.707

48.5 % Leu.ext -> Leu.c

( 2.42, 12.98) |

80. 1.916 ± 0.830

48.6 %

( 0.60, 3.84)

Gln.ext -> Gln.c

Met.ext -> Met.c
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

81. 3.298 ± 1.639

54.6 %

Phe.ext -> Phe.c

82. 23.050 ± 9.789

47.6 % Ser.ext -> Ser.c

( 4.37, 42.55)

83. 3.436 ± 1.672

53.4 % Tyr.ext -> Tyr.c

( 0.80, 7.32)

84. 7.782 ± 3.329

45.2 % Val.ext -> Val.c

( 1.90, 14.88)

85. 1.938 ± 0.339

18.5 % Thr.ext -> Thr.c

( 1.14, 2.46)

86. 1.902 ± 0.311

16.5 % Arg.ext -> Arg.c

( 1.44, 2.66)

87. 0.731 ± 0.120

16.5 % Cys.ext -> Cys.c

( 0.55, 1.02)

88. 0.731 ± 0.120

16.5 % His.ext -> His.c

( 0.55, 1.02)

89. 2.889 ± 0.473

16.5 % Lys.ext -> Lys.c

( 2.19, 4.04)

90. 0.219 ± 0.036

16.5 % Trp.ext -> Trp.c

( 0.17, 0.31)

91. 10.963 ± 5.498

59.4 %

Ala.c -> Ala.ext

( 0.28, 21.72)

92. 8.947 ± 4.497

59.4 % Gly.c -> Gly.ext

( 0.22, 17.76)

93. 2.231 ± 0.988

50.5 % Pro.c -> Pro.ext

( 0.33, 4.19)

94. 18.962 ± 4.446

24.9 % Glu.c -> Glu.ext

( 10.43, 27.77)

95. 175.999 ± 17.520

10.3 % Lact.c -> Lact.ext

( 141.51, 209.84)

96. 42.719 ± 12.711

31.1 % Lact.tr -> Lact.c

( 23.23, 72.81)

97. 25.731 ± 4.282

17.1 % Ru5P.c <=> X5P.c (net)

( 15.99, 32.69)

98. ( 54.9, >1e4) ± >1000

>100 % Ru5P.c <=> X5P.c (exch)

( 0.00, >10000)

99. 36.571 ± 5.988

16.5 % Biomass equation (v72)

( 27.73, 51.09)

100. 31.150 ± 7.203

24.3 % FA.c -> Lipids

( 15.55, 43.64)

224

Confidence Interval
( 0.94, 7.33)

Table D.5 MFA results for the MDA-MB-231 cells for the control condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

1. 367.744 ± 29.665

8.3 %

Gluc.ext -> G6P.c

( 314.56, 430.25)

2. 286.820 ± 25.084

9.0 %

G6P.c <=> F6P.c (net)

( 241.50, 339.33)

3. ( 0.0, >1000) ± >1000

>100 % G6P.c <=> F6P.c (exch)

( 0.00, >10000)

4. 339.152 ± 26.946

8.2 %

F6P.c -> FBP.c

( 291.03, 396.12)

5. 339.152 ± 26.946

8.2 %

FBP.c <=> DHAP.c + GAP.c (net)

( 291.03, 396.12)

6. ( 0.0, >1e4) ± >10000

>100 % FBP.c <=> DHAP.c + GAP.c (exch)

( 0.00, >10000)

7. 339.152 ± 26.946

8.2 %

DHAP.c <=> GAP.c (net)

( 291.03, 396.12)

8. 1224.863 ± >100

12.4 %

DHAP.c <=> GAP.c (exch)

( 982.48, >1000)

9. 704.470 ± 56.310

8.2 %

GAP.c <=> 3PG.c (net)

( 603.67, 823.28)

10. ( 0.0, >1000) ± >1000

>100 % GAP.c <=> 3PG.c (exch)

( 0.00, >10000)

11. 704.470 ± 56.310

8.2 %

( 603.67, 823.28)

12. ( 697.2, >1e4) ± >1000

>100 % 3PG.c <=> PEP.c (exch)

( 0.00, >10000)

13. 709.705 ± 57.900

8.4 %

PEP.c -> Pyr.c

( 606.71, 832.52)

14. 79.607 ± 13.946

18.7 % G6P.c -> CO2 + Ru5P.c

( 53.92, 108.31)

15. 26.166 ± 4.647

19.0 % Ru5P.c <=> R5P.c (net)

( 17.61, 35.74)

16. ( 0.0, >1e4) ± >10000

>100 % Ru5P.c <=> R5P.c (exch)

( 0.00, >10000)

17. 52.332 ± 9.293

19.0 % X5P.c <=> EC2.c + GAP.c (net)

( 35.23, 71.47)

18. ( 0.0, >1e4) ± >1000

>100 % X5P.c <=> EC2.c + GAP.c (exch)

( 0.00, >10000)

19. -26.166 ± 4.647

16.6 % F6P.c <=> EC2.c + E4P.c (net)

( -35.74, -17.61)

20. 6.289 ± 6.347

>100 % F6P.c <=> EC2.c + E4P.c (exch)

( 0.00, 24.75)

3PG.c <=> PEP.c (net)
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21. -26.166 ± 4.647

16.6 % S7P.c <=> EC2.c + R5P.c (net)

( -35.74, -17.61)

22. ( 0.0, >1e4) ± >1000

>100 % S7P.c <=> EC2.c + R5P.c (exch)

( 0.00, >10000)

23. -26.166 ± 4.647

16.6 % F6P.c <=> EC3.c + GAP.c (net)

( -35.74, -17.61)

24. ( 0.0, >1e4) ± >1000

>100 % F6P.c <=> EC3.c + GAP.c (exch)

( 0.00, >10000)

25. 26.166 ± 4.647

19.0 % S7P.c <=> EC3.c + E4P.c (net)

( 17.61, 35.74)

26. ( 0.0, >1e4) ± >10000

>100 % S7P.c <=> EC3.c + E4P.c (exch)

( 0.00, >10000)

27. 615.000 ± 55.905

9.4 %

( 495.11, 713.15)

28. ( 0.0, >1e4) ± >1000

>100 % Pyr.c <=> Lact.c (exch)

( 0.00, >10000)

29. ( 0.0, 43.7) ± 51.914

>100 % Pyr.c -> Pyr.snk

( 0.00, 202.46)

30. 101.038 ± 30.524

36.2 % Pyr.c -> Pyr.m

( 49.49, 168.53)

31. 93.498 ± 27.433

33.9 %

( 46.40, 153.39)

32. 113.406 ± 26.704

26.5 % AcCoA.m + OAC.m -> Cit.m

( 66.91, 171.05)

33. 34.300 ± 4.465

14.1 % Cit.m <=> AKG.m + CO2 (net)

( 23.20, 40.61)

34. 5.606 ± 1.624

31.2 % Cit.m <=> AKG.m + CO2 (exch)

( 2.69, 9.02)

35. 52.635 ± 5.817

11.5 % AKG.m -> CO2 + Suc.m

( 40.25, 62.94)

36. 62.617 ± 8.055

13.4 % Suc.m <=> Fum.m (net)

( 45.41, 76.83)

37. ( 0.0, >1e4) ± >1000

>100 % Suc.m <=> Fum.m (exch)

( 0.00, >10000)

38. 68.821 ± 8.852

13.4 % Fum.m <=> Mal.m (net)

( 50.17, 84.70)

39. ( 0.0, 6.2) ± >1000

>100 % Fum.m <=> Mal.m (exch)

( 0.00, >10000)

40. 91.078 ± 23.928

29.2 % Mal.m <=> OAC.m (net)

( 50.09, 143.41)

41. 22.999 ± 42.782

>100 % Mal.m <=> OAC.m (exch)

( 0.00, 166.85)

42. 14.787 ± 2.568

17.5 %

Mal.m -> Pyr.mII + CO2

( 10.22, 20.24)

43. 22.328 ± 6.977

38.8 % Pyr.mII + CO2 -> OAC.m

( 10.13, 37.35)

44. 7.540 ± 5.901

>100 % Pyr.m <=> Pyr.mII (net)

( -1.13, 21.89)

Pyr.c <=> Lact.c (net)

Pyr.m -> CO2 + AcCoA.m
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Table D.5 (Continued) MFA results for the MDA-MB-231 cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

45. 0.000 ± 0.663

>100 % Pyr.m <=> Pyr.mII (exch)

( 0.00, 2.59)

46. 33.742 ± 12.740

44.3 % Mal.c -> Pyr.c + CO2

( 3.90, 53.58)

47. ( -45.6, -33.8) ± 20.667

45.4 % Mal.m <=> Mal.c (net)

( -85.00, -4.40)

48. ( 0.0, 2.0) ± >1000

>100 % Mal.m <=> Mal.c (exch)

( 0.00, >10000)

49. ( -82.5, -59.3) ± 26.084

31.6 % Mal.c <=> OAC.c (net)

(-128.92, -27.20)

50. ( 0.0, >1e4) ± >1000

>100 % Mal.c <=> OAC.c (exch)

( 0.00, >10000)

51. 5.235 ± 9.700

>100 % OAC.c -> PEP.c + CO2

( 0.00, 37.83)

52. 79.106 ± 24.083

35.0 % Cit.m <=> Cit.c (net)

( 39.36, 133.28)

53. ( 0.0, >1e4) ± >10000

>100 % Cit.m <=> Cit.c (exch)

( 0.00, >10000)

54. 79.106 ± 24.083

35.0 %

( 39.36, 133.28)

55. 79.106 ± 24.145

35.1 % AcCoA.c -> FA.c

( 39.12, 133.28)

56. 39.828 ± 4.040

10.5 % Gln.c -> Glu.c

( 32.54, 48.29)

57. 18.335 ± 4.199

24.7 % Glu.c <=> AKG.m (net)

( 10.90, 27.27)

58. ( >1000, >1e4) ± >1000

>100 % Glu.c <=> AKG.m (exch)

59. 2.561 ± 0.610

25.7 % Glu.c <=> Pro.c (net)

( 1.37, 3.75)

60. ( 0.0, >1e4) ± >10000

>100 % Glu.c <=> Pro.c (exch)

( 0.00, >10000)

61. -3.085 ± 0.939

28.3 % Asp.c <=> OAC.c (net)

( -5.32, -1.66)

62. ( 0.0, >1e4) ± >10000

>100 % Asp.c <=> OAC.c (exch)

( 0.00, >10000)

63. 1.386 ± 0.329

25.4 % Asp.c -> Asn.c

( 0.74, 2.03)

64. 13.877 ± 5.540

45.7 % Pyr.c <=> Ala.c (net)

( 3.08, 24.68)

Cit.c -> AcCoA.c + OAC.c
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( 612.11, >10000)

Table D.5 (Continued) MFA results for the MDA-MB-231 cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

65. ( 0.0, >1e4) ± >10000

>100 % Pyr.c <=> Ala.c (exch)

( 0.00, >10000)

66. 5.253 ± 8.372

>100 % Ser.c <=> Pyr.c (net)

( -10.67, 21.98)

67. ( 812.9, >1e4) ± >1000

>100 % Ser.c <=> Pyr.c (exch)

68. 10.561 ± 4.047

43.6 % Ser.c -> Gly.c + MEETHF

( 2.67, 18.45)

69. 0.000 ± 0.138

>100 % Thr.c -> AcCoA.c + Gly.c

( 0.00, 0.54)

70. 1.350 ± 0.852

82.8 % Met.c + CO2 -> Suc.m + CO2 + MEETHF ( 0.00, 3.32)

71. 5.124 ± 3.073

76.6 % Val.c + CO2 -> Suc.m + 2 CO2

( 0.00, 11.98)

72. 3.509 ± 2.160

79.6 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2

( 0.00, 8.42)

73. 3.015 ± 1.782

74.8 % Phe.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 6.95)

74. 3.189 ± 1.825

71.4 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2

( 0.00, 7.12)

75. 1.331 ± 1.389

>100 % Leu.c + CO2 -> 3 AcCoA.m + CO2

( 0.00, 5.42)

76. 41.353 ± 4.074

10.2 % Gln.ext -> Gln.c

( 33.99, 49.88)

77. 0.000 ± 0.497

>100 % Asp.c -> Asp.ext

( 0.00, 1.94)

78. 5.068 ± 2.255

52.7 % Ile.ext -> Ile.c

( 1.14, 9.93)

79. 4.034 ± 1.598

47.0 % Leu.ext -> Leu.c

( 1.70, 7.94)

80. 2.008 ± 0.895

52.9 % Met.ext -> Met.c

( 0.47, 3.96)

81. 4.055 ± 1.841

53.8 %

( 0.78, 7.96)

82. 17.858 ± 7.209

44.9 % Ser.ext -> Ser.c

( 4.24, 32.36)

83. 4.055 ± 1.869

54.6 % Tyr.ext -> Tyr.c

( 0.67, 7.96)

84. 7.099 ± 3.194

53.2 % Val.ext -> Val.c

( 1.46, 13.92)

Phe.ext -> Phe.c
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( 812.88, >10000)

Table D.5 (Continued) MFA results for the MDA-MB-231 cells for the control condition.
Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

85. 1.837 ± 0.435

25.4 % Thr.ext -> Thr.c

( 0.99, 2.68)

86. 1.802 ± 0.427

25.4 % Arg.ext -> Arg.c

( 0.97, 2.63)

87. 0.693 ± 0.164

25.4 % Cys.ext -> Cys.c

( 0.37, 1.01)

88. 0.693 ± 0.164

25.4 % His.ext -> His.c

( 0.37, 1.01)

89. 2.738 ± 0.649

25.4 % Lys.ext -> Lys.c

( 1.47, 4.00)

90. 0.208 ± 0.049

25.4 % Trp.ext -> Trp.c

( 0.11, 0.30)

91. 11.000 ± 5.498

59.4 % Ala.c -> Ala.ext

( 0.28, 21.72)

92. 7.996 ± 3.999

59.4 % Gly.c -> Gly.ext

( 0.20, 15.79)

93. 1.071 ± 0.500

54.7 %

( 0.10, 2.05)

94. 17.095 ± 4.297

27.1 % Glu.c -> Glu.ext

( 8.80, 25.56)

95. 615.000 ± 55.905

9.4 %

( 495.11, 713.15)

96. 52.332 ± 9.293

19.0 % Ru5P.c <=> X5P.c (net)

( 35.23, 71.47)

97. ( 0.0, >1e4) ± >1000

>100 % Ru5P.c <=> X5P.c (exch)

( 0.00, >10000)

98. 34.660 ± 8.216

25.4 % Biomass equation (v72)

( 18.60, 50.64)

99. 79.106 ± 24.145

35.1 %

( 39.12, 133.28)

Pro.c -> Pro.ext

Lact.c -> Lact.ext

FA.c -> Lipids
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Table D.6 MFA results for the MDA-MB-231 cells for the high-lactate condition. Fluxes
measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

1. 223.612 ± 18.929

8.7 %

Gluc.ext -> G6P.c

( 184.77, 258.60)

2. 174.917 ± 14.716

8.6 %

G6P.c <=> F6P.c (net)

( 144.40, 201.79)

3. ( >1000, >1e4) ± >1000

>100 % G6P.c <=> F6P.c (exch)

( 57.35, >10000)

4. 206.134 ± 17.295

8.6 %

F6P.c -> FBP.c

( 170.13, 237.58)

5. 206.134 ± 17.295

8.6 %

FBP.c <=> DHAP.c + GAP.c (net)

( 170.13, 237.58)

6. ( 0.0, >1e4) ± >10000

>100 % FBP.c <=> DHAP.c + GAP.c (exch)

( 0.00, >10000)

7. 206.134 ± 17.295

8.6 %

( 170.13, 237.58)

8. ( >1000, >1000) ± >1000

34.6 % DHAP.c <=> GAP.c (exch)

( >1000, >10000)

9. 427.878 ± 36.033

8.7 %

( 352.92, 493.45)

10. ( 728.7, >1000) ± >1000

>100 % GAP.c <=> 3PG.c (exch)

( 0.00, >10000)

11. 427.878 ± 36.033

8.7 %

( 352.92, 493.45)

12. 0.000 ± 18.112

>100 % 3PG.c <=> PEP.c (exch)

( 0.00, 70.64)

13. 492.882 ± 40.788

8.5 %

PEP.c -> Pyr.c

( 407.35, 566.43)

14. 47.681 ± 6.178

13.5 % G6P.c -> CO2 + Ru5P.c

( 36.14, 60.24)

15. 15.609 ± 2.040

13.6 %

( 11.67, 19.62)

16. ( >1000, >1e4) ± >1000

84.2 % Ru5P.c <=> R5P.c (exch)

17. 31.218 ± 4.080

13.6 % X5P.c <=> EC2.c + GAP.c (net)

( 23.34, 39.25)

18. ( 0.0, >1e4) ± >1000

>100 % X5P.c <=> EC2.c + GAP.c (exch)

( 0.00, >10000)

19. -15.609 ± 2.040

12.9 % F6P.c <=> EC2.c + E4P.c (net)

( -19.62, -11.67)

20. 0.000 ± 2.420

>100 % F6P.c <=> EC2.c + E4P.c (exch)

( 0.00, 9.44)

DHAP.c <=> GAP.c (net)

GAP.c <=> 3PG.c (net)

3PG.c <=> PEP.c (net)

Ru5P.c <=> R5P.c (net)
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( >1000, >10000)

Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate
condition. Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

21. -15.609 ± 2.040

12.9 %

S7P.c <=> EC2.c + R5P.c (net)

22. ( >1000, >1e4) ± >1000

>100 % S7P.c <=> EC2.c + R5P.c (exch)

( >1000, >10000)

23. -15.609 ± 2.040

12.9 % F6P.c <=> EC3.c + GAP.c (net)

( -19.62, -11.67)

24. ( >1000, >1e4) ± >1000

>100 % F6P.c <=> EC3.c + GAP.c (exch)

( 0.00, >10000)

25. 15.609 ± 2.040

13.6 % S7P.c <=> EC3.c + E4P.c (net)

( 11.67, 19.62)

26. 5.821 ± 4.101

73.3 % S7P.c <=> EC3.c + E4P.c (exch)

( 0.00, 15.99)

27. 319.887 ± 39.362

12.9 %

( 240.49, 394.00)

Pyr.c <=> Lact.c (net)

28. ( >1000, >1000) ± >1000 >100 % Pyr.c <=> Lact.c (exch)

( -19.62, -11.67)

( 610.82, >10000)

29. 151.385 ± 60.019

43.9 % Pyr.c -> Pyr.snk

( 27.75, 261.82)

30. 29.456 ± 14.042

53.5 % Pyr.c -> Pyr.m

( 7.07, 61.83)

31. 29.456 ± 13.983

53.3 %

( 7.07, 61.60)

32. 83.441 ± 11.740

14.8 % AcCoA.m + OAC.m -> Cit.m

( 64.67, 110.46)

33. 52.152 ± 5.596

11.1 % Cit.m <=> AKG.m + CO2 (net)

( 41.31, 63.13)

34. 33.556 ± 4.761

14.8 % Cit.m <=> AKG.m + CO2 (exch)

( 25.71, 44.28)

35. 91.381 ± 7.623

8.5 %

AKG.m -> CO2 + Suc.m

( 76.83, 106.56)

36. 114.345 ± 9.941

8.9 %

Suc.m <=> Fum.m (net)

( 95.10, 133.87)

37. ( 23.6, 57.9) ± >100

>100 % Suc.m <=> Fum.m (exch)

( 0.00, 715.93)

38. 123.152 ± 9.921

8.2 % Fum.m <=> Mal.m (net)

( 103.82, 142.51)

39. ( >1000, >1e4) ± >1000

>100 % Fum.m <=> Mal.m (exch)

( 85.61, >10000)

40. 83.441 ± 12.509

15.8 % Mal.m <=> OAC.m (net)

( 61.67, 110.46)

Pyr.m -> CO2 + AcCoA.m
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate
condition. Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

41. ( 0.0, >1e4) ± >10000

>100 % Mal.m <=> OAC.m (exch)

( 0.00, >10000)

42. -0.000 ± 0.191

>100 % Mal.m -> Pyr.mII + CO2

( -0.00, 0.74)

43. 0.000 ± 2.704

>100 % Pyr.mII + CO2 -> OAC.m

( 0.00, 10.55)

44. 0.000 ± 2.895

>100 % Pyr.m <=> Pyr.mII (net)

( -0.74, 10.55)

45. ( 0.0, >1e4) ± >10000

>100 % Pyr.m <=> Pyr.mII (exch)

( 0.00, >10000)

46. 0.000 ± 1.840

>100 % Mal.c -> Pyr.c + CO2

( 0.00, 7.18) |

47. 39.711 ± 13.998 39.1 % Mal.m <=> Mal.c (net)

( 8.59, 63.18)

48. ( >1000, >1e4) ± >1000

>100 % Mal.m <=> Mal.c (exch)

( >1000, >10000)

49. 39.711 ± 13.941

39.0 % Mal.c <=> OAC.c (net)

( 8.59, 62.96)

50. ( 70.3, 209.5) ± >1000

>100 % Mal.c <=> OAC.c (exch)

( 23.17, >10000)

51. 65.004 ± 6.011

9.5 %

( 52.77, 76.21)

52. 31.289 ± 12.826

48.0 % Cit.m <=> Cit.c (net)

( 12.83, 62.85)

53. ( 0.0, >1e4) ± >10000

>100 % Cit.m <=> Cit.c (exch)

( 0.00, >10000)

54. 31.289 ± 12.826

48.0 % Cit.c -> AcCoA.c + OAC.c

( 12.83, 62.85)

55. 31.289 ± 12.826

48.0 % AcCoA.c -> FA.c

( 12.83, 62.85)

56. 50.097 ± 3.745

7.6 %

Gln.c -> Glu.c

( 42.81, 57.42)

57. 39.229 ± 4.026

10.6 % Glu.c <=> AKG.m (net)

( 31.14, 46.84)

58. 567.474 ± >100

40.0 % Glu.c <=> AKG.m (exch)

( 354.06, >1000)

59. 2.121 ± 0.553

26.6 % Glu.c <=> Pro.c (net)

( 1.14, 3.30)

60. ( 0.0, >1e4) ± >10000

>100 % Glu.c <=> Pro.c (exch)

( 0.00, >10000)

OAC.c -> PEP.c + CO2
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate
condition. Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

61. -5.996 ± 1.874

28.2 % Asp.c <=> OAC.c (net)

( -10.04, -2.74)

62. ( 0.0, >1e4) ± >10000

>100 % Asp.c <=> OAC.c (exch)

( 0.00, >10000)

63. 1.068 ± 0.326

31.3 % Asp.c -> Asn.c

( 0.42, 1.69)

64. 11.218 ± 4.241

39.9 % Pyr.c <=> Ala.c (net)

( 3.54, 20.08)

65. ( 0.0, >1e4) ± >10000

>100 % Pyr.c <=> Ala.c (exch)

( 0.00, >10000)

66. 19.064 ± 9.322

58.7 % Ser.c <=> Pyr.c (net)

( -0.68, 35.68)

67. ( 436.5, >1e4) ± >1000

>100 % Ser.c <=> Pyr.c (exch)

( 0.00, >10000)

68. 9.949 ± 3.650

38.0 % Ser.c -> Gly.c + MEETHF

( 3.59, 17.83)

69. 0.000 ± 0.236

>100 % Thr.c -> AcCoA.c + Gly.c

( 0.00, 0.92)

70. 1.598 ± 0.848

66.1 % Met.c + CO2 -> Suc.m + CO2 + MEETHF ( 0.00, 3.31)

71. 9.616 ± 3.754

43.2 % Val.c + CO2 -> Suc.m + 2 CO2

( 2.11, 16.75)

72. 11.749 ± 3.662

34.5 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2

( 4.51, 18.79)

73. 4.337 ± 1.862

49.8 % Phe.c -> Fum.m + 2 AcCoA.m + CO2

( 0.62, 7.88)

74. 4.470 ± 1.883

48.6 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2

( 0.75, 8.10)

75. 8.207 ± 2.872

39.4 % Leu.c + CO2 -> 3 AcCoA.m + CO2

( 2.25, 13.45)

76. 51.271 ± 3.641

7.2 %

( 44.40, 58.61)

77. 3.620 ± 1.894

63.2 % Asp.c -> Asp.ext

( 0.00, 7.39)

78. 12.950 ± 3.502

28.0 % Ile.ext -> Ile.c

( 6.41, 20.06)

79. 10.289 ± 2.996

31.9 % Leu.ext -> Leu.c

( 4.62, 16.31)

80. 2.106 ± 0.931

51.9 % Met.ext -> Met.c

( 0.41, 4.04)

Gln.ext -> Gln.c
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate
condition. Fluxes measured in nmol/106 cells/h.
Flux ± SD

%SD

Reaction

Confidence Interval

81. 5.138 ± 1.860

41.0 % Phe.ext -> Phe.c

( 1.61, 8.87)

82. 30.589 ± 9.170

33.1 % Ser.ext -> Ser.c

( 12.63, 48.40)

83. 5.138 ± 1.860

41.0 % Tyr.ext -> Tyr.c

( 1.61, 8.87)

84. 11.138 ± 3.636

34.2 % Val.ext -> Val.c

( 4.15, 18.33)

85. 1.415 ± 0.383

29.7 % Thr.ext -> Thr.c

( 0.58, 2.07)

86. 1.388 ± 0.424

31.3 % Arg.ext -> Arg.c

( 0.55, 2.20)

87. 0.534 ± 0.163

31.3 % Cys.ext -> Cys.c

( 0.21, 0.85)

88. 0.534 ± 0.163

31.3 % His.ext -> His.c

( 0.21, 0.85)

89. 2.109 ± 0.645

31.3 % Lys.ext -> Lys.c

( 0.83, 3.34)

90. 0.160 ± 0.049

31.2 % Trp.ext -> Trp.c

( 0.06, 0.25)

91. 9.002 ± 4.499

59.4 % Ala.c -> Ala.ext

( 0.23, 17.77)

92. 7.974 ± 3.999

59.6 % Gly.c -> Gly.ext

( 0.18, 15.77)

93. 0.973 ± 0.499

61.2 % Pro.c -> Pro.ext

( 0.00, 1.95)

95. 380.000 ± 37.990

10.4 % Lact.c -> Lact.ext

( 303.17, 451.33)

96. 60.113 ± 11.222

19.9 % Lact.tr -> Lact.c

( 37.97, 81.74)

97. 31.218 ± 4.080

13.6 % Ru5P.c <=> X5P.c (net)

( 23.34, 39.25)

98. ( 0.0, >1e4) ± >10000

>100 % Ru5P.c <=> X5P.c (exch)

( 0.00, >10000)

99. 26.695 ± 8.159

31.3 % Biomass equation (v72)

( 10.49, 42.31)

100. 31.289 ± 12.826

48.0 % FA.c -> Lipids

( 12.83, 62.85)
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